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Summary of this thesis 
It is clear that South Asians living in the West have substantially greater relative 
(coronary heart disease) CHD mortality and morbidity than the general population. 
Despite this current risk functions based on classical risk factors alone underestimate 
risk in non-diabetic South Asians. After reviewing the available literature for 
longitudinal studies exploring the relationship between South Asian ethnicity, as an 
independent factor, and CHD an adjustment factor suitable for use with the paper- 
based risk prediction functions was derived. The exploration of possible explanations 
for the excess risk identified dysglycaemia as one possible explain. 
Adding 10 years to age, although crude and based on the single prospective study, 
provides adequate sensitivity and specificity to take into account an "ethnicity factor" 
accounting for average excess risk in individual UK South Asians. Using this 
adjustment it was shown that more South Asian men and women, living in the UK, are 
iii 
candidates to receive lipid-lowering therapy for primary and secondary prevention 
than their Caucasian counterparts. Although the evidence base for a CVD risk 
estimation procedure in South Asians is slight it is better that they have their risk 
estimated, albeit with less precision, than be excluded. The present work provides a 
properly researched evidence base. Moreover, it provides its own very simple, but 1. 
practice acceptable, adjustment for currently used paper risk estimation tools. 
Acceptance of ant1hypertensives as a primary prevention treatment was looked at in 
the South Asians community. South Asians are at least equally accepting of treatment 
as Caucasians when given information about the personal impact of CVD and the 
effect and tolerability of antihypertensive treatment. With South Asians having a 
greater need and at least equal acceptance of preventive therapy, they should receive 
more such treatment. Current evidence suggests that this is not the case and targeted 
intervention may be needed. 
Further research is still required in many areas such as risk factors, risk estimation and 
recalibration, lifestyle intervention, and efficacy of preventive drug therapy in ethnic 
minorities. Because this population is at high risk, the benefits of appropriate research 
will also be high. 
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CHAPTER 1 
BACKGROUND OF THE PRESENT 
RESEARCH 
('- 
'1 
1.1 INTRODUCTION 
Over the 20"' century, most countries in the world have experienced great transition 
in social structures, economics, politics, education, and home envirorErrient. This 
has resulted in a shift fTom agricultural and rural societies to industrial and urban 
societies in the first 3 quarters of the 20th century, with a further shift in the last 
quarter to infon-nation-based societies. These social and economic transitions have 
I resulted in major changes in population 
demography, industrial structure, income 
levels, expenditure patterns, education levels, family structures, eating habits, and 
physical activity (Yusuf et al., 2001). Along with these changes cardiovascular risk 
factors and disease rates have markedly increased. One in three deaths across the 
world is now due to heart disease and stroke, and this figure is rising rapidly. In 
absolute number this is 17 million deaths a year, six times more than due to 
HIV\AMS related deaths, and this Cardiovascular (CVD) epidemic is not limited 
to industnalised countries (WHF, 2001). CVD is a major contributor to the global 
burden of disease among the non-communicable diseases. Coronary heart disease 
(CHD) is likely to be the most common cause of disability adjusted life years 
(DALYs) loss in 2020 as compared with its fifth position in 1990 (Murray & 
Lopez, 1996). 
In the United Kingdom (UK) diseases of the heart and circulatory system are the 
main cause of death, accounting for over 235,000 deaths in 2000. More than one 
person in three (39%) die from CVD. The main forms of CVD are coronary heart 
disease and stroke. About half of deaths from CVD are from CHD and about a 
quarter are from stroke and the other quarter die from other CVDs such as heart 
failure, rheumatic heart disease, hypertensive disease, and other circulatory system 
disease (BHF, 2006). CHD itself is the most common cause of death in the UK. 
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One in four men and one in six women die from the disease. CHD caused around 
125,000 deaths in the UK in 2000, and was the most common cause of premature 
death in the LJK with just under 45,000 premature deaths. Premature death is a 
death which occurs prior to that which is expected of the person In relation to 
developmental, physiological, psychological, and socio-cultural expectations or 
before the averacre age of death within a given population. Twenty four percent of tn 
premature deaths in men and 141ýo of premature deaths in women were from CHD 
(Petersen & Rayner, 2002). 
South Asian migrants are at increased risk of cardiovascular disease. This 
susceptibility is well demonstrated in places as diverse as the UK, South Africa, 
the Caribbean, Singapore, the United States (US), and Canada. Even within India 
people moving from rural areas to large cities are at increased risk (McKeigue & 
Sevak, 1994). Based on British research there is a virtual consensus that the 
proportionate excess risk of CHD in South Asians, as compared with the 
population of England and Wales, is greater than 40 per cent (McKeigue, 1989; 
McKeigue & Sevak, 1994; Shaukat & de Bono, 1994; Enas et al., 1992). Moreover 
the 1999 Health Survey for England shows Pakistani and Bangladeshi men had 
prevalence rates of CVD about 60% to 70% higher than men in the general 
population, and the picture was similar for women (Erens & Primatesta, 1999; 
Erens et al., 200 1). CVD is the primary cause of mortality among Asian Indians in 
the US. They appear to be at higher risk of heart disease compared with other 
ethnic groups (nearly three times the rate was seen in South Asian physicians 
living in the US compared with the Framingham offspring study) (Ivey et al., 
2002) . 
South Asians, in Canada, had a greater prevalence of cardiovascular 
3 
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disease compared with Canadians of European or Chinese descent; 11%, 5%, and 
2%, respectively, P=0.0004 (Anand et al., 2000). 
The latest estimate of the ethnic minority population in Great Britain from the 2001 
census shows that approximately half was made up of the three groups originating 
fTom the Indian subcontinent - the Indian, Pakistani, and Bangladeshi populations. 
These represent 1,916,000 South Asians of a total 4,039,000 minority population 
(Haskey & Scott, 2001). 
Because cardiovascular disease has become the number one killer worldwide since 
the end of the 20 th century, widespread deployment of affordable preventive 
strategies is essential for both developed and developing countries. However this is 
not possible without exact knowledge of the nature of the disease, its risk factors,, 
and how it may be prevented in the different susceptible populations (Murray & 
Lopez, 1996). Diabetes and insulin resistance, characterised by glucose 
intolerance, raised plasma insulin, increased triglycerides, decreased high density 
lipoprotem (HDL) cholesterol, and central obesity, are more prevalent in UK South 
Asians than European whites. These are proposed as the underlYing factors in high 
rates of coronary heart disease among South Asians worldwide and have been 11-1) 
related to lack of exercise and obesity (Shaukat & de Bono, 1994). 
1.1.1 What are risk factors? 
A risk factor is a characteristic which predisposes the individual to the 
development or progression of a particular disease. Risk factors are defined on the 
basis of epidemiological studies but a distinction must be made between 
characteristics which are simply associated with CHD and those which actually 
cause it. For causation to be established the following criteria must be fulfilled 
(Hennekens & Buring, 1987): 
4 
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e Having a strong, temporal correlation between the existence of the 
characteristic and the incidence of CHD 
0 is correlation must be consistent, dose responsive and predicti Thi Ii ive 
There must be a plausible mechanism of action by which the risk factor can 
exert its influence 
o The association must be reversible and modification of the risk factor 
should alter the incidence of the disease which is a very restricted criterion 
only for modifiable risk factors. 
There are a large number of characteristics which have been identified as risk 
factors for CHD (Wong et al., 1991; Grundy, 1997; O'Connor et al., 1989; Levy et 
al., 1996; Wald & Hackshow 1996; Schwartz et al., 1992). A small number of 
these function are known as independent risk factors, exerting their influence 
independent of the presence of any other risk factor. In contrast, many others are 
secondary risk factors that require the presence of other risk factors to have a 
positive correlation with CHD- In the clinical setting risk factors are divided into 
those which can be modified, either by lifestyle changes or therapeutic 
intervention, and those which are not modifiable, Table 1.1. 
It is important to grasp that CHD risk factors do not generally occur in isolation but 
tend to cluster in an individual (Kannel, 1990). This is significant because when 
risk factors co-exist they tend to interact such that their combined effect is much 
greater than would be expected from the sum of their individual influence. 
Furthermore in the list of non-modifiable CHD risk factors age, as well as having 
its own direct influence, has a major impact on some of the other main risk factors 
(Frost et al., 1996). 
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Table 1.1 Risk factors for coronary heart disease 
Modifiable 
Cigarette smoking Z: ) 
Raised blood pressure, LDL cholesterol, triglyceride 
Low HDL cholesterol 
Diabetes mellitus 
Diet, Obesity, and excessive alcohol consumption 
Lack of exercise 
Poverty 
Non-modiflable 
Age 
Male gender 
Family history of CHD 
Personal history of CHD 
Blood pressure rises with age due to the reduced elasticity of the arterial system. 
The average total cholesterol concentration in older people is higher than in middle I'D 
aged people. In addition, insulin resistance increases with age and the prevalence 
of the metabolic syndrome and diabetes increases (Fink et al., 1983). 
Importantly the influence of risk factors was investigated mainly in the White 
population and there is no certainty that conventional risk factors can be applied in 
different ethnic groups like South Asians. 
1.1.2 Definition of South Asian and Caucasian 
South Asian: 
A person whose ancestry is in the countries of the Indian sub-continent , including 
India, Pakistan, Bangladesh, and Sri Lanka (in terms of racial classi ications, most 
people in this group probably fit best into Caucasian or Caucasoid but this is 
is label is usually assigned, for individuals confusing and is not recommended). Thi 11 
rarely identify with it (Bhopal, 2004). 
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Caucasian: 
An Indo-European. This is Blumenbach's 18th century terin for the white race of 
mankind, which he derived from the people who lived in the Caucasus. This term is 
usually used synonymously with Caucasoid, European, or White. Alone among 
terms derived from traditional racial classification, Caucasian remains popular in 
both science and everyday language (Bhopal, 2004). 
1.1.3 What is "South Asia". 
South Asia is a part of Asia and the ten-n came into use after World War 11 as a 
way of grouping the newly independent countries of the British Indian Empire 
(WWW. Wikipedia. org). South Asia occupies most of the Indian subcontinent. This 
region is commonly taken as including the countries of India, Pakistan, 
Bangladesh, Nepal, Sh Lanka, Bhutan, the Maldives, and Tibet. Afghanistan is 
variably included in Central Asia or South Asia. For the location of these countries, 
view the South Asia Map. 
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Chapter 1 
Just over one fifth of all the people in the world live in this region. India alone has 
a population of just over one billion and is the second most populous country in the 
world after China. Relative to other parts of Asia, South Asia is geographically 
isolated. On the west is the Oman Sea, to the east is the Bay of Bengal and to the 
south is the Indian Ocean which stretches from Africa to Southeast Asia to 
Australia. 
When the British left South Asia, the country then known as India split along 
religious lines. India became mainly Hindu while Pakistan, which had geographic 
halves located on either side of India, became mainly Muslim 
(www. wlkipedia. org). There is a difference between South Asian groups due to 
time since they migrated to the UK. Immigrants fTom India and Pakistan arrived in 
the UK mainly during the 1960s. Bangladeshi people came to Britain with the peak 
phase of migration during the 1980s and most of them come from rural area in 
North East Bangladesh. 
1.1.4 Defining ethnicity 
The concept of ethnicity contains notions of shared ongins, culture and tradition. 
Ethnicity has a dynamic relationship to both the historical and contemporary 
experiences of social groups and is related to the living conditions of individuals 
(Nazroo, 1997). Central to the concept of ethnicity is that it is a reflection of the 
self-definition of individuals with particular cultural traditions. Despite the 
complexity of the concept of ethnicity some research on health and eth-nicity has 
taken a crude approach to the allocation of individuals into ethnic groups. This has 
partly been a consequence of limitations of available data. For example country of 
birth is recorded on death certificates and in national census. As a result most of 
the published papers in this area have allocated ethnicity based on this record of 
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birth country which is inadequate. An approach that acknowledges the role of 
ethnicity in self-perception has been adopted since the 1991 census. It allows 
individuals to assign themselves into an ethnic group. Some investigators assign 
ethnicity according to country of family origin which is highly related to the 
perceived etl-micity (Nazroo, 1997). Senior and Bhopal argue that ethnicity implies 
one or more of three conditions: 
(1). a common language or religious tradition; 
(2) shared origins or social background; and 
(3) shared culture and traditions that are distinctive, maintained between 
generations, and conducive to a sense of identity and group (Senior & Bhopal, 
1994). It suggests that ethnicity, whatever else it may be, is inseparable from Z: ) 
shared social experience or culture and avoids genetic or biological markers as a 
main reason for between ethnic variations. Despite this in many studies ethnicity is 
used as a means of identifying grouping belong to consist of geographically 
relatively homogenous. 
1.1.5 CHD prevalence in South Asians 
Rudat (1994) carried out a general health survey of a national sample of people 
from ethnic minorities mainly those in English inner city. Indians had a lower 
prevalence of self-reported heart disease than Pakistanis and Bangladeshis. A 
different sampling procedure was used for Whites and the results were therefore 
not directly comparable with South Asians. 
Nazroo (1997) measured crude prevalence, and age and gender standardized 
prevalence rate of diagnosed heart attack or angina in a national sample in England 
and Wales. In this study, whereas Indian and AfTican Asian groups combined had a 
lower prevalence ratio for diagnosed angina or heart attack than the white 
9 
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population, Pakistani and Bangladeshis combined had a higher prevalence. 
Adjusted prevalence ratios 
. 
accounting for standard of living were 0.67 in Indian 
and African Asians and 1.24 in Pakistanis and Bangladeshis (Nazroo, 1997). 
Bhopal et al., (1999) and McKeigue et al., (1993) measured CHD prevalence based 
on the data from self-reports and electrocardiogram (ECG) evidence. Although 
there were no differences between South Asians and Europeans in self-reported 
CHD, based on ECG evidence there was a 37% excess of CHD in South Asians 
(Bhopal et al., 1999). South Asians had more ischernic ECG abnon-nalities than 
Europeans (17% versus 12%, P<0.001), with an excess of major Q waves 
(Minnesota codes 1-1 or 1-2) in younger South Asian men (P = 0.01 for the 
age-ethnicity interaction) (McKeigue et al., 1993). Other researchers have shown 
that myocardial infarction develops 5-10 years earlier in South Asians than in other 
populations, and its occurrence in patients under 40 is 5 to 10-fold higher than 
general population (Chambers et al., 1999; 2000; Obeid et al., 1998). 
Williams et al., (1993) reported a higher prevalence rate of CHD in South Asian 
women compared to Whites based on self-reported heart disease and angina 
symptoms (Rose questionnaire) in Glasgow, P<0.05. The differences when data 
from men and women were combined, were however not statistically significant. 
Admission rates with myocardial infarction among the South Asians were twofold 
higher despite being of younger age and less likely to smoke. In addition South 
Asians undergoing coronary artery bypass grafting (CABG) had almost twice the 
mortality of Caucasians (Zindrou -et al., 200 1). 
Similar findings were discovered for South Asian migrants to other Western 
countries. Findings from the SHARE study (Study of Health Assessment and Risk 
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in Ethnic groups) were that South Asians had a higher prevalence of established 
cardiovascular disease than Europeans and Chinese (10.7%, 5.4%, and 2.4% 
respectively, P=0.0004) (Anand et al., 2000). In addition, when the definition of 
cardiovascular disease was expanded to include silent myocardial infarction 
detected by electrocardiogram, South Asians had a greater burden of disease than 
Europeans and Chinese. Despite this finding Canadians of European origin had 
more atherosclerosis (mean of the maximum intimal medial thickness 0.75 
[SD=0.16] mm) than South Asians (0.72 [SD=0.15] mm), P=0.00098 (Anand et 
al., 2000). 
Headline prevalence rates are similar in some urbanised non-migant South Asian 
conununities. Mohan et al. (200 1) reported aprevalence rate of I I% of coronary 
artery disease in native urban South Indian population. Elsewhere rates may be 
lower. Mendis and Ekanayake (1994) investigated prevalence of CHD in the 
Central province of Sri Lanka in a sample of 975 men aged 35-59 years. They 
estimated prevalence rates as 5.4% (95% CI, 40 to 71) and 3.2% (95% CI, 21 to 
46) based on history of coronary heart disease and ECG changes respectively. 
Prevalence data will underestimate incidence when the case fatality rate is high, as 
is the case in the UK (Enas et al., 1996). Therefore the burden of CHD in South 
Asians may be even higher than that reflected by the prevalence data. 
1.1.6 Mortality 
The relative risk of CHD mortality in South Asians is 20-50% higher than Whites 
in Canada, South AfTica, and UK. Studies of cross-sectional design based upon the 
LTK Censuses of 1971,1981, and 1991 have shown various excess in the 
standardised mortality ratio for South Asians. Marmot and colleagues (1984) 
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reported 15% excess deaths due to CHD in both men and women in the 1971 
Census. Analysis of the 1981 Census suggested that the excess was greater, 
varying from 30 to 50% in different ethnic groups (McKeigue & Marmot, 1988; 
Balarajan et al., 1984). Balarajan (1991) compared mortality from cardiovascular 
isease in 1970-1972 with that in 1978-1983. Over this time mortality from 
ischaernic heart disease increased in Indians, 6% in men and 13% in women. In 
contrast from 1971 to 1991 the national average standardised mortality ratios for 
ischaemic heart disease fell by 29% for men and by 17% for women within the 
ethnic minorities. Wild & McKeigue (1997) analysed the 1991 Census data and 
reported that standardised mortality ratios for ischaemic heart disease were highest 
for South Asian men and women compared with the general population. Caribbean 
immigo. Tants showed a steeper decrease (38% for men and 40% for women) of 
morta ity, and South Asian immigrants showed a shallower decline (20% for men 
and 7% for women) than White people. 
Balarajan (1996) and Mckeigue et al. (1991) showed Indian, Bangladeshi, and 
Pakistani people bom on the Indian subcontinent but living in England and Wales 
had a 40- 50% higher mortality from coronary heart disease than the population 
average. The excess risk of CHD in South Asians appears to be greater at younger 
ages. In the UK the relative risk of CHD mortality in South Asian men compared 
with White men is 3.3 between ages 20-29 but only 1.4 overall (Balarajan, 1991). 
This raises the possibility that risk might be greater in second generation 
immigrants. 
Wilkinson et al. (1996) reported that six month mortality after acute MI was 
twofold higher in UK Indian Asians compared to Europeans, despite similar use of 
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thorombolysis, beta-blockers, and aspirin. They attributed this worse outcome to a 
higher prevalence of diabetes. The high mortality from all causes for South Asian 
immigrants could largely be explained by their high mortality from ischaemic heart 
disease. 
1.2 CORONARY HEART DISEASE RISK FACTORS 
These observed differences in morbidity and mortality between South Asians and 
Caucasians could be due to differences in conventional risk factors, due to 
differences in the hazard associated with a given risk factor or due to novel risk 
factors. 
1.2.1 Lipid abnormalities 
Lipid abnorinalities may contribute to the high rate of CHD among South Asians. 
These abnormalities include low levels of high-density lipoprotein cholesterol, 
high levels of low-density lipoprotein (LDL), elevated triglyceride and lipoprotein 
(a) levels. Bohpal et al. reported that South Asian men and women had a lower 
HDL cholesterol concentration compared to Europeans, 95% CI for differences 1.1 
to 2.3 nunol/l and 0.6 to 1.3 mmol/I respectively (Bohpal et al., 1999). 
Bangladeshis had the highest concentration of triglycerides (2.04 mmol/1) and the 
lowest level of HDL cholesterol (0.97 mmol/1). South Asians, of both sexes, were 
more likely to have total cholesterol: HDL cholesterol ratio higher than 5.0 
compared to Europeans, mean difference (A) 12.0% 95% Cl: 6.7% to 17.9% 
(Bhopal et al., 1999). 
Anand et al. (2000) found South Asians living in Canada had the highest total 
cholesterol, LDL cholesterol, and triglyceride concentrations compared with 
Chinese and Europeans although there was no difference in the proportion of 
individuals receiving lipid lowering drug. In a study of 1150 subjects from seven 
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ethnic groups in Singapore, mean lipoprotein (a) levels among Asian Indians were 
double those of all other ethnic groups, with the exception of the Sudanese 
population (Sandholzer et al., 1991). 
1.2.2 High blood pressure 
In a study of Glaswegian men Williams and colleagues found diastolic but not 
systolic blood pressure was higher among South Asians (predominantly Punjabi) 
than the general population, but this was not so for South Asian women (Williams 
ct al., 1993). 
In contrast Bhopal et al. (1999) found hypertension to be less co=on in South 
Asians than Europeans. Within the South Asian community there were no 
significant differences in the prevalence of hypertension between ethnic groups but 
Bangladeshis had, if anything, the lowest. Reported hypertension or blood 
pressure > 160/95 mmHg were 14%, 9%, and 4% in Indians, Pakistanis, and 
Bangladeshis (P = 0.202). In the HSE 1999, mean systolic blood pressure was 
sigmificantly lower in Pakistani and Bangladeshi men after age standardization, 
relative risks of having hypertension compared to the general population were 0.98 
and 0.94 respectively, in contrast to the significantly higher mean in Indian men 
(Erens et al., 2001). 
Anand et al. (2000) reported no significant differences in mean systolic blood 
pressure between South Asians and Europeans in Canada, 118 and 119 mm Hg 
respectively (P = 0.90), although South Asians had higher diastolic blood pressure 
than Europeans, 79 and 73 nun Hg respectively, P=0.006. 
Figure 1.1 shows differences between the mean systolic (P < 0.000 1) and diastolic 
(P < 0.001) blood pressures of those who developed CHD and those who did not 
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developed the disease in the longitudinal epidemiological study of coronary heart 
disease in a rural population of Kheda district, Gujarat, India (Trivedi et al., 1996). 
160.0- 
- --- - --------- -- --- 
140.0- 
z 
zlý 
143.9 
120.0- 
E 
E, 100.0- " 
80 0- , "Z IT 
91.2 
o CHID 
. 
CH A , io Non- D 
1 0- 60.0- ll i 
0 CO 
40.0- " 
20.0- 
0 0 
. Mea n syst olic BP Mean diastolic BP 
Figure 1.1 Mean systolic and diastolic blood pressure in CHD 
and non-CHD patients 
Trivedi et al. (1996) reported a high degree of association between hypertension 
and CHD in an Indian population. As 8.1% of the hypeitensive developed CHD, 
while only 1% of non-notensives and 1.7% of those with borderline blood pressure 
subsequently suffered from CHD. 
1.2.3 Metabolic syndrome 
Insulin resistance, characterised by glucose intolerance, raised plasma insulin, and 
diabetes are more prevalent in UK Indian Asians than European whites (McKeigue 
et al., 1993; Wild & McKeigue, 1997) and may form part of the metabolic 
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syndrome (more details on the metabolic syndrome provided in chapter 2). 
Certainly both diabetes and impaired glucose tolerance are associated with an 
increase risk of CHD. However other populations with a higher prevalence of 
iabetes such as Hispanic-Americans, African-Americans and Native Americans 
do not have higher rates of CHD showing that this cannot be the only explanation ZD 
(Rao & Kakkar, 2001). The prevalence of myocardial infarction is lower in 
Mexican-Amencan men, with or without diabetes, than In the corresponding 
category of non-Hispanic white men, but there is no similar ethnic difference in 
women. Hispanic Americans tended to have a lower prevalence of MI than 
non-Hispanic whites despite their greater prevalence of diabetes (Stem & Mitchell, 
1995). Furthennore in the UK Afro-Caribbean migrants, prevalence of diabetes is 
almost as high as in South Asians but the lipid disturbances characteristic of the 4D 
insulin resistance syndrome do not occur to the same extent (McKeigue, 1996) and 
their mortality and morbidity due to CHD is less than South Asians. Higher insulin 
concentrations can be associated with higher levels of potentially atherogenic and 
diabetogenic metabolic parameters. However, depending on ethnic origin, the mean 
levels of these parameters seems to differ, with the consequence that, even if they 
are elevated with increasing insulin levels, they may not reach values high enough 
to determine a substantial risk of disease. 
The increased likelihood of developing diabetes in middle age in South Asians has 
been described by many authors and this diabetic tendency has been demonstrated 
for different subgroups living in diverse locations. In UK South Asians, diabetes is 
reported to be 3-6 times more common than in the White population (Mather & 
Keen, 1985). Pakistanis and Bangladeshis of both sexes are more than five times as 
likely as the general population to have diabetes, and in Indian men and women 
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this risk is three fold greater. In the Health Survey for England 1999 the observed 
prevalence of diabetes is higher in South Asians than in the general population. 
The age-standardised prevalence of diabetes was 3.3% in the general population 
compared to 10.6,8.7, and 7.7% in Bangladesh,, Pakistan,, and Indian groups 
respectively (Erens & Primatesta, 2001). 
The Study of Health Assessment and Risk in Ethnic groups (Anand et al., 2000) in 
Canada reported that non-diabetic South Asians were more likely to have impaired 
glucose tolerance (a 2-h glucose of 7.8 mmol/l or more and less than 11.1 mmol/1) 
than Chinese and Europeans (19%, 15%, and 12% respectively; overall P=0.03). 
In addition their mean fasting blood glucose concentration (5.47 mmol/L) was 
higher than that in Chinese (5.19 nunol/L) or Europeans (5.13 mmol/L), overall tý 
P=0.000 1. After exclusion of people with diabetes at entry, the prevalence of 
newly diagnosed glucose intolerance (impaired glucose tolerance or new diabetes) 
was 28% (87 of 308) in South Asians v 20% (61 of 302) in Chinese, and 18% (55 
of 305) in Europeans (overall P=0.04) suggesting that incidence is also increased. 
The age standardized prevalence of diabetes is similar in both genders living in 
urban areas in India, 11.9% and 12.5% respectively (Ramachandaran et al., 2001). 
This is less than the prevalence for UK South Asians but more than of Caucasians. 
In addition the prevalence of impaired glucose tolerance is also high in both 
genders (14%). 
1.2.4 Smoking 
Several studies demonstrated a similar or lower prevalence of current smoking 
among South Asians compared to Whites (Trived' et al., 1996; MIller et al., 1988). 
However there is heterogeneity in the rates of current smoking within UK South 
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Asian men according to origin with 50%, 33%, and 20% for Bangladeshis, 
Pakistanis, and Indians respectively (Nazroo, 1997). In another study, Bangladeshi 
men had the highest prevalence of current smoking, at 57%, compared to Indian 
and Pakistanis, P<0.001, but overall South Asians had a similar current smoking 
pattern to that of Whites (Bhopal et al., 1999). In the Health Survey for England 
1999 risk ratios relative to the general population for current self-reported cigarette 
smoking were 1.57,0.90, and 0.78 for Bangladeshi, Pakistani, and Indian men 
respectively (Erens et al., 2001). 
Tobacco use among Asian Indians living in the US appears to be lower than for 
other Asian Americans (Kuo & Porter, 1998). A survey of South Asians in 
Northern California showed only 12% of respondents had ever smoked. (Ivey et 
al., 2002). 
Pals et al reported current smoking of cigarettes or beedis (a local forin of tobacco) 
as the most important predictor of acute MI in Indian men in Bangalore in hidia, 
with odds ratio 3.6,95% CI 2.20 to 3.07 comparing smokers with non-smokers 
(Pais et al., 1996). 
1.2.5 Physical inactivity 
South Asian men were less likely to take vigorous exercise than the general 
population in Glasgow (Williams et al., 1993). In the HSE 1999, there was an 
ethnic gradient in participation in sports and recreational exercise among adults, 
'on, followed by Indian, then with the highest level seen in the general populati I 
Pakistani and finally Bangladeshi men and women (Erens et al., 2001). In a sample 
01 ians were the most physically active South of the Newcastle Heart Pr *ect Ind' I 
Asians and Bangladeshis the least, 29.2% and 13.2% having weekly aerobic 
activity (a 30 minutes episode of at least moderate activity on most days of the 
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week) respectively. Moreover South Asians did less than half the physical activity 
done by European, 30% and 19% less in South Asian men and women respectively 
(Haynes et al., 2002). This probably reflects the original rural lifestyle of South 
Asians in general rather than being specific to migrants. Fischbacher et al. (2004) 
carried out a systematic literature review of studies describing levels of physical 
activity and fitness in UK South Asians. All studies reported substantial lower 
levels of physical activity and fitness in Indian, Pakistani, and Bangladeshi ethnic 
groups compared to the general population or those defined as White or Europeans 
in the UK (Fischbacher et al., 2004). In Gupta's study of Indian men in India,, 83% 
of them had no leisure-time physical activity (Gupta & Sharma, 1994). 
1.2.6 Alcohol consumption 
Williams et al. (1993) demonstrated that alcohol use was uncommon in women 
and also in people practicing Islam among South Asians. Results of the Fourth 
National Survey of Ethnic Minorities showed very few of the almost entirely 
Muslim Pakistani and Bangladeshi respondents ever drank alcohol, whilst one in 
five Indians were regular drinkers (Nazroo, 1997). Another study showed that 17% 1 
of Indian men drank alcohol (Gupta & Sharma, 1994). Pals et al. (1996) reported 
more Indians with a first MI (44%) consumed alcohol than healthy Indians (3 1 
But this probably reflected the confounding effect of smoking as after adjustment 
for the effect of smoking, alcohol was no longer a risk factor (P = 0.22). 
1.2.7 Diet 
There is a dietary diversity amongst the UK South Asians ranging from strict 
vegetarian to meat and fish containing diets. South Asians ate meat, fruit,, salad and 
vegetables more frequently than the general population in Glasgow (Williams et 
al., 1993). Dietary patterns of South Asians in urban Glasgow show that traditional 
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South Asian rural diets are augmented with the high fat and hjigh sugar foods of the 
majority culture, including crisps, confectionery and sweetened carbonated 
beverages (Anderson & Lean, 1995). Pais et al. (1996) classified individuals in a 
case-control study as being vegetarian or non-vegetarian. Vegetarianism appeared 
to have a protective effect against coronary heart disease (OR 0.55,95% Cl 0.35- 
0.85; P=0.006), which remained significant after adjusting for smoking, blood 
glucose, HDL and LDL cholesterol, and triglycerides. However in the Gupta study, 
25% and 35% of Indian men ate non-vegetarian and high fat diets respectively 
(Gupta & Shan-na, 1994). 
It is important to notice that dietary habits of second generation UK South Asians 
are changing to become more similar to those of the general UK population 
(Landman & Cruickshank, 2001). 
1.2.8 Socio-econornic situation 
Socio-economic status vanes between the South Asian communities. The 
Newcastle upon Tyne study showed Indians were most and Bangladeshis least 
educated (Bhopal et al., 1999). Indians were most likely to be in social classes 1, R, 
and IR (70%) and Bangladeshis least (26%). Europeans and Indians had the 
highest median income and Bangladeshis the lowest. Indians were socio- 
economically advantaged compared with Pakistanis and Bangladeshis, based on 
the Townsend deprivation score derived from 1991 census data (Bhopal et al., 
2002). 
However, an analysis by Mannot and colleagues based on the 1971 Census 
reported no relation between social class and coronary mortality in immigrants 
from the Indian subcontinent (Man-not et al., 1984). McKeigue & Marmot (1988) 
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demonstrated that both relatively poor Bangladeshis, and more affluent Indians , in 
London were at similarly high risk of coronary mortality. In contrast Nazroo 
(1997) reported that self-reported CHD in South Asians, in a national 
cross-sectional survey in 1993-1994, was associated inversely with standard of 
living as measured by social class (according to the Registrar General's criteria), 
unemployment, and living in poor housing. 
1.2.9 Other biological factors 
While lipids and lipoprotein (a) in particular, appear to be specific risk factors 
among South Asians, other recent research has focused on abnormalities of 
vascular endothelial function among even healthy South Asian men and elevated 
serum homocysteme, among other metabolic abnormalities. In the studies of 
Chambers et al. (1999; 2000) and Obeid et al. (1998) homocysteine concentrations 
were higher in UK South Asians than European Whites. They also confirmed that 
homocysteme is a risk factor for CHD in South Asians. From these data it was 
possible to estimate that an elevated homocysteine concentration may contribute 
twice as many CHD deaths in LTK South Asians as in Europeans (Chambers et al., 
1999; 2000). 
The SHARE study in Canada demonstrated that South Asians' excess 
cardiovascular disease prevalence may be partially attributable to elevated levels of 
plasminogen activator inhibitor-I (PAI-I) in addition to elevated lipoprotein (a) 
(Anands et al., 2000). Also, a study in the UK found that elevated levels of 
C-reactive protein (CRP) were associated with risk factors for cardiovascular 
disease in Indian Asian men compared to Europeans (Chambers et al., 2000). 
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1.2.10 CHD and CVD risk prediction tools for South Asians 
In people with no history of CVD estimating the absolute risk of vascular event, 
mainly using the Framingham equation, is a strategy for primary prevention that 
provides an opportunity for taking appropriate action according to the level of risk 
(more details can be found at the introduction of chapter 3 of this thesis). The 
performance of the Framingham risk scores vanes considerably between 
populations and evidence supporting the use of cardiovascular risk scores for 
primary prevention is scarce (Brindle et al., 2006a) however this risk estimation 
and consequent prevention strategies are better than doing nothing. At the time of 
collectincr background information there was no evidence for suggesting proper L) 
CHD or CVD risk estimation in South Asian group however two studies were 
found in updating attempt of the literature review. Cappuccio et al. (2002) 
suggested that primary care doctors should use a lower threshold of CHD risk 
when treating mild uncomplicated hypertension in South Asians. Brindle et al. 
(2006b) recalibrated the Framingham risk score and produced a web-based tool for 
estimating the I 0-year risk of CHD and CVD in the UK south Asians as well as six 
other ethnic minorities. 
1.3 CONCLUSION 
Although the increased prevalence of the classical risk factor of diabetes may 
explain some of the increased cardiovascular disease in South Asians it is not clear 
whether novel risk factors or even ethnicity itself might contribute to the difference 
in risk. It is tempting to attribute increased CVD risk in South Asians to differences 
in a single established risk factor e. g. diabetes. However other metabolic 
differences have been demonstrated although the importance of these is as yet 
unknown. 
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1.4 AIMS OF THIS THESIS 
The purpose of this thesis was to study several aspects of CHD in the UK South 
Asians. The problems were approached fTom the epidemiological and clinical 
angles. 
The aims of the study were; 
1. To explore qualitative and quantitative differences in the impact of 
established risk factors for CHD between South Asians and Caucasians in 
order to identify and quantify any additional independent "ethnic" risk 
factor. 
2. To compare the level of dysglycaemia in non-diabetic South Asians and 
Caucasians in the UK population. 
3. To develop a practical risk estimator tool for the South Asians. 
4. To identify a method for adjusting the input to Framingham equations for 
use in South Asian individuals to accommodate their greater risk of CHD 
and apply this to the simple practical paper based tools. 
5. To determine the prevalence of subjects eligible for primary and secondary 
prevention of CHD among the British South Asian population and to 
compare that with British Caucasians. 
6. To explore the relationship between ethnicity and individual attitude to 
prescribed primary prevention drug. 
7. To investigate prevalence, treatment, and control of hypertension in the UK 
South Asians using Health Survey for England 1998 and 1999 data. 
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CORONARY RISK IN SOUTH ASIANS: 
ROLE OF DYSGLYCAEMIA 
11 Role of dysglycaemia 
2.1 INTRODUCTION 
A multitude of risk factors has been implicated in the development of coronary 
heart disease (CHD) (Tunstall-Pedoe et al., 1997). The conventional risk factors 
are associated with the risk of coronary heart disease in South Asians but may not 
fully explain the excess burden of CHD in this group. Although believed at higher 
risk of CHD, surprisingly, South Asians have a lower prevalence of hypertension, 
hypercholesterolernia, obesity, and smoking when compared to Caucasians and 
additional risk factors may well be responsible. However, there is marked 
heterogeneity between groups within the South Asian population in terms of 
prevalence of risk factors, e. g. Bangladeshi smoke a lot and Indian smoke less 
(Erens et al., 2001). Factors proposed to explain the higher CHD risk in South 
Asians include diabetes, raised plasma insulin, increased triglycerides, decreased 
high-density lipoprotein (HDL) cholesterol, and central obesity, all of which are 
more prevalent in UK South Asians. However it is not clear whether even these 
differences explain all of the increased risk of CHD in South Asians, an issue of 
some importance when attempting to predict CHD risk in individuals (Shaukat & 
de Bono, 1994). South Asians commonly develop the insulin resistance syndrome 
(metabolic syndrome) if they experience only moderate weight gain (Chandalia et 
al., 1999). The metabolic syndrome described by Reaven and other researchers 
(Reaven & Chen, 1988; Reaven & Laws 1994; Garvey & Hen-nayer 1998; Gaudet 
et al., 1998; Haffner et al., 1999; Meigs et al., 2000; Misra et al., 1999) provides a 
pathophysiologic framework for investigating the increased cardiovascular. risk and 
subsequent development of clinical events related to atherosclerosis. Although the 
components of the metabolic syndrome as originally described included obesity, 
hypertension, dyslipidemia, impaired glucose tolerance, and diabetes mellitus, it 
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has been assumed that insulin resistance is the central pathogenic basis for the 
syndrome, with hyperinsulinemia frequently used as its marker. The Adult 
Treatment Panel (ATP) III of the National Cholesterol Education Program (NCEP) 
recently proposed a definition for metabolic syndrome to aid identification of 
individuals at increased risk of both CHD and type 2 diabetes (NCEP-1111,2001). 
The definition incorporates thresholds for 5 easily measured variables linked to 
insulin resistance: waist circumference, plasma concentration of triglycendes, HDL 
cholesterol, fasting glucose, and blood pressure. The World Health Organization 
(WHO) definition (VMO, 1999) and the European Group for the Study of Insulin 
Resistance require glucose intolerance or insulin resistance as an essential 
component. Both VMO and NCEP definitions of the metabolic syndrome include 
widely accepted clusterings of risk factors for CVD, but neither of them recognises 
that the nature and contribution of each component may vary across ethnic groups. 
The metabolic syndrome is a precursor of diabetes and a common pathogenic 
mechanism for the development of CHD (Stem, 1995; Wilson et al., 1999). Insulin 
resistance generally nses with increasing body fat content, yet a broad range of 
insulin sensitivities exists at any given level of body fat. Most people with 
categoncal obesity (body mass index [BMI] ý! 30 k g/M2 ) have postprandial 
hypennsulinemia and relatively low insulin sensitivity (Bogardus et al., 1985), but 
variation in insulin sensitivities exists even within this population (Abbasi et al., 
2002). Overweight people (BM1 25 to 29.9 kg /M2) likewise exhibit a spectrum of 
insulin sensitivities, suggesting an inherited component to insulin resistance. South 
Asians tend to have more visceral adipose tissue, despite having low BMI (Banerji 
et al., 1999; Chandalia et al., 1999) and this may contribute to their high 
prevalence of insulin resistance, type 2 diabetes, and premature cardiovascular 
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disease (CVD). They have higher upper-body adiposity and higher visceral fat for 
a given BMI when compared with the Western population (Baneiji et al., 1999). A 
similar picture is also seen in Australian aboriginals, who have an epidemic 
proportion of glucose intolerance and have BMI values much lower than the 
obesity limits suggested by Western standards (Daniel et al., 2002). South Asians 
and others who manifest insulin resistance when only mild-to -moderately 
overweight can be said to have primary insulin resistance. Even with primary 
insulin resistance, however, weight gain seems to enhance insulin resistance and 
metabolic syndrome (Grundy et al., 2004). Thus, dissociation of obesity and 
primary insulin resistance as causes for the metabolic syndrome is difficult. This 
propensity for insulin resistance is seen particularly in South Asians who have 
migrated to other regions or who have moved into urban settings and become 
relatively affluent in their own countries. However, the prevalence of the metabolic 
syndrome and particularly diabetes is rising very rapidly even within the Indian 
subcontinent (Ramachandaran et al., 1997). Tillin et al. analysed the datasets from 
the Brent and Southall studies and reported a significant association between the 
metabolic syndrome and prevalent CHD in South Asian men [NCEP definition, 
OR=2.1, (95% Cl 1.5 to 3.1); WHO definition, OR=1.6 (95% Cl 1.1 to 2.3)] (Tillin 
et al., 2005). 
Coronary risk prediction has evolved as a method of helping clinicians prioritize 
preventive measures in patients who do not yet have overt cardiovascular disease. 
The Framingham risk equation (Anderson et al., 199 1) and the clinical decision 
rules that have been derived from it are the mainstay of treatment decisions for 
CHD primary prevention. Some reviews also suggest that patients at low risk gain 
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nothing or may even be harmed by intervention. Risk assessment is essential to 
ensure that such patients are not exposed to unnecessary drug treatment. 
There are three steps in the development of a clinical decision rule: deriving the 
rule, testing the rule, and assessing the impact of the rule on clinical behaviour 
(McGinn et al., 2000). No studies have attempted to identify the common factors 
or characteristics that contribute to CVD in South Asians by following its 
development over a long period of time in a large number of participants who had 
not yet developed overt symptoms of CVD or suffered a heart attack or stroke. 
Consequently it is not possible to derive a primary rule, to test it or assess its 
impact in this ethnic group. Nor have there been studies investigating the valld, ty 
of any Framingham-based risk or other established equation in South Asians. As a Z-: ) 
result current prediction models, that do not take into account the effect of 
ethnicity, will probably provide inaccurate risk estimation in South Asian people 
and hinder estimation of their prevention needs. An alternative way of dealing with 
this type of problem is to use an adjustment factor for the current prediction 
equations. Such an adjustment factor could be derived fTom longitudinal studies 
studying both South Asians and Caucasians recording risk factors and 
cardiovascular outcome measurements. This would allow estimation of a 
differential factor associated with ethnicity (South Asian) independent of currently 
used risk factors. 
2.2 AIM AND OBJECTIVES 
To explore qualitative and quantitative differences in the impact of established risk 
factors for CHD between South Asians and Caucasians in order to identify and 
'c" risk factor. My pri quantitative any additional independent "ethm I incipa aim was 
to develop a practical risk estimator tool for the South Asians. When it became 
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evident that dysglycaemia might explain part of the higher risk in South Asians I 
also compared the level of dysglycaemia in non-diabetic, South Asians and 
Caucasians in the UK population in order to explore a possible readily identifiable 
pathophysiologycal mechanism behind any such difference. 
2.3 METHODS 
2.3.1 Methods of review 
Using the Centre for Review and Dissemination guidance (CRD, Report 4,2001) a 
search was performed for published papers up to March 2002 in MEDLINE, 
EMBASE, and citations from references. All longitudinal studies identifying both 
CHD and CVD events and putative risk factors in South Asian (Indian, Pakistani, 
I 
and Bangladeshi) adults were sought. Inclusion and exclusion criteria for this 1.0 
search can be found in Table 2.1. 
Table 2.1 Inclusion and exclusion criteria for searching longitudinal studies in 
South Asians 
Selection criteria Inclusion Exclusion 
Population ("South Asian" or Indian or Pakistani or 
Bangladeshis) 
Intervention ("Coronary heart disease" or CHD or 
/Diagnosis (CVD or "cardiovascular disease") and 
"risk factor" 
Outcomes CHID or CVD Mortality or Morbidity 
Comparisons with Caucasian or non-migrant South 
Asians 
Study designs ("Cohort study" or "prospective study" or 
"longitudinal study" or "randomized 
clinical trial") 
Publication year From 1966 - 2002 
Language English 
Others 
Novel risk factors 
Other studies 
(e. g. qualitative) 
Before 1966 
Other language 
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The search of the MEDLINE and EMBASE led to 108 and 15 references. After 
rea ing of all abstracts, one cohort study (Heng et al., 2000; Lee et al., 2001) and 
four prospective population surveys (Khattar et al, 2000; Miller et al., 1990; 
Trivedi et al., 1996) were the only longitudinal studies identified. 
2.4 RESULTS OF REVIEW 
2.4.1 Prospective surveys 
Trivedi et al. (1996) studied a cohort of 714 (429 male) participants in a rural 
population of Kheda district in Gujarat, India from 1987- 1992. A sample of 1460 
was selected by the process of stratified random sampling from the voters' list aged 
32-62 years. 549 (76.1%) of the subjects came from this sampling strategy and the 
other 172 (23.9%) were volunteers who were included after contacting local 
leaders. All subjects were examined in a clinic set up at a local hospital. The 
overall five-year incidence of CHD (myocardial infarction, angina pectons, and 
sudden death) was 25.2 per thousand (95% CI: 15.0 to 39.1). Trends relating CHD 
incidence to family history, HDL cholesterol, and total cholesterol were in the 
expected direction but failed to reach statistical significance. The rate of CHD in 
men was about three times higher than in women. The systolic blood pressure in 
those who developed CHD was higher than in those who did not, mean difference 
19.6 mmHg (95% Cl: 18.3 to 20.0, P<0.001). Hypertensives were 4.2 times more 
likely to develop CHD compared with people who had normal blood pressure. 
Rates of CHD were also higher in diabetics and smokers but again differences 
were not statistically significant. However, in what appears to be a post hoc 
subdivision according to the number of cigarettes smoked per day, the incidence of 
CHD among males smoking > 10 cigarettes was significantly higher than either 
non-smokers or smokers of -< 10 cigarettes (P = 0.002) (Trivedi et al., 1996). 
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Statistical analysis in this study was limited by its relatively small size and the low 
incidence of CHD. People in the lower socioeconomic strata were less likely to be 
included in this study. Volunteers formed almost a quarter of the sample which is a 
possible additional source of bias. 
Miller et al. (1990) investigated the association between fasting serum lipoprotein 
concentrations and CHD in a population cohort including different ethnic groups in 
Trinidad. 960 men (321 Indian) aged 35 to 69 years and free of CHD between 1977 
and 1986 were studied. Ethnicity was determined by grand parental origins. 
Indians had a higher rate of coronary events than Africans and men of mixed 
descent; RR=2.2 (95% CI: 1.3 to 3.6). The authors reported a curvilinear relation 
between HDL cholesterol concentration and age adjusted CHD risk with a 30% 
reduction in CHD per standard deviation increase in logio HDL cholesterol 
(P = 0.003). Adjusted for other coronary risk factors the standardized hazard ratio 
for logio HDL cholesterol was 0.73 (P = 0.025) with no difference between ethnic 
groups (Beckles et al., 1986). 
Khattar et al. (2000) reported an observational study of 688 hypertensive patients 
(106 South Asian) in England with a mean follow up of 9.2 years (Khattar et al., 
2000). All participants were originally referred for the management of 
hypertension based on a persistently raised clinic blood pressure. Patients with a 
secondary cause of hypertension were excluded. The prevalence of previous 
CVD 
at 7% was similar in both ethnic groups. The South Asians studied were on average 
younger, had significantly lower values of total cholesterol, and had the 
lowest 24 
hour mean, daytime mean,, and night time mean ambulatory systolic blood 
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pressures. Despite the lower prevalence of most classical risk factors South Asians 
suffered more than twice the coronary events than Caucasians, 2.86 v 1.32 events 
per 100 patient-years respectively, P=0.002. South Asians had higher all 
cardiovascular event rates of 3.5 events/100 patients-years compared with 2.5 
events/100 patients-years for Caucasians. This was only partially explained by 
their higher prevalence of diabetes (17% v 6%) even when adjusted for other risk 
factors. The estimated hazard ratio for the differences in race (South Asian: 
Caucasian) as predictor of time to a first cardiovascular event was RR=1.79,95% 
CI: 1.16 to 3.66 (P = 0.008) (Khattar et al., 2000). This study is limited by the 
retrospective collection of drug therapy inforination and lack of follow-up blood 
pressure data and may therefore have missed important differences in risk factor 
control during follow up. In addition as the study included both diabetic and non- 
diabetic patients it provides only a contaminated estimate of any ethnic factor in 
non-diabetic men. 
The UK Prospective Diabetes Study (UYPDS) was a randomised controlled trial 
which showed that both intensive treatment of blood glucose and of blood pressure 
lowers the risk of diabetes-related complications in individuals newly diagnosed 
with Type 2 diabetes (Stevens et al., 2001). The 4520 patients studied from 23 
participating U-KPDS hospitals included 432 Asian Indians. All patients aged 
25-65 years had no recent history of myocardial infarction, angina or heart failure. 
The investigators fitted a model of the influence of baseline risk factors on the 
using 29878 person-years of incidence of subsequent coronary heart di I 
follow-up data. Significant factors in the final model were age, sex, ethnicity 
(Afro-Caribbean or not), smoking, HbAlc, systolic blood pressure, and total 
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cholesterol: HDL cholesterol ratio. A factor distinguishing Asian Indians from 
Caucasians was tested during model building but was not found to be significant, 
with a relative risk of CHD in Type 11 diabetes in Asian-Indians of 0.99 compared 
to Caucasians, with 95% confidence interval 0.66 to 1.32, P>0.5 (personal 
communication & Stevens et al., 2001). 
2.4.2 Retrospective studies 
The Singapore Cardiovascular Cohort Study linked individual risk factor 
information collected in thxee previous cross-sectional surveys to first CHD events 
identified from national registry databases (Heng et al., 2000; Lee et al., 2001). 
Record linkage with these registers was made possible by use of the National 
Registration Identity Card number which is a unique national registration 
identification number issued to all Singaporeans. The 2879 males (481 Indian) 
were followed for an average of 8.9 years. Indians had the highest incidence of 
ischemic heart disease; 10.6 per 1000 person-years (95% Cl: 7.8 to 14.5) and 3.7 
per 1000 person-years (95% CI: 2.3 to 6.2) in males and females respectively. 
Compared with Chinese and Malays Indian males had overall- adjusted hazard 
ratios for CHD of 3.1 (95% CI: 2.0 to 4.8) and 3.4 (95% CI: 1.9 to 3.3) 
respectively (Lee at al., 2001). The numbers studied were insufficient to allow 
assessment of possible interaction between ethnic and independent risk factors. In a 
global univariate analysis adjusted only for age and ethnic group HDL cholesterol, 
triglyceride, BMI, hypertension and diabetes were associated with CHD whereas in 
a multivariate analysis only ethnic group, diagnosis of diabetes and hypertension 
remained significant (Table 2.2). As registry data were used to identify events 
issues of accuracy and completeness of the dataset for interpreting these findings 
are crucial. 
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Table 2.2 Predictors of coronary heart disease in South Asians 
Study Significant predictors of CHD in multivariate 
analysis 
Singapore cardiovascular 
cohort Study 
(Heng et al., 2000) 
Observational follow up in 
hypertensive patients 
(Khattar et al., 2000) 
Prospective population 
survey in Trinidad 
(Miller et al., 1990) 
Trivedi et al study 
(Trivedi et al., 1996) 
Ethnic group, Diagnosis of Diabetes and Hypertension 
Ethnic groups, Diabetes Mellitus, Age, Sex, Previous 
History of cardiovascular disease, 24 Hour mean systolic 
blood pressure 
Log1O HDL Cholesterol (other risk factors not 
investigated) 
Hypertension * 
* Univariate analysis 
2.4.3 Understanding differences between study results 
Despite the almost universal belief that South Asians are at higher risk of CHD 
only the studies of Khattar and colleagues (Khattar et al., 2000) and the UKPDS 
gTOUP (Stevens et al., 2001) investigated the role of ethnicity in risk independent of 
other risk factors. Even these two studies produced apparently discrepant results, 
only Khattar's suggesting a higher risk in South Asians when other risk factors had 
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been taken into account. This apparent contradiction might be explained by the 
populations studied. Khattar included mainly non-diabetic hypertensives whilst 
UKPDS investigated the management of patients with Type 11 diabetes. 
Exploration of whether this might explain the different results is warranted. 
2.5 DYSGLYCAEMIA AND CARDIOVASCULAR DISEASE 
The relation between blood glucose concentration and adverse clinical outcomes is 
still hotly debated especially whether any relationship is stepped or continuous. For 
microvascular complications, there appears to be a threshold in fasting glucose (6.1 
nunol. /I [110 mg/100]), post challenge glucose (11.1mmol/I [200 mg/100]), and 
HIbAIc (7%) (Dagogo-Jack, 1995; Krolewski et al., 1995; Warram et al., 2000; 
Ohkubo et al., 1995; Tanaka et al., 1998; Shaw et al., 1999) below which those are 
rarely seen. In contrast, a review and meta-regression analysis of 20 prospective 
studies, mainly in male Caucasians, concluded that the relation between glucose 
concentrations and cardiovascular disease is continuous and extends below the 
threshold for the diaposis of diabetes (Coutinho et al., 1999). Bjomholt & 
colleagues (1999) demonstrated that the highest quartile of non diabetic men 
ranked according to fasting glucose (> 4.8 mmol/I [86.5 mg/100]) had a 
significantly higher cardiovascular mortality at 22 years than those in the three 
lowest quartiles. The relative risk remained significant after adjustment for other 
risk factors, 1.4 (95% Cl 1.0 to 1.8). 
2.5.1 HbAl c and cardiovascular events in non-diabetics 
in adults about 98% of the haemoglobin in the red blood cell (RBC) is 
haemoglobin A. About 7% of it consists of a type of haemoglobin (HbAl) that can 
combine strongly with glucose in a process called glycosylation. Once It occurs, It 
is not easily reversible. MAI is actually made up of three components 
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(haern'oglobin Ala, Alb, and Alc- HbAlc is the component that most strongly 
combines glucose and makes up about 70% of MAI. Blood glucose levels are a 
i ma . or detem-linant of HbAlc levels. Population studies in patients with diabetes 
have shown that HbA Ic is highly correlated with preceding long term mean blood 
glucose (Koenig et al., 1976; Svendsen et al., 1982; DCCT, 1987). The amount of 
glycohaernoglobin depends on the amount of gloucose available in the bloodstream 
over the RBCs' 120-day lifespan. Therefore deten-nination of its value reflects the 
average blood sugar level for the 100 to 120 day period before the test. HbAlc is 
of course an indirect measure of long-term glycaemia. In diabetic patients HbAlc 
may not accurately reflect diabetic control in situations in which red blood cell 
lifespan is reduced (Reynolds et al., 2006). Whether this applies to non-diabetic 
populations remains unknown. 
Two prospective studies in Caucasians investigated the relationship between 
HbAlc and future cardiovascular disease in non-diabetic subjects (Khaw et al., 
2001; Park et al., 1996). In the Norfolk cohort (Khaw et al., 2001), the effect of the 
HbAlc concentration on mortality was evident even at the lower end of the 
population distribution, and there was no apparent threshold effect: men with 
HbAlc concentrations above 5% had greater risk than the group with 
1111YIDAIc < 5%. In this regard, glycated haemoglobin appears to resemble blood 
pressure and blood cholesterol concentration demonstrating a continuous relation 
with cardiovascular risk. A one percent increase in HbAlc is associated with a 
28%, (P < 0.002) increase in risk of death independent of age, blood pressure, 
serum cholesterol, body mass index, and smoking habits. This remained significant 
(relative risk 1.46, P=0.05) after excluding men with known diabetes or a HbAlc 
concentration z-2! 7% (Khaw et al., 2001) who could possibly have undiagnosed 
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diabetes. Park et al. (1996) reported that glycated haemoglobin, but not FBG or 
post-challenge plasma glucose, was significantly related to CVD and CHD 
mortality in women but not men. The age-adjusted relative hazard for those in the 
highest quintile of glycated haemoglobin (ýý! 6.7%) compared with women in the 
lower levels was 2.4 for fatal CVD (95% CI 1.3 to 4.3, P=0.005) and 2.4 for CHD 
(1.1 to 5.3, P=0.024) (Park et al., 1996). 
Fasting blood glucose and HbAlc measuring different things; FBG measures blood 
glucose after fasting for 8 hours whereas HbAlc measures cumulative post-food 
sugars in blood. HbAlc is related to the development of microvascular disease 
(UKPDS-33,1998; DCCG, 1993) in diabetes although there is evidence that it also 
associated,, controversially, with macrovascular disease (Selvin et al., 2004). For 
CHD patients with nonnal glucose tolerance and different extends of 
atherosclerotic disease, postload glycaemia and HbAlc level are not equally 
distributed but are significantly higher with cardiovascular risk according to a 
linear model (Sasso et al., 2004). However HbAlc level were associated with an 
increased risk of cardiovascular mortality in CHD patients without diabetes (De 
Vegt et al., 1999). 
2.5.2 South Asians and dysglycaemia 
Marked abnormalities of glucose metabolism are particularly common in South 
Asians with high rates of both impaired glucose tolerance and diabetes. Whilst 
these conditions are accepted as strong risk factors for CHD it is becoming 
increasingly evident that disturbances of glucose metabolism short of that needed 
for definition of glucose intolerance may also be associated with an increased risk. 
in 1991 McKeigue et al. (1991) reported the existence of an insulin resistance 
syndrome more prevalent in UK South Asians compared with Caucasians that was 
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characterized by higher concentrations of fasting insulin and an increased waist-hip 
ratio. The insulin resistance syndrome is a precursor of diabetes and may be a 
common pathogenic mechanism for developing coronary artery disease (Wilson et 
al. , 1999). This syndrome consists of hyperinsulinemia, atherogenic dyslipidemia, 
glucose intolerance, a prothrombotic state, central obesity, and hypertension. 
In the Canadian Study of Health Assessment and Risk in Ethnic goups (SHARE) 
(Anand et al., 2000) South Asians were more likely to have diabetes than Chinese 
and European (overall P=0.03), were more frequently diagnosed as having 
impaired glucose tolerance (overall P=0.03), and had higher mean fasting blood 
glucose (overall P=0.0001). In a case-control study of patients with a first MI 
(Gerstein et al., 1999), South Asians were more likely to have impaired fasting 
glucose (OR 3.2; 95% CI 1.5 to 6.9), impaired glucose tolerance (OR 4.1; 95% CI 
2.3 to 7.2), or diabetes (OR 5.5; 95% CI 3.3 to 9.0) than controls. Even after 
excluding participants with diabetes, patients with impaired glucose tolerance, and 
impaired fasting glucose South Asians were still more likely to have an fasting 
blood glucose (FBG) in the third (5.2 to 6.3mmol/1) and fourth quartile (>6.3 
mmol/L), OR 6 (95% Cl 3.3 to 10.9) and OR 3.4 (95% Cl 1.9 to 5.8). These odds 
ratios were independent of lipid concentrations, smoking, abdominal obesity, and 
insulin concentrations. This study showed glucose elevation above a relatively low 
concentration appears to be a continuous risk factor for cardiovascular disease in 
South Asians. It is possible, however, that some undiagnosed diabetics were 
included in this analysis. The results suggest that glucose elevation short of 
diabetes is an independent marker for atherosclerosis in South Asians as well as in 
Caucasians. 
38 
Role of dysgiycaemiaa 
2.5.3 Methods of Comparison of dysglycaemia in South Asians and Caucasians 
Data from the Health Survey for England 1999 (HSE 1999) was used to study 
ethnic differences in blood glucose and HbA Ic concentrations. 
2.5.3.1 The Health Survey for England series 
The Health Survey for England (HSE) comprises a series of annual surveys 
beginning in 1991. The series is part of an overall programme of surveys 
commissioned by the UK Department of Health and designed to provide regular 
information on various aspects of the nation's health. All surveys have covered the 
adult population aged 16 and over living in private households in England and 
Wales. The sampling frame for the HSE ensures the group is nationally 
representative of people of different ages, sex, geographic area and socio- 
demographic circumstances. Each eligible person was interviewed face to face. 
They were also visited by a nurse who made a number of simple clinical 
measurements and obtained a sample of blood. 
In 1999 in order to increase the number of infon-nants from the six most populous 
minority ethnic groups: Black Caribbean, Indian, Pakistani, Bangladeshi, Chinese 
and Irish the design included a 'boost' component, designed solely to yield 
additional interviews with these groups. Cardiovascular diseases were included as 
a special topic for adults. At least 71% of eligible boost sample households adults 
were interviewed, 47-63% of South Asians had their blood pressure measured, and 
33-54% agreed to give a blood sample. 
From the HSE 1999 dataset, Caucasians and South Asians aged 35-69 years with 
no history of myocardial infarction (MI), angina, stroke, diabetes or taking lipid 
lowering drugs, and with fasting blood glucose :! Eý7.77mrnol/l (140 mg/100) were 
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identified (Table 2.3). Values of FBG and glycosylated haernoglobin were 
compared between Caucasians and South Asians. 
Table 2.3 Selection of subjects from HSE 1999 for investigating 
dysglycaemia by ethnicity 
Caucasian South Asian 
Aged 35-69 years 753 1678 
History of CVD (MI, angina, or stroke) 38 119 
Diabetes or FBG ý!! 7.77 mmol/I 22 193 
HbAlc not measured (missing) 268 831 
Remained number for analysis 425 535 
2.5.3.2 Statistical analysis 
Statistical analysis was performed using SPSS version 11.2. Fasting blood glucose 
and glycosylated haemoolobin avera es were used for analysis. The I'D 91 
students t-test was used to compare South Asian and Caucasian groups where 
necessary. Adjusted means were derived and compared using analysis of 
covariance model. Spearman correlation coefficient was used to assess associations 
between FBG and glycosylated haemoglobin in each ethriic group. The Fisher's 
z-score transformation was employed to compute the significance of the difference 
between two correlations in South Asians and Caucasians (Blalock, 1972). Each 
correlation coefficient was transformed into a z-score by dividing the correlation 
plus 1, by the same correlation minus 1. Then the natural log of the absolute value 
of the result divided by 2. The difference between the two z-scores was divided by 
the standard error of difference between the two correlations (SE=SQRT[(I/(nl-3) 
(1/(n2-3)]. 
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For all tests, the alpha level for statistical significance was 0.05. 
2.5.4 Comparison of dysglycaemia in South Asians and Caucasians in HSE 1999 
Table 2.4 shows baseline charactenstics of Caucasians and South Asians included 
in the analysis. Caucasians were older than South Asians (6.1 year; 95% CI 4.3 to 
7.2), had higher mean systolic blood pressure (mean difference [A] 4.0 mm. /Hg; 
95% CI 1.6 to 6.5), total and HDL cholesterol (A 0.3 mmol/l; 95% CI 0.2 to 0.4) 
and (A 0.2 mmol/l; 95% CI 0.1 to 0.3) respectively. Caucasians were more than 
twice as likely to smoke than South Asians, P<0.0001 . 
Other than diastolic blood 
pressure, the differences in coronary risk factors between South Asians and 
Caucasians were all statistically significant. 
HabuAlc levels ranged from 4.3 to 7.7% in South Asians and 4.5 to 6.7% in 
Caucasians. HbAlc level correlated with FBG in both Caucasians and South 
Asians, Spearman r=0.28 (P < 0.001) and Spearman r=0.36 (P < 0.001) 
respectively. The difference in the correlations between two groups was not 
statistically significant; A 0.08 (SE = 0.06), P >0.05. 
u 
oi- 
41 
Chapter 2 
Table 2.4 Characteristics of selected Caucasians and South Asians in HSE 1999 
Caucasians (n=425) South Asians (n=535) 
Mean (95%Cl) or 
Age* (year) 51.7 (50.5 to 53.0) 
Sex *(men) 169(39.8%) 
Systolic blood pressure* (mmHg) 133.8 (131.9 to 135-7) 
Diastolic blood pressure (mmHg) 76.0 (74.8 to 77-2) 
Total cholesterol* (mmol/1) 5.6 (5.5 to 5.7) 
HDL cholesterol* (mmol/1) 1.47 (1.42 to 1.51) 
Fasting blood glucose (mmol/l)* 5.25 (5.17 to 5.32) 
H bAl c (%)* 5.45 (5.40 to 5.51) 
Smoking* 131 (30.8%) 
Mean (95%Cl) or 
45.6 (44.8 to 46.5) 
253(47.3%) 
129.8 (128.1 to 131.4) 
76.5 (75.5 to 77.6) 
5.3 (5.2 to 5.4) 
1.28 (1.25 to 1.31) 
5.40 (5.32 to 5.47) 
5.77 (5.72 to 5.81) 
76(14.2%) 
*p<0.001 
Table 2.5 displays ethnicity by overall quartiles of HbAIc. The distribution of 
HbAlc in South Asians was shifted to the right as compared with that of 
Caucasians (Figure 2.1). Caucasians had proportionately more HbA Ic values in 
quartiles I and -H, whilst 
48% of South Asians were in the 3rd and 4thquartiles 
compared to 27% of Caucasian participants. 
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Table 2.5 Haemoglobin Aic measurements in non-diabetic Caucasians and South Asians in HSE 
1999 
Mean Median 
(95% Cl) (IQR*) Quartile I Quartile 11 Quartile ill Quartile IV 
Caucasians 
South Asians 
Total 
5.6 
(5.5 to 5.6) 
5.9 
(5.8 to 5.9) 
5.6 
(5.3 to 5.8) 
5.8 
(5.6 to 6.1 
5.7 
(5.4 to 5.9) 
4.5-5.3 5.4-5.6 5.7-5.8 5.9-10.3 
3.2-5.5 5.6-5.8 5.9-6.0 6.1 -13.3 
3.20-5.40 5.41-5.70 5.71-5.90 5.91-13.30 
*IQR-. Interquartile 
5.7 
(5.7 to 5.8) 
Figure 2.1 HbAl c values in South Asians and Caucasians in 
different quartiles 
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Mean difference of FBG and HbAlc between South Asians and Caucasians are 
shown in the Table 2.6. South Asians had significantly higher fasting blood 
glucose and HbAlc compared to Caucasians after adjustment for age, sex, systolic 
BP, total and HDL cholesterol, and smoking status. 
Table 2.6 Univariate analysis of fasting blood glucose and Glycated 
haernoglobin in selected Caucasians and South Asians in HSE 1999 
Mean differences P value* 
(95% Cl) 
Fasting blood glucose (mmol/1) 
Glycosylated haemoglobin (%) 
0.15 (0.06 to 0.25) p=0.001 
0.3 (0.2 to 0.3) p<0.001 
*After adjustment for age, sex, systolic BP, total & HDL cholesterol, and smoking status 
2.6 DISCUSSION 
Despite the almost universal acceptance of the increased risk of cardiovascular 
disease in South Asians, the evidence to support this from longitudinal studies is 
limited. The Khattar study (Khattar et al., 2000) suggests a nsk of CHD 
independent of other risk factors 1.79 higher is consistent with evidence from 
cross-sectional surveys. In contrast the larger UKPDS (Stevens et al., 2001), a 
robust randomised controlled trial confined to patients with diabetes, failed to show 
any independent effect of South Asian ethnicity with fairly tight confidence 
intervals. The 79% excess CHD risk in South Asians is the best estimate and will 
be used in further modelling of CHD and CVD risk for this ethnic group in this 
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thesis. However this estimate is derived from a single study of hypertensive 
patients with higher proportion of men (about 80%). 
This discrepancy would seem to be explained at least in part by a difference in 
glycaemia in the non-diabetic South Asian and Caucasian populations, and the 
strong evidence of a link between this level of glycaemia and risk of cardiovascular 
disease. However, South Asian diabetic patients also have higher HBAIc than 
Caucasians. The excess dysglycaemia may represent part of the insulin resistance 
syndrome common in South Asians (McKeigue et al., 1991). The reasons for the 
enhanced susceptibility to insulin resistance are disputed. A genetic predisposition 
has been postulated (Chaturvedi, 2003), although no specific polymoiphism has 
been isolated. In general social and economic differences are associated with 
inequalities in CHD although this link in UK South Asians is controversial. 
Europeans fared better in some indicators of socio-economic status and South 
Asian in others (Bhopal et al., 2002). None of the longitudinal studies I identified 
accounted for socio-economic status. In South India people with middle income 
socioeconomic status had a higher intake of calories, fat and sugar compared to 
low income groups who had a statistically significant lower prevalence of 
metabolic syndrome (Mohan et al., 2001). 
Although the Khattar and UKPDS studies were in specific groups at high risk of 
CHD their results were used because of a dearth of population based prospective 
epidemiological cohort studies. The number of South Asians subjects in the 
Khattar study was small and these results must be interpreted with this in mind. 
Neither study differentiated between different groups within the South Asian 
population. Bhopal et al (Bhopal et al., 1999) however reported considerable 
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heterogeneity within South Asians, Indians being least and Bangladeshi most 
disadvantaged in ternis of coronary risk. 
Only English language databases were searched and as a result, it is possible that 
some data published in native languages in the Indian subcontinent was missed. 
These results suggest that there is an increased risk of CHD in South Asians 
unexplained by differences in traditional risk factors. Although conventional risk 
factors are qualitatively similar in South Asians their quantitative impact may be 
different (Yusuf et al., 2004). At least part of the higher CHD risk in South Asians 
may be due to differences in blood sugar in non-diabetic subjects. This is 
consistent with Gerstein and colleagues (Gerstein et al., 1999) finding of a graded 
risk of MI with glucose elevations within the norinal range in South Asians. If 
these observations are confinned,. the population attributable risk of dysglycaemia 
may be several times greater than the population attributable risk of diabetes alone. 
This may lead to consideration of the diagnosis of a pre-diabetic state in South 
Asian people. Randomised controlled trials confirin that effective lifestyle 
intervention can prevent or delay the progression to type 2 diabetes in groups at 
high risk, such as overweight people with impaired glucose tolerance (Narayan et 
aL , 2002). 
Unfortunately it has been shown that people from the South Asian 
groups participate less in sport and recreational activities when compared to the 
general population (Hayes et al., 2002; Erens & Primatesta, 1999; Johnson, 2000). 
Targeted promotion of lifestyle modifications to people with pre-diabetes could be 
applied in South Asians. However health promotion in ethnic minority groups 
requires an additional major effort to understand attitudes, 
beliefs, and barriers to 
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lifestyle modifications so that advised changes are appropriate. Unwin et al. (1998) 
carried out a secondary analysis of the Newcastle heart project on the prevalence of 
diabetes and pre-diabetes, age and sex adjusted using standard population of 
England and Wales. The prevalence of diabetes and pre-diabetes in South Asians 
were reported as 20.1% and 30.5% respectively. One fifth of the South Asian 
population have diabetes and need a clinical approach to targeting and treating. An 
additional third of the population could therefore be categorized as having 
pre-diabetes and need effective lifestyle intervention. This would be an immediate 
and difficult challenge for general practitioners. Further - work is required to 
confirin the hypothesis and to develop a validated risk prediction tool to guide 
intervention decisions for South Asians. 
For the expatriate population, the effect of migration on coronary risk is also 
important. Between countries comparisons (UK and India) have shown that 
migration confers a higher risk of CHD with an increase in body weight, serum 
cholesterol, and blood pressure (Bhatnagar et al., 1995). There is additionally a 
trend towards the acquisition of westernized behaviours consistent with a sedentary 
lifestyle, high salt and fat and low fiber diet and new stresses. The likelihood of an 
increase in insulin resistance , its expression as 
frank diabetes mellitus and glucose 
intolerance probably increases on migration (Misra & Vikram, 2004). A 
combination of these factors may therefore unmask the underlying genetic risk of 
CHD. 
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PREDICTING CORONARY RISK IN UK SOUTH 
ASIANS: AN ADJUSTMENT METHOD FOR 
FRAMINGHAM BASED TOOLS 
An adjUstment method'for Framingham function 
3.1 INTRODUCTION 
A basic principle of prevention of cardiovascular disease (CVD) is that the 
intensity of risk-reduction therapy should be adjusted to a person's absolute risk. 
Hence, the first step in selection of any therapy is to assess a person's risk status. 
Risk in diabetic South Asians is predicted by classical risk factors whilst risk in the 
non-diabetic population is 79% greater than predicted (chapter 2 of this thesis). 
This figure is grater than that suggested in current guideline (JBS-1,1998) which 
used an increment of 50% for South Asian people. However they give no 
justification or evidence base for this figure. Given the apparent variation in risk 
between groups within the South Asian community it is probable that for some the 
excess risk above Caucasians is only 50%. However this figure of 79% remains the 
best evidence based of estimate of risk ratio. 
Because of the increased risk of coronary heart disease (CHD), many people of 
South Asian descent should be eligible for lifestyle recommendations and a greater 
use of antihypertensive and lipid lowering drugs for the primary prevention of 
CHD. However, use of such treatments is usually guided by an explicit assessment 
of risk, and currently available tools which do not take account of ethnic specific 
factors are accepted as inaccurate for this group. This means that South Asians may 
receive less preventive treatment than appropriate either because their risk is 
underestimated or because they are excluded from the risk assessment process 
completely. 
The risk of developing CHD depends on a number of deten-ninants. The first 
attempt at assessing the absolute risk of CHD date back to 1973 when the 
Committee on Reduction of Risk of Heart Attack and Stroke of the American 
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Heart Association published the "Coronary Risk Handbook" with the estimates 
derived from the Framingham Heart Study (Lindsay & Gaw, 2004). This study 
identified several risk factors that interact in a deleterious manner to have a 
cumulative impact on the incidence of CVD. The effect of these risk factors in the 
population was encapsulated in a mathematical time to failure model which has 
been used as the basis of several tools for the prediction of individual risk 
(Anderson et al., 1991). The rationale for estimating total CVD risk based on the 
major risk factors is that: -* 
(a) CVD is multifactorial in ongin; 
(b) risk factors tend to cluster; 
(c) co-existent nsk factor tend to have a multiplicative effect on CVD risk. 
The level of any single risk factor in isolation is an inadequate guide to overall 
cardiovascular risk and further intervention. For the same blood pressure level 
some people are eligible for antihypertensive therapy and others not, depending on 
their absolute risk of developing CVD. Absolute CVD risk is expressed as a 
probability (% chance) of developing CVD over a defined period of time, e. g. 20% 
risk over 10 years means the person has 20% chance of developing CVD in the 
next 10 years. This cumulative score does not aim to provide a precise risk 
indicator for a disease of such complexity but it does provide the healthcare 
practitioner and patient with a better estimation of overall risk where several risk 
factors are present. This nsk based threshold does not preclude treatment of 
extreme values of single risk factors. As the number of patients with severe 
hypertension or familial hypercholestrolaemia in a population like Framingham is 
small the accuracy of the risk factor equation may not capture the 
impact of blood 
pressure or cholesterol at these extreme values. In addition extreme values of risk 
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factors may necessitate treatment because they are associated with adverse 
outcomes not encapsulated in the Framingham equation e. g. renal failure 
consequent to malignant hypertension. 
Most risk functions are based on logistic regression, Cox regression, or time to 
failure statistical models. Whilst the first two can only provide information about 
the likelihood or not of suffering an outcome or not within a fixed time interval the 
results are often simplistically converted to a rate and applied to different time 
intervals. An advantage of the time to failure models is that risk of events for a 
range of time intervals can be considered (Anderson et al., 1991). 
In order for multivariable risk assessment and treatment guidelines to have optimal 
use and acceptability, we need to be confident that absolute risk prediction 
functions can be transported to other settings beyond those in which they were 
originally developed. The Diverse Population Collaborative Group (DPCG, 2002) 
reported that traditional risk factors are qualitatively associated with CHD 
mortality in a diverse set of population using person-level data from 161,955 
participants in 16 cohort studies. However significant heterogeneity was observed 
in three aspects: risk ordering, magnitude of relative risk, and estimation of 
ni-11 ausolute risk. 
The Framingham equation works reasonably well among both black and white 
American men and women for prediction of CHD events within 5 years of follow- 
up. However, it systematically overestimated the risk among Japanese-origin 
American and Hispanic men and American Indian (members of Indian tribal 
nations who live in the United States) women. It could 
however be recalibrated for 
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these groups (D'Agostino et al., 2001). It also predicts the risk of cardiovascular 
events accurately in an ethnically mixed cohort, 85% European, in New Zealand 
(Milne et al., 2003). The Framingham prediction function has been validated for 
European populations to predict future risk of CHD (Haq et al., 1999) but may 
overestimate risk of CHD in other ethnic groups with different rates of CHD. A 
study in the British population contrasting Framingham risk with annual hospital 
in-patient admission data reported that the risk function estimates CVD events well 
according to annual number of CVD events derived from the 2001 UK hospital 
in-patient episode statistics (Shearer et al., 2005). In contrast the British regional 
heart study investigators reported an overestimation of the risk of CHD mortality 
by the Framingham equation in their prospective cohort study of men, aged 40-59 
years at entry (Brindle et al., 2003). There are other reports indicating that the 
Framingham equation overestimates risk in Italy and Denmark in Europe (Menotti 
et al., 2000; Thomsen et al., 2002). This overestimation is probably reflecting the 
lower incidence in those countries with a lower CHD mortality rate. However the 
relative risks did not differ significantly with the Framingham population in 
Denmark study (Thomsen et al., 2002). Similarly the Framingham function 
estimates were more than double the observed risk of CHD observed in north east 
Spain (Marrugat et aL, 2003). Even where the Framingham equation has been 
shown to overestimate CHD risk significantly, it still provides a reasonable ranking 
of risk or estimate of relative risk and implies that those at highest risk would be 
identified independently of the model that has been chosen. Because of this simple 
adjustment has produced tolerable estimates of absolute risk in some populations 
(Launer et al., 1994). 
52 
An adjustment method for Framingham function 
Cardiovascular risk assessment has an impact on treatment allocation in primary 
prevention s nce clinical guidelines tend to employ predicted absolute values as a 
tool for clinical decision making. Whilst population level lifestyle changes should 
be made by everyone aggressive preventive treatment and intervention are only 
justified if a patient's absolute risk exceeds a certain cut off point. In this context, it 
is important that the prediction of individual absolute risk be valid. Inaccuracies 
will lead either to people being exposed to the adverse effects of treatment with 
very little chance of benefit or deprive them of substantial benefit. Grover and 
colleagues (Grover et al., 1995) studied community based doctors and showed that 
their assessment of absolute risk of coronary disease was inaccurate without a risk 
prediction tool. They were, however, much better at assessing relative CHD risk. 
As a result algorithms, functions, and scores have an important role in clinical 
practice in the prediction of the probability of a subsequent cardiovascular event in 
individuals initially free of symptomatic heart and other vascular disease. Several 
factors may be responsible for the inaccuracy of a risk prediction model in diverse 
populations including: differences in CVD prevalence and/or diversity in the 
prevalence and distribution of risk factors. When testing the performance of a 
clinical prediction model in different populations, the accuracy of the predicted 
probability has two components (calibration and discrimination) which both need to 
be assessed (Justice et al., 1999). A well-calibrated model has predictions that are 
neither too high nor too low i. e. the baseline risk is correctly assessed (the 
estimates are close to a "real" probability). A model that discriminates well ranks 
individual risk in the correct order, i. e. between cases with "event" and "no event". 
Unfortunately, there are no data linking individual risk factors with future 
incidence of CVD that can be used to test the validity of the Framingham equation 
53 
Chapter 3 
in the South Asian ethnic minority against either of these criteria. 
In the case of a systematic overestimation or underestimation of risk, transporting a 
prediction function from one setting to another requires recalibration. D'Agostino 
and colleagues tested the validity and transportability of the Framingham CHD 
prediction function in male and female black Americans (D'Agostino et aL, 2001). 
The sex-specific Framingham CHD prediction functions perform well among 
whites and blacks in different setting and can be applied to other ethnic groups 
after recalibration for different prevalences of risk factors and underlying rates of 
CHD events. Likewise the recalibrated Framingham function has become an 
effective method of estimating the CVD nsk in north east Spain (Marrugat et al., 
2003). Little is known about the accuracy of the Framingham equation for 
predicting risk in South Asians although it is believed to order estimated risk 
(Cappuccio et al., 2002). Having a recalibration for South Asians would need a 
cohort study with sufficient fatal and non-fatal cardiovascular endpoints or a well 
established CVD register and the prevalence of their risk factors. No single cohort 
study sufficiently large for this purpose is available for the UK South Asian 
population. Brindle and colleagues have recently developed a model using 
available nsk factor and disease prevalence infonnation in the absence of 
prospective data for black and ethnic minority groups (personal communication). 
This model may potentially improve identification of high risk people in ethnic 
minorities but still requires refinement and validation. 
In practice three different forms of scoring systems are being used: 
Iy displayed as a Computer based scoring systems provide the probabilit 
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percentage of suffering a cardiovascular event within a specified period of 
time (usually 10 years). Users enter the required risk factor values, and the 
software provides the risk estimate. Examples include "The 
Boehringer-Mannheim Infarct Risk Calculator" (Lindsay & Gaw, 2004) 
which is similar to an ordinary calculator, "The Joint British Societies' 
Cardiac Risk Assessor Software" (JBS-1,1998), or "The UK Prospective 
Diabetes Study (LTKPDS) Risk Engine" (Stevens et al., 2001). 
9 In paper based tools values in tables, graphs, or cells matrices of different 
colours represent different CHD or CVD risk levels or categories. 
Examples of this are "The Joint British Societies' CVD risk prediction 
charts" (JBS-2,2005), "The Sheffield Table" (Wallis et al., 2000), "The 
SCORE project risk estimator" (Conroy et al., 2003) and "The New 
Zealand Table" (Jackson, 2000). They are generally based on age, gender, 
total to HDL cholesterol ratio, systolic blood pressure, smoking habit, and 
diabetes. Such charts do provide a pictorial representative of nsk which 
may facilitate patient (and doctors) comprehension. 
9 Summation of different points to score risk factors is the basis of the third 
scoring system. Points scoring systems are easily derived from parameters 
in logistic or Cox proportional statistical models. Depending upon the 
strength of the covariate in the analysis points are attributed to individual 
risk factors. Summing the points can then provide a numerical estimate of 
nsk via a look-up table. This method is employed by the National 
Cholesterol Education Programme (ATP-M, 2001). 
Multidimensional risk factor interaction is however difficult to represent in a single 
two dimensional table or chart and most invoke some form of approximation or use 
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only a sub-set of risk factors. 
The various systems use different endpoints such as; fatal and non-fatal CVD or 
CHD and CVD mortality alone or combined. Including all fatal and non-fatal CVD 
events provides a better estimate of true burden of total CVD risk. However 
different patients may attribute quite unequal weights to the various endpoints e. g. 
many, but not all, people believe severe disabling stroke is a fate worse than death 
(Solomon et al., 1994; Gage et al., 1996). Risk threshold for professional 
intervention (lifestyle and appropriate drug therapies) is an important property of 
any risk prediction tools. Currently updated guidelines have suggested ý! 20% CVD 
risk over 10 years, which is equivalent to a CHD risk of ý! 15 over the same period 
(Yeo & Yeo, 2002), as the intervention threshold. 
When the clinical risk prediction tool is implemented as software or in a calculator 
which provides a numerical estimate of risk a simple ethnic factor multiplier can be 
applied to the estimated risk. Where the tool categorizes patients into nominal risk 
groups e. g. low, intennediate or high or indicates only eligibility or not for 
treatment no similar simple adjustment can be used. 
3.2 AIM AND OBJECTIVES 
e To identify a method for adjusting the input to Framingham equations for 
use in non-diabetic South Asian individuals to accommodate their 79% 
greater risk of CHD and apply this to the simple practical paper based tools. 
9 To confirm the discriminatory ability of this adjustment method in a South 
Asian sample in separating those above and below a 20% cardiovascular 
event risk threshold. 
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3.3 METHODS 
3.3.1 Population 
In testing different methods of adjustment typical distributions of risk factors were 
ensured by using values from a large UK population survey. 
3.3.1.1 Health Survey for England Series 
Two datasets of the health survey for England series have been used: 
9 The HSE 1998 dataset (HSE, 1998) was used to examine the mathematical 
effect of different adjustment methods in risk factor distributions derived 
from a large number of subjects similar to the Framingham Study 
population. 
9 For sensitivity analysis, the HSE 1999 dataset (HSE, 1999) which provides 
a representative sample of South Asians living in England and Wales was 
used. 
Using HSE 1998: 
The HSE 1998 dataset was used to examine the distribution of CHD risk in people 
without pre-existing symptomatic disease and to test the mathematical properties of 
different adjustment methods. In the HSE 1998 study 9,208 people were 
interviewed, 58% had their blood pressure measured, and 49% agreed to give a 
blood sample. For analysis, those with angina, myocardial infarction, stroke, or 
treatment with lipid lowering drugs were excluded. In addition, 2440 subjects with 
one or more of the variables necessary for risk calculation missing were excluded 
from any analysis (Figure 3.1 - a). 
Using 
-HSE1 
999, 
The HSE 1999 dataset was used to examine the sensitivity and specificity of the 
adjustments to the Framingham equation in South Asian subjects without vascular 
disease. In this HSE dataset adults were interviewed at 71% of known eligible 
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boost sample households, 33 - 54% of South Asians had their blood pressure 
measured, and 33-61% agreed to give a blood sample. The exclusion and inclusion 
criteria were the same as those applied to the HSE 1998 and are shown in the 
Figure 3.1 - b. 
The number of subjects for analysis is different here from the number of selected 
subjects for dysglycaemia analysis in chapter 2 of this thesis (2.5.3.1-page 37). 
This discrepancy is explai II ined by exclusion of people without fasting blood glucose 
ý!! 7.77 mmol/I (140 mg/100) as well as missing data for the variables under 
investigation in each chapter. 
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Figure 3.1 Selection of subjects from the HSE 1998 (1 -a) and HSE 1999 (1 -b) 
investigation of adjustment methods 
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3.3.2 Prediction equation 
The magnitude of the absolute risk of CHD is commonly expressed as the per cent 
chance of suffering a fatal or non-fatal coronary event over the next 5 or 10 years. 
3.3.2.1 The Framingham equation 
The Framingham equation derived from the Framingham Heart Study was used as 
a standard for predicting the risk of CHD in people who had no history of vascular 
disease. As background to the use of this equation it is important to know a little 
nu about how it was developed. In 1948,5209 men and women between the ages of 
30 and 62 from the town of Framingham, Massachusetts were recruited for this 
study and began the first round of extensive physical examinations and lifestyle 
interviews that were analyzed for common patterns related to CVD development. 
Since then, the subjects have continued to return to the study every two years for a 
detailed medical history, physical examination, and laboratory tests. Although the 
Framingham equation has been updated (Wilson et al., 1998), risk prediction tools 
in current use are based on the older equation (Anderson et al., 1991) and this has 
been used throughout for consistency. In the original study blood pressure was 
based on the average of two office measurements, diabetes was defined as 
treatment with insulin or oral agents or a fasting blood glucose of 7.77 mmol/l (140 
mg/dl) or above, and smoking as being a current cigarette smoker or having quit 
within the last year. These along with gender, age, ratio of total to HDL 
cholesterol, and ECG evidence of LVH were shown to be powerful predictors of 
future CHD in a time to failure model. There is no information available regarding 
the left ventricular hypertrophy in the HSE series and it was assumed that subjects 
have no LVH. In addition South Asians have similar ECG voltage to Caucasians 
which suggests a similar prevalence of LVH (Spencer et al., 2004). 
N 
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The definition of CHD used in the risk function- includes fatal and non-fatal MI, 
acute coronary insufficiency and new onset angina pectoris. Box 3.1 shows the 
Framingham risk equations for CHD events based on the coefficients for the 
Framingham regression model. Risk derived from the Framingham equation was 
multiplied by a factor of 1.79 to provide the reference risk in non-diabetic South 
Asians identified in the HSE 1998 dataset (chapter 2, this thesis). 
Box 3.1 Framingham risk equation for coronary heart disease events 
15.5305 + 28.4441 (sex female) - 1.4792 (LN age )2 _ 14.4588 ((LN age)(sex female)) + 
1.8515 ((LN age )2 (sex female)) - 0-9119 (LN systolic blood pressure) - 0.2767(cigarettes smoking) -0.7181 
(LN total: HDL-C) - 0.1759 (diabetes) - 0.1999 (diabetes x sex) 
** *** *** *** *** ***** *** 
Log sigma = 0.9145 - 0.2784 
Sigma = EXP (Log sigma) 
U= (Log 10 - p) / sigma 
Framingham CHD events = 100*(l-(EXP(-l*(EXP(U))))) 
** ******** ** ** 
Systolic blood pressure measured in mmHg and age in years. Variables cigarettes 
smoking, diabetes and female gender are set to 1 when present and 0 when absent. 
3.3.3 Method of adjustment 
Feasible adjustments, which might be applied to the paper-based risk prediction 
tools such as "the Joint Societies Chart" and "the Sheffield Table" to identify South 
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Asians warranting treatment, were studied. Continuous independent risk E actor 
variables included in the Framingham equation, which might be manipulated 
simply to allow for the increased risk observed in non-diabetic South Asians were 
selected. The different adjustments investigated were: 
0 fixed increments to the age, 
total cholesterol (TC), 
o TC: HDL cholesterol ratio, 
* and systolic blood pressure and multipliers for the TC: HDL cholesterol 
ratio. 
Table 3.1 describes the different adjustment methods. 
Table 3.1 Different adjustments to the Framingham equation used to approximate a 
1.79 fold increase in risk 
Variable Adjustment method 
Age Addition of 1 to 10 years to the age 
Total cholesterol (TC) Addition of 0.5 to 3.2 mmol/I to the TC 
(TC: HDL cholesterol) ratio Addition of 0.5 to 2.0 to the (TC: HDL cholesterol) ratio 
(TC: HDL cholesterol) ratio Multiplying the (TC: HDL cholesterol) ratio by 1.1 to 2.0 
Systolic blood pressure Addition of 10 to 60 mm Hg to the systolic blood 
pressure 
To ensure a representative distribution of risk factors on which to test the 
adjustments, risk factor data from 4497 individuals identified from the HSE 1998 
dataset, was used. For each individual the Framingham equation was used to 
calculate a baseline CHD risk and then inserted modified values for the risk factor 
under study, on each occasion estimating the ratio of new risk to baseline risk. 
Interpolation allowed selection of the value of adjustment of the risk factor that 
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gave a mean ratio of ad usted to baseline risk closest to 1.79. i 
Distribution and dispersion of individual ratios of adjusted to baseline risk were 
then investigated. Where distributions were non-normal, a Bootstrap method 
(Bradley & Gill, 1983) was used to estimate 95% confidence intervals. A sample 
of a size of 10,000 was generated from the data by random sampling with 
replacement. The sample was sorted into ascending order and the value of the 
250th provided the lower 95% confidence limit while the value of the 9750th that 
of the upper 95% confidence limit. 
3.3.4 Test of sensitivity and specificity 
Diagnostic accuracy is a fundamental characteristic of a test that measures the test's 
n, k ability to discriminate among alternative states. The receiver-operating 
characteristic curve (ROC curve) (Zweig & Campbell, 1993) provides a pure index 
of accuracy by demonstrating the limits of a test's ability to distinguish between 
two different states. Information in the Table 3.1 gives a measure of scientific 
accuracy of the various adjustments but the ROC curve demonstrates how well an 
adjustment function discriminates between two states in practice. The ROC curve 
was used to compare the different adjustments in their primary role of identifying 
South Asian individuals above or below a given threshold using risk factor 
information from HSE 1999. To maintain consistency with current UK guidelines 
the 10-year CHD event risk threshold of 15% was investigated. The proportion of 
subjects with a CHD risk greater than 30% was too small to allow any meaningful 
analysis. Sensitivity against one minus the specificity was plotted for different 
values of each of the adjustment methods (adding to the age, TC, systolic blood 
pressure, TC: HDL ratio, and multiplying TC: HDL ratio). The area under the 
curve was calculated for each method to determine the most accurate in this role. 
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3.4 RESULTS 
3.4.1 Adjustment methods 
In the HSE 1998,4497 subjects provided sufficient information to have their risk 
of a first CHD event calculated by the Framingham equation (Table 3.2). 
Table 3.2 Basic characteristics of CHID risk factors in eligible subjects in 
HSE 1998 
Characteristics 
Number of subjects 
Age (years) 
Gender (female) 
Diastolic Blood Pressure (mmHg) 
Systolic Blood Pressure (mmHg) 
Total cholesterol (mmol/1) 
HDL cholesterol (mmol/1) 
Diabetes 
Cigarette smokers 
Mean (SD) or number (%) 
4497 
44(8) 
2444 (54.3%) 
76.2(11.6) 
132.9 (17.0) 
5.7(1.1) 
1.45(0.4) 
64(l. 4%) 
1098 (24.4%) 
The effects of the four methods of adjustment on prediction risk used are shown in 
Figure 3.2. All adjustments produced a graded monotonic, almost linear increase in 
risk. By interpolation it was possible to select a value for each adjustment factor 
that would provide mean increment in risk of 1.79. For practicality an integer or 
imal places was chosen as the optimal real number with limited number of deci I 
value of the adjustment factor. The effect of using this modification on individual 
risk estimates was then studied. 
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Figure 3.2 Different methods used for adjustment the Framingham equation 
The simplest adjustment that of adding years to age produced a wide range of 
individual relative increments in predicted risk over ten years. The precision of 
64 
11" X? ", 4ý', r1o P) 
Number added lo the vystolic bk)od pwessure 
An adjustment method for Framingham function 
other methods was better although these would be slightly more complex to 
implement with a paper-based tool, Table 3.3 shows distribution of risk ratios of 
the different adjustment methods around values which gave an increased mean 
ratio closest to a factor of 1.79. 
Table 3.3 Distribution of individual ratios of adjusted to baseline risk with the 
different methods of adjustment 
Mean Median Range of values 
(95% Cl*) (IQR**) 
Age +10 1.88 1.60 1.04-7.86 
(1.09 to 4.50) (1.36 - 2.03) 
TC +2.8 1.83 1.73 1.16-4.45 
(1.29 to 2.92) (1.55 - 2.04) 
(TC/HDL) + 1.8 1.82 1.67 1.05-6.32 
(1.18 to 3.30) (1.42 - 2.05) 
(TC/HDL) * 1.5 1.77 1.73 1.21-3.08 
(1.34 to 2.44) (1.56 to 1.93) 
Systolic BP +50 1.80 1.74 1.19-3.68 
(1.30 to 2.64) (1.55 to 1.99) 
*Confidence interval (calculated by Bootstrap method) 
** Inter-quartile Range 
3.4.2 Sensitivity and specificity 
For each method sensitivity and specificity and ROC plots were used to compare 
the different adjustments in their role of identifying high-risk individuals. The 
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Framingham equation with risk multiplied by 1.79 was used as the standard for 
calculation of CHD risk and subjects were characterised as having a risk of greater 
or less than 15%. Their allocation according to an "adjusted" paper based method 
was compared with that according to the reference risk assessment. Table 3.4 
shows sensitivity and specificity for the different adjustment methods. 
Table 3.4 Sensitivity and Specificity for adjustment methods 
Sensitivity (%) 
Age + 10 
TC + 2.8 
(TC: HDL) + 1.7 
(TC: HDL) x 1.5 
Systolic BP + 50 
83.4 
87.7 
77.0 
89.3 
88.2 
Specificity (%) 
97.9 
96.2 
97.1 
97.1 
96.4 
The areas under the curve are very close in four different methods (Figure 3.4). 
Although multiplying TC: HDL cholesterol ratio by 1.5 gave the largest area under 
the curve, 0.984, all the methods had an area greater than 0.903 and gave us 
acceptable accuracy in recognising South Asians above and below a 15% 
CHD 
risk threshold in UK South Asians. 
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Figure 3.3 ROC plots of different adjustment factors in South Asians against a 
10 year CHID event risk threshold of 15% 
3.5 DISCUSSION 
Increasingly risk prediction will be performed using computer-based algorithms 
and adjustments to these will be straightforward by multiplying calculated risk by 
1.79 for UK South Asians. However paper based tools are still in wide use and 
need continued support. Any changes to algorithms that are simple to implement 
on a personal computer may be much less straightforward for use with charts or 
tables. It is tempting to use simple "rules of thumb" for adjustment but these may 
introduce unforeseen systematic inaccuracies. It has shown been that the 1.79 
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increased CHD risk in non-diabetic UK South Asians is most accurately 
accommodated by multiplying the TC: HDL cholesterol ratio by a factor of 1.5. 
Other methods, although more simple to achieve by mental arithmetic, are less 
precise and in some subjects may significantly underestimate or overestimate risk. 
However in their primary role of deten-nining whether a patient is above or below a 
risk threshold adding 10 years to age has tolerable sensitivity and specificity. 
Adding to systolic blood pressure is equally sensitive and specific but use of this 
method would preclude use of some paper tools and would make risk incalculable 
for many subjects whose adjusted blood pressure would be out of the included 
range. 
It has already been suggested that a lower CHD risk threshold should be used in 
UK South Asians but this is to allow for their greater risk of cardiovascular as 
opposed to coronary heart disease (Cappucclo et al., 2002). However these authors 
did not test the accuracy of risk prediction tool in UK South Asians nor did they 
investigate the effects of specific thresholds. 
Using 10-year CHD risk of 15% as a threshold for treatment rather than a 10-year 
CVD risk of 20% needs to be based on two assumptions: 
1. that CHD risk is an accurate of CVD risk 
2. and that the ratio of CHD risk to CVD risk is 3: 4. 
Yeo & Yeo (2002) showed that the second assumption does not hold mild 
hypertension in those aged 55-74 years or in women aged 35-54 years. Moreover 
the relationship between CVD and CHD differs in South Asians and Caucasians, 
the former group suffering more non-coronary vascular disease. Nevertheless the 
figure of a 79% excess is derived from an assessment of CVD risk an in this study 
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the ratio of CHD was even grater. 
Bhopal et al. reported a 22% higher predicted risk of CHD, calculated by the 
Framingham model, for South Asian men compared to Caucasians in the 
Newcastle Heart Project population (Bhopal et al., 2005). The small number of 
participants limited the analysis, however the hazard ratio adjusted for age and sex 
for observed CHD death in South Asian subjects compared to Caucasian was 2.2 
(95% CI: 1.1 to 4.4). The standard mortality rate for CHD in South Asian men in 
England and Wales was 142 compare to the predicted risk by the Framingham 
model in their study, 122. Clearly these or similar data will be of great use in the 
future to refine the accuracy of any "ethnicity factor". Results of this chapter can 
currently be used to achieve the systematic evaluation of each individual for 
primary prevention of CHD in general practice. 
I 
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PREVENTION OF CORONARY HEART 
DISEASE WITH STATINS IN UK SOUTH 
ASIANS AND CAUCASIANS 
Chapter 4 
4.1 INTRODUCTION 
Coronary heart disease (CHD) is a preventable disease that kills more than 11 ONO 
people in England every year, the biggest killer in the country. More than 1.4 
million people suffer from angina and 275,000 people have a heart attack annually. 
Its prevention is a govermuent priority in the UK and the Government is 
committed to reducing the death rate from coronary heart disease and stroke and 
related diseases in people under 75 by at least 40% (to 83.8 deaths per 100,000 
population) by 2010. To this end Primary Health Care Teams and General 
Practitioners have the task of identifying all people at significant risk of 
cardiovascular disease but who have not yet developed symptoms and offer them 
appropriate advice and treatment to reduce their risks (NSF Standards 4, 
Preventing CHD in high risk patients) (NSF-CHD, 2000). In patients without 
symptomatic disease the absolute risk of developing CHD or other atherosclerotic 
disease during the subsequent 10 years is used to decide whether or not to advise 
drug treatment. The current risk threshold in the National Service Framework for 
coronary heart disease is a 10 year CHD risk of 30% but other guidelines 
(Williams et al., , 2004; JBS-2,2005) suggest the 
lower threshold da 20% 
cardiovascular disease (CVD) equivalent to a 15% risk of CHD. The secondary 
threshold for treatment of a total cholesterol of > 5.0 mmol/l (193 mg/100) is 
gradually being abandoned (Williams et al., 2004) as evidence of benefit when 
treating patients with lower cholesterol concentration accumulates (HPS, 2002). 
Based on the NSF the interventions that patients at high risk of CHD, people 
without diagnosed CHD or other occlusive arterial disease with a CHD risk greater 
than 30% over ten years, should receive, unless contraindicated, are: 
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* Advice about how to stop smoking including advice on the use of nicotine 
replacement therapy 
9 Information about other modifiable risk factors and personalised advice 
n I.. about how they can be reduced (including advice about physical activity, 
diet, alcohol consumption, weight and diabetes) 
* Advice and treatment to maintain blood pressure below 140/85 mm Hg 
e Addition of statins to lower serum cholesterol concentrations either to less 
than 5 mmol/l (LDL cholesterol to below 3 mmol) or by 30% (whichever is 
greater) 
* Meticulous control of blood pressure and glucose in people who also have 
diabetes 
In clinical trials, ant1hypertensive therapy has been associated with reductions in: 
(1) stroke incidence, averaging 2-35 percent; 
(2) myocardial infarction (MI), averaging 2-33 percent; 
(3)) heart failure, averaging >50 percent (Neal et al., 2000). 
It is estimated that in patients with stage I hypertension (SBP 140-159 mmHg 
and/or DBP 90-99 mmHg) and additional cardiovascular risk factors, achieving a 
sustained 12 mmHg reduction in SBP over 10 years will prevent I CVD event for 
every 11 and I CVD death for every 27 patients treated, after correction for 
regression dilution bias. In the added presence of CVD or target organ damage, 
only 9 and 18 patients would require such BP reduction to prevent one CVD event 
and CVD death respectively (Ogden et al., 2000). More than two-thirds of 
hypertensive individuals cannot be controlled on one drug and will require two or 
more anti hyp ertensi ve agents selected from different drug classes. For example, in 
ALLHAT, 60 percent of those whose BP was controlled to <140/90 mmHg 
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received two or more agents, and only 30 percent overall were controlled on one 
drug (Cushman et al., 2002). 
Several large scale randomized controlled trials of statins have shown the 
impressive effect of statins in preventing cardiovascular events, including 
myocardial infarction and stroke (4S, 1994; Shepherd et al., 1995; Sacks et al., 
1996; LIPID-Study, 1998; Downs et al., 1998; LaRosa et al., 1999; HPS, 2002; 
Seriruys et al., 2002; Shepherd et al., 2002; ALLHAT-LLT, 2002; Sever et al., 
2003). The MRC/BHF Heart Protection Study (HPS) showed that the benefits of 
statins extended to a wider range of patients at risk of cardiovascular events, 
including those with peripheral vascular disease, cerebrovascular disease, diabetes 
(type I and type 11) and hypertension (men over 65 years old) (HPS, 2002). On the 
other hand, a reduction in strokes was not observed in the Prospective Study of 
Pravastatin in the Elderly at Risk (PROSPER) (Shepherd et al., 2002), whilst there 
was no significant reduction in coronary events or all-cause mortality in the 
subjects randomized to pravastatin treatment in the Antihypertensive and Lipid- 
Lowenng Treatment to Prevent Heart Attack Tnal-Lipid Lowenng Trial 
(ALLHAT-LLT, 2002). One possible explanation in this study was that the control 
group received usual care, and lipid lowering therapy was widely used by the time 
the study was completed, thus reducing the contrast between treatment and control. 
The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Ann 
(ASCOT-LLA) study also examined the effect of statin treatment in hypertensive 
patients (Sever et aL, 2003). Patients with a total cholesterol of less than 6.5 
mmol/I were randomized to either statin or placebo. This part of the study was 
terminated early after a median follow-up of just 3.3 years showing a benefit that 
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was small in absolute terms but statistically significant. ASCOT-LLA is 
remarkable for the short duration of the study and the modest dosage of statin used. 
Meta-analysis of the clinical trials of statins (Cheung et al., 2004) showed that 
these drugs reduce coronary events and all-cause mortality, with no increase in 
non-coronary mortality. With the exception of pravastatin, statins also have a 
strong effect on reducing the incidence of stroke. Benefits accrue in men and 
women, hypertensives and nonnotensives, diabetics and non-diabetics, and 
particularly in smokers. Because of the evidence for widespread eligibility for 
statin treatment there was considerable concern about the cost of providing this to 
all suitable patients not only in ten-ns of drugs but also personnel to prescribe and 
monitor treatment. It may be more cost-effective to treat those at the highest 
cardiovascular risk, for example patients with CHD, diabetes and multiple risk 
factors. 
There is evidence of different responses to preventive treatment according to 
eth-nicity. Not only may some groups to be at higher risk they may also respond 
differently to drug treatment e. g. Black and ACE inhibitors. There are no clinical 
trials or subgroups within trials investigating the treatment of either high blood 
pressure or hyperlipidaemia in South Asians and until recently it was impossible to 
estimate their CHD risk, the Framingham equation being acknowledged to 
underestimate risk in them. We have devised an evidence based adjustment to the 
Framingham equation to allow accurate estimation of CHD risk in this population 
in chapters 2&I 
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4.2 AIM AND OBJECTIVES 
To detem-iine the prevalence of subjects eligible for primary and secondary 
prevention of coronary heart disease (CHD) among the British South Asian 
population and to compare that with the British Caucasians population. 
4.3 METHODS 
4.3.1 Study population 
For this analysis, the Health Survey for England 1998 and 1999 (HSE 1999 and 
HSE 1998) datasets were used. From the two datasets 9950 and 1938 subjects 
(Caucasians and South Asians respectively) were in the age range 35-74 years 
covered by Framingham risk prediction tools (Fig 4.1). The Health Survey for 
England was described in chapter 2 in detail (2.5-3). All participants in these two 
surveys provided data about previous history of cardiovascular disease. Of those in 
the target age range, 3029 (30.4%) Caucasians and 915 (47.2%) South Asians did 
not have a total cholesterol (TC) measurement. The number remaining who had 
sufficient information to calculate vascular risk was used as the denominator for 
estimation of the prevalence of need for primary and secondary prevention and 
forms the basis of subsequent analysis. Based on the Heart Protection Study (BPS, 
2002), subjects with total cholesterol higher than 3.5 mmol/l (135 mg/100) were 
deemed eligible for primary prevention if their CHD risk exceeded 30% or for 
secondary prevention if they had a history of vascular disease. 
4.3.2 Secondary prevention 
Full data about myocardial infarction, angina, and stroke were provided for 6868 
Caucasians and 1003 South Asians. To estimate the prevalence of secondary 
prevention needs, those with a history of myocardial infarction; angina but no 
myocardial infarction; stroke, but no myocardial infaretion or angina were 
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identified (Fig 4.1). Separate analyses were perforined for a history of CVD based 
on self- reported and doctors diagnosis. 
4.3.3 Primary prevention 
None of the 7404 subjects without history of myocardial infarction, angina, or 
stroke was taking lipid-lowering drugs. However 129 subjects had to be excluded 
because they were missing one or more variables necessary for risk calculation 
(Fig 4.1), leaving 6360 Caucasians and 920 South Asians. For the purpose of this 
analysis, it was assumed that statin therapy would be considered after 
implementation of all other lifestyle strategies. 
4.3.4 Prediction tools 
The Framingham equation (Anderson, 1991) and age, sex, systolic blood pressure, 
smoking habit, history of diabetes, and total: high density lipoprotein cholesterol 
ratio from the HSE databases were used to estimate individual CHD risk in those to 
be considered for primary prevention. Left ventricular hypertrophy was assumed to 
be absent and there is no difference between South Asians and Caucasians. The 
definitions used for the required variables were: 
e for systolic blood pressure, the mean of final two of three readings; 
* for smoking habit, current cigarette smoking or smoking within the 
preceding year; 
9 for diabetes, treatment with insulin or an oral hypoglycaemic drug, or 
doctor diagnosed diabetes. 
ing the predicted isk Risk in non-diabetic South Asians was adjusted by multiplyl n 
from the native Framingham equation by a factor of 1.79. The basis of this factor is 
described in detail in chapter 2 of this thesis. Calculated risks were categorised into 
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three groups: less than 15%, 15-30%, and more than 30% according to risk of CHD 
events per ten years. 
Nunib er of subjects 35-74 ye-ars 
Caucasians/ South Asians 
9950/193s 
( C- 
Denominator f6r 
Subject-S ý; vlth no sserum 
cholesterol meaSurement 
AW 
3 
)89/66 
ýDubject, sý with 1113tory of 
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cl 
,ý Ubi ec ts: 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For prhnary prevention 
Figure 4.1 Selection criteria of data from Health Survey for 
England 1998 and 1999 to estimate primary and secondary 
prevention needs 
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4.3.5 Cost of treatment 
The cost of lipid-lowering therapy was estimated assuming treatment with 
sirnvastatin at the dose used in the Heart Protection Study (40 mg daily). Drug 
costs were taken from the British National Formulary March 2005 (BNF, 2005) 
and were f 3.90 per week (E202.00 per year). Costs relating to medical, nursing or 
laboratory services, other parallel strategies for a comprehensive package of risk 
reduction and also any saving resulting from prevention of CHD were not 
considered. 
Number needed to treat (NNT) was calculated using the relative risk reduction for 
people without pnor CHD denved from the HPS study, 0.226 (HPS, 2002) and the 
mean 10 year CHD risk in people with a 15% or more coronary event risk over the 
next 10 years (Figure 4.2). For secondary prevention the absolute risk reduction for 
major vascular event observed in the HPS was used. 
4.3.6 Statistical analysis 
Data analysis was perfonned using the Statistical package for Social Sciences 
(SPSS) for Windows, version 12.0.2. Basic characteristics of all subjects aged 
35-74 years were compared between ethnic groups using t-tests and Chi-Square 
tests as appropriate. The proportion of South Asian subjects eligible for primary 
and secondary prevention was compared to that of Caucasians meeting the same 
eligibility criteria using the Chi- square test. Analysis of covariance and logistic 
regression were used to adjust for age and gender. Prevalence rates of 
cardiovascular diseases in each category were directly standardized to the 
combined age distribution of the groups being compared (South 
Asians and 
Caucasians). 
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Selecting people with 10 years CHD >= 15% for the next 10 years 
Calculating the mean risk for both ethnic groups 
I 
Using relative risk reduction of people without prior CHD in the HPS 
study 
Calculating absolute risk reduction for both ethnic groups 
Estimation of number needed to treat 
Figure 4.2 Calculating number needed to treat for primary 
prevention in South Asians and Caucasians 
4.4 RESULTS 
4.4.1 Characteristics of the population 
Table 4.1 and 4.2 show mean data for all men (N = 5590) and women (N = 6298), 
aged 35 - 74 years, separated according to ethnicity and availability of serum 
cholesterol measurement. Participating South Asians were 3.9 years younger than 
Caucasians (95% Cl: 3.3 to 4.4), P<0.0001 after adjustment for sex. 
As can be seen, a higher proportion of Caucasians of both sexes provided blood for 
a cholesterol measurement. Those with no cholesterol measurement tended to be 
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older, had higher systolic blood pressure and were more likely to have a history of 
cardiovascular disease (myocardial infarction,, angina or stro 111f-ý ke). 
Table 4.1 Basic characteristics of men aged 35 -74 years according to presence of serum 
cholesterol measurement 
Caucasians South Asians 
TC measured TC not measured TC measured TC not measured 
Number 3255 (71%) 1320(29%) 555 (55%) 460(45%) 
Total cholesterol 5.71 5.53 
(MMOUI) (5.67 to 5.74) (5.44 to 5.61) 
Hiah density lipoprotein 1.29 - 1.15 
cholesterol (mmol/1) (1.27 to 1.30) (1.12 to 1.17) 
Age (years) 51.3 53.1 47.4 50.4 
(50.1 to 51.7) (52.5 to 53.7) (46.5 to 48.3) (49.4 to 51-4) 
Systolic blood pressure 
(mm-Hg) 
Diastolic blood pressure 
(mmHg) 
Smokers 
Diabetes 
137.9 136.1 1j -ý). u 
1-)/. 4 
137.3 to 138.5) (137.3 to 140.0) (133.5 to 136.5) (134.2 to 140.7) 
79.8 79.2 79.8 80.1 
(79.4 to 80.2) (78.3 to 80.2) (78.8 to 80.7) (7 S. 0 to 82.1) 
885 (27.2%) 418(31.7%) 166(29.9%) 170(37.0%) 
105 (3.2%) 67(5.1%) 73(13.2%) 80(17.4%) 
* P<0.01 after adjustment for age 
(Comparison between Caucasians and South Asians for whom cholesterol measurement was available) 
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Table 4.2 Basic characteristics of women aged 35 -74 years according to presence of serum 
cholesterol measurement 
Caucasians 
umber 
Total cholesterol 
(Mmoul) * 
High density lipoprotein 
cholesterol (mmot/1) 
1. Age (years) 
Systolic blood pessure 
(mmHg) 
Diastolic blood pressure 
(mm. Hg) 
Smokers 
Diabetes 
TC measured 
3666(69%) 
5.77 
(5.74 to 5.8 1) 
1.57 
(1.56 to 1.59) 
51.4 
TC not measured 
1709(31%) 
South Asians 
TC measured TC not measured 
468(51%) 455(49%) 
5.20 
(5.11 to 5.29) 
1.35 
(1.31 to 1.38) 
53.2 
(5 1.1 to 5 1.8) 
133.4 
(132.8 to 134.0) 
73.8 
(73.4 to 74.2) 
1035 (28.2%) 
68(l. 9%) 
46.3 48.8 
(52.7 to 53.8) (45.4 to 47.1) (47.5 to 49.7) 
137.1 131.0 133.1 
(135.7 to 138.5) (129.1 to 132.9) (129.6 to 136.7) 
74.4 74.4 75.6 
(73.5 to 75.2) (73.4 to 75.5) (73.7 to 77.4) 
503(29.4%) 18 (3.8%) 12(2.6%) 
62(3.6%) 44(9.4%) 54(11.9%) 
* P<0.01 after adjustment for age 
(Comparison between Caucasians and South Asians for whom cholesterol measurement was available) 
4.4.2 Cardiovascular disease risk factors 
The mean total and high density lipoprotein cholesterol concentrations were higher 
in Caucasians than South Asians and the difference persisted after adjustment 
for 
age and sex, mean differences were 0.18 mmol/l (95% Cl: 0.09 to 0.27, 
P 0.002) 
and 0.20 mmolll (95% Cl: 0.18 to 0.23) respectively. More Caucasian women were 
smokers, odds ratio =9.8 (95% Cl: 6.1 to 15.8). In general the prevalence of 
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diabetes in both genders was more than three times higher in South Asians, 11 . 5% 
versus 2.9% in Caucasians (Chi-Square Test, P<0.0001). 
4.4.3 Current lipid lowering treatment 
Overall rates of current lipid lowering were similar in South Asians (3.8%) and 
Caucasians (3.1 %) P= 0.227. However Caucasian women were nearly twice as 
likely to receive lipid-lowenng drugs than South Asian women; 2.4% and 1.4% 
respectively; Chi-Square Test; P= 0.062. 
4.4.4 Cardiovascular disease prevalence and secondary prevention 
needs 
Figure 4.3 shows the age-standardized prevalence of cardiovascular disease in I: ) ID 
South Asian and Caucasian men and women. 
subjects aged 35-74 years including all participants with total 
cholesterol measurement 
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Figure 4.3 Age -standardized prevalence of cardiovascular 
disease in 
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The prevalence of angina and history of previous stroke was higher in South Asian 
men and women than in Caucasians. Taking all cardiovascular diseases together, in 
men, 12.1 % of South Asian and 7.4% of Caucasian would need to receive statins 
as secondary prevention, Chi-Square test, P<0.0001. The secondary prevention 
needs in women were 4.6% for Caucasians and 5.1 % for South Asians. 
4.4.5 Candidates for Primary prevention 
South Asians were more likely to be in the higher risk group for CHD events 
(Fig 4.4,4.5). Because of this both South Asian men and women in all age groups 
were more than twice as likely to meet the eligibility criteria for drug treatment for 
the primary prevention of CHD than Caucasians (P<0.001). Overall 43 % of South 
Asian men were predicted to have a CHD risk > 15% (20% CVD risk), ranking 
from 20.0% at age 35-44 years to 98.0% at age 65-74 years. These proportions 
were 29.8%, 5.0%, and 90.0% in Caucasian men respectively. In women,, overall, 
13.5% and 7.2% of South Asian and Caucasian women were above this level of 
CHD risk. The most stnking feature of those figures is that more than 93.0% of 
South Asian men and nearly 68.0% of Caucasian men aged 55-74 years would 
have a risk of CHD events of 15% or higher over 10 years. Among South Asian 
and Caucasian women, older than 55 years, the prevalence of this level of CHD 
nsk was 55.7% and 18.5% respectively. 
Within the South Asian ethnic groups both male and female Bangladeshis were 
more likely to be at higher CHD event risk when compared to 
Pakistanis and 
Indians (Table 4.3). However, the numbers in sub-groups of the South Asian 
population are too small to allow meaningful 
investigation of heterogeneity and 
comparison between groups. 
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Table 4.3 CHID event risk according to ethnic group in subjects aged 35-74 years 
Caucasian Indian Pakistani Bangladeshi 
No. with TC measured 2946 254 145 91 
Less than 15% 2000 136 83 38 
10- vear risk (67.9%) (53.5%) (57.2%) (41.8%) 
15-30% 787 75 39 29 
Men 10- year risk (26.7%) (29.5%) (26.9%) (31.9%) 
Greater than 30% 159 43 23 24 
10- year risk (5.4%) (16.9%) (15.9%) (26.4%) 
No. with TC measured 3412 256 116 58 
Less than 15% 3140 220 98 47 
10- year risk (92%) (85.9%) (84.5%) (82.5%) 
15-30% 255 31 16 8 
Women 10- year risk (7.5%) (12.1%) (13.8%) (12.4%) 
Greater than 30% 17 5 2 n 
10- year risk (0.5%) (2%) (1.7%) (5.2%) 
4.4.6 Drug treatment costs 
Extrapolating from the prevalence calculated in this study, Table 4.4 shows the 
proportion of the population who may be candidates for primary (>15% CHD risk 
in ten years) and secondary prevention; the total numbers are based on the 2001 
Census. The total drug cost using simvastatin for both primary and secondary 
prevention would be about f 172 and f 18 million per year 
for Caucasian and South 
Asians men respectively (the costs has fallen since then). Although these costs are 
high treatment at this level of risk is cost-effective (Ebrahim et al., 1999). 
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Approximately 9 people would need treatment for 10 years to prevent one coronary 
e\'ent as a secondary prevention, at a cost of f 1,818.00 per event prevented. In 
primary prevention 36 and 29 Caucasian and South Asian men aged 35-69 years 
Nvould need statins therapy for 10 years to prevent one coronary event, at a cost of 
E7,277.00 and E5,858.00 per event prevented respectIvely. More women need 
treatment for 10 years to prevent an event; 44 Caucasians and 41 South Asians 
with costs of f 8,888.00 and E8,282.00 per CHD event prevented respectively. 
Table 4.4 Implications of primary* and secondary prevention in UK population aged 
35-74 years 
Men Women 
Caucasians South Asians Caucasians South Asians 
(n=6698930) (n=325194) (n=7053059) (n=302837) 
Total requiring treatment 
for primary and secondary 850)764 89ý428 894ý28 205896 
prevention (12.7%) (27.5%) (4.2%) (6.9%) 
Total cost (million pounds) f 171.9 f 18.1 f 59.8 E4.2 
* CHD risk > 15% in ten years (equivalent to CVD risk > 20% over ten years) 
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4.5 DISCUSSION 
The current work predicts the number of British South Asians eligible for lipid 
lowering treatment based on guideline specified risk thresholds and an ethnically 
adjusted risk estimate. More South Asian men aged 35-74 years, 18.4% (95% Cl: 
14.9 to 21.8), are at the NSF-CHD risk level (>30%) which warrants lipid-lowering 
treatment, whilst the proportion of Caucasians, at 5.4% (95% Cl: 4.6 to 6.2) is 
much lower. The picture in women is similar with 2.3% (95% CI: 0.9 to 3.8) and 
0.5% (95% Cl: 0.3 to 0.7) of South Asian and Caucasian women respectively being 
eligible. 
For secondary prevention, 12.1% (95% Cl: 9.3 to 14-8) of South Asian and 7.4% 
(95% Cl: 6.4 to 8.2) of Caucasian men are candidates for drug treatment. Fewer 
women are eligible with a fractionally higher need in South Asians at 5.1% (95% 
CI: 3.2 to 7.3) compared with 4.6% (3.9 to 5.3) in Caucasians. 
4.5.1 CVD risk investigation in ethnic minorities and sample bias 
Any study of etbnic differences in cardiovascular risk distribution requires a 
representative sample. The HSE 1999 is well designed to provide this with an ideal 
sample frame and response rates for interview of 71-92% in adults in all ethnic 
groups. However no data were available about non-respondents to interview and 
44 - 48% of the South Asians and 27% of the Caucasians had no total cholesterol 
measurements. Although this leaves the data open to response bias it is unlikely 
that superior information could be achieved by any method depending on voluntary 
consent to providing information and samples. It is therefore important to consider 
the possible implications of any bias present. Subjects not providing a sample for 
total cholesterol were much more likely to have a history of previous vascular 
disease, had higher blood pressure and more commonly smoked (Table 4.1 & 4.2). 
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Even amongst respondents without a prior history of vascular disease blood 
pressure and smoking prevalence were higher in those not providing a blood 
sample. Davis et al. reported a higher cardiovascular risk in non-responders to the 
British family heart study (Davel 1994). Any bias therefore likely to is et al, I 
underestimate the need for treatment. However I estimate that the impact of any 
such bias would be small. Assuming the cholesterol values were identical in groups 
who did not provide blood samples would change the percentage eligible for 
treatment by only 0.2% in men. In addition, with an assumption based on the Davis 
report of 3.21% higher total cholesterol concentration in non-respondents to total 
cholesterol measurement the proportions of people with CHD risk > 30% only 
would increase by 0.5% and 0.3% in men and women respectively. 
Furthermore the low response rate to cholesterol sampling does not detract from 
the comparison of ethnic groups in their need for primary prevention treatment. 
4.5.2 Accuracy of the Framingham equation 
A study in the British population contrasting Framingham risk with annual hospital 
in-patient admission data reported that the risk function estimates CVD events well 
according to annual number of CVD events derived from the 2001 UY, hospital 
in-patient episode statistics (Shearer et al., 2005). There are however populations 
within the LTK for whom Framingham may overestimate risk (Brindle et al., 2003). 
The assumption that no-one had LVH of the severity used as a risk predictor in the 
Framingham equation is unlikely to be a major source of bias as its prevalence 
even in hypertensive populations is exceedingly low (Levy, 1988). Although use of 
on treatment blood pressure rather than pre-treatment may bias estimates of CHD 
risk the proportion of Caucasians and South Asians who received antihypertensive 
treatment was similar. It has been shown in chapter 2 of this thesis that a 
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reasonable estimate of CHD risk in non-diabetic South Asians is derived by 
multipl ing risk from 11 Yl the Framingham equation by a factor of 1.79. The validity of 
this estimate might be in further question for women as it is derived from data 
mostly in men (about 80%). Ethnicity clearly impacts on risk in South Asian 
women who have a similar prevalence of CVD to that of Caucasian women despite 
dramatically lower rates of smoking. The impact of most known risk factors for 
CVD does not vary with gender and it is likely that a finding in men can, with 
caution, be extrapolated to women. Coronary risk in diabetic South Asians is 
similar to that in Caucasians (personal communication, LTKPDS group). Whatever 
the accuracy of the Framingham equation, this currently forms the basis for 
calculating risk in clinical practice and is central to judging eligibility for 
treatment. Therefore under or over estimation of risk by this equation should not 
effect the accuracy of predictions of the number of patients likely to be offered 
treatment for primary prevention. 
4.5.3 Different total cholesterol thresholds 
Ul Haq et al. (1996) used data from subjects aged 35-69 years in the Health Survey 
for England 1993 with serum cholesterol higher than 5.5 mmol/l to calculate the 
number of possible candidates, aged 35-69, for secondary and primary prevention. 
They reported 5.9% and 3.6% of men and women, respectively, might be 
candidates for lipid-lowering treatment for secondary prevention and 6.2% of men 
and 0.4% of women for primary prevention, CHD risk over 10 years ý! 
15 %. Their 
estimates are similar to my findings suggesting that abandoning the cholesterol 
threshold in the NSF impacts little on the need for statin treatment. 98% of those 
with a history of CVD had cholesterol > 3.5 mmol/l and if we assume 
that all with 
such history were above the cholesterol 
threshold data from those without a 
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measurement of cholesterol concentration can be included in my estimates of the 
need for secondary prevention. Eligibility for statins will then be slightly higher in 
Caucasian men and women, 10.8% and 5.7% respectively compared to 9.8% in 
South Asian men, and 4.5% in women. 
4.5.4 Updated gqidelines 
Initial recommendations were that a threshold of 3 0% over 10 year CHD event risk 
be used to judge eligibility for statin treatment. This has now been modified to a 
CVD risk threshold of 20%, approximately equivalent to CHD risk threshold of 
15% (Williams et al., 2004; JBS-2,2005). As can be see fTom Figure 4 and 5 this 
will increase the numbers eligible for treatment dramatically but does not diminish 
the reported differences between South Asians and Caucasians. However the 
CHD : CVD risk ratio might be different in South Asian as this relationship is 
different for Caucasian men and women, and within each gender for younger and 
older groups (Yeo & Yeo, 2002). On this basis Cappuccio proposed an even lower 
threshold of CHDT-isk for ethnic minorities (Cappucclo et al., 2002). 
4.6 CONCLUSION 
Although statins may be cost-effective and produce reasonable benefits both in 
Caucasians and South Asians providing appropriate treatment for the high numbers 
needing primary or secondary preventions (Table 4.4) will require substantial new 
resources and may well have a societal impact, the majority of the elderly 
becoming patients. 4.6% of the LJK population aged 35-74 are South Asians 
whereas about 10% of possible candidates for primary and secondary preventions 
are from this group. Therefore South 
Asians will have to be specifically targeted in 
primary prevention strategies. In addition the management 
(manpower) costs of 
implementing the targets might 
be higher for South Asian population because of 
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the additional input from the specialist nurses and linked workers required for this 
Particular gToup. These costs were estimated about 40% higher in the United 
Kingdom Asian Diabetes Study (UKADS) compared to costs in the UK 
Prospective Diabetes Study (UKPDS) (O'Hare et al., 2004). 
Underpinning these estimates of treatment need are the assumptions that desire for 
treatment, compliance, and effectiveness are identical between populations. 
Although patient factors are critical for the population effectiveness of drug 
interventions they have received little research attention. 
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PATIENTS'ACCEPTANCE OF 
ANTI HYPERTENSIVE THERAPY TO 
PREVENT CARDIOVASCULAR DISEASE: 
A COMPARISON BETWEEN SOUTH 
ASIANS AND CAUCASIANS IN THE UK 
Chapter 5 
5.1 INTRODUCTION 
Increasingly patients' preferences and values are explicitly incorporated into 
decisions about treatment (Hayens et al., 2002 & RPSGB, 1997). The importance 
of patients' involvement in decision-making is because of their right to. know the 
risks and benefits they accept in undertaking treatment and the as yet unproven 
hope that this will improve compliance. Patients will bring a range of views to their 
decision amongst the treatment options, incorporating personal values, personal 
and family experience (e. g. illness), degree of aversion to risk, and willingness to 
take medicines (in general) (Devereaux et al., 2001). Patients' priorities, in relation 
to treatment, may also differ from those of clinicians, and may lead to choices 
, apparently contrary to guidelines which are usually derived from clinical trial 
evidence of safety and efficacy alone. Whilst many people wish to be involved in 
decisions about their medical treatment, most prescribing decisions are still not 
made jointly (Charles et al., 1997). There are two key elements in any decision: the 
likelihood of any event consequent on the specific choice and the value of this 
outcome to the decision maker (Taylor, 2000). A patient's preference for one 
outcome over another is a reflection of the likelihood infon-nation provided as well 
as understanding of the outcome and the value they attitude to it. As the response 
to treatment is not absolutely guaranteed, patient's decisions are made in the 
uncertainty of whether the eventual outcome might or might not be the desired one. 
Patients make specific health decisions infrequently, and most decisions are made 
with little preparation or repetition. In contrast physicians have a relatively good 
understanding of the range of outcomes and the risks and benefits of treatment and 
are accustomed to making complex decisions. However, involving the patient in 
the decision making process brings a completely new set of circumstances into 
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play. The way of describing choices and the language used to describe possible 
outcomes have marked effects and may influence which options are eventually 
chosen. It is crucial that patients receive relevant and accurate information in a 
fon-n that is amenable to them to assist in selecting the treatment option most 
appropnate for them. 
The multifactonal nature of atherogenesis makes the process of cardiovascular 
prevention complex. Analysis of the results of randomised clinical trials has 
demonstrated that the risk of cardiovascular disease (CVD) detennines the chance 
of benefiting from primary prevention drug therapy such as antihypertensive or 
lipid lowering therapy, such that those at highest risk gain greatest benefit 
(Anderson et al., 1991; HPS, 2002). Current UK guidelines recommend treatment 
with ant1hypertensive drugs for those with mild hypertension whose 10 years CVD 
event nsk is at least 20% (JBS-2,2005). People of South Asian descent are at 
higher risk of CVD mainly because of an excess of dysglycaemia and frank 
diabetes. They should therefore have more to gain fTom primary prevention with 
lipid-lowenng and ant1hypertensive drug treatment and as a consequence be more 
likely to be prescribed such treatment. Observational data do not however 
satisfactory support this. Age-standardized rates of lipid testing in South Asians 
and non-South Asian men , in 14 general practices 
in Manchester, were reported 
similar and the rate was higher in South Asian women compared to non-South 
Asian women (France et al., 2003). Importantly in this study the change in 
cholesterol level on retesting did not differ between South Asians and other groups. 
There is however evidence that South Asians are less likely to receive preventive 
treatments. Patients in practices with a greater South Asian population are less 
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likely to be prescribed lipid lowering drugs (Patel et al., 2002). During an average 
of nearly 5 years follow-up in a group of diabetic patients in Glasgow, South 
Asians were prescribed significantly fewer prescriptions for antihypertensive 
agents and had smaller improvement in blood pressure than Caucasians 
(Mukhopadhyay et al., 2005). 
5.1.1 Eliciting patient preference 
Fundamental to eliciting patient preferences is the assumption that these already 
exist in the patient's mind, and that by presenting the patient with data in an 
appropriate way the choices be elicited (Llewellyn-Thomas et al., 1982). In the 
process of eliciting patient preferences, inforination has to be provided on the 
outcomes, benefits,, complications, and costs of each treatment. To elicit a patient's 
view about treatment two methodological approaches can be employed: "medical 
decision-making" and "probability trade-off' techniques. The first approach is 
derived from formal decision analysis, and is widely advocated for formulating 
health policy and constructing clinical guidelines. A decision analysis begins with 
construction of a formal decision tree which models the various outcome health 
states. Then, the probability that a particular treatment option will lead to each of 
the health states is estimated using the clinical literature relating the particular 
health-care problem. In the next stage the relative desirability of each outcome 
health state is estirpated using a technique that generates utilities like the standard 
gamble. A patient's choice then depends indirectly upon their personal valuation of 
each possible health outcome. The "probability trade-off' approach is a direct 
assessment of patient preferences for treatment. It can be structured to illustrate in 
a highly graphic way the actual complex dilemmas patients often face and its 
procedures can be arranged as to engage the patient in explicitly considering the 
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trade-offs involved (Llewellyn-Thomas 1997). Patients are given information 
about the treatment options, outcomes, and probabilities. This information is 
presented sequentially and arranged in pairwise columns to permit gradual 
assimilation of the information as well as clear comparisons. Then the described 
efficacy of the treatment is systematically varied until patients switch their 
treatment preferences (Bowling & Ebrahim, 2001). In other words, the preferences 
of patients can be elicited by determining the smallest differences that they 
perceive as beneficial and which would warrant, after considering cost, 
inconvenience, and side effects of receiving treatment. This is termed the minimal 
clinically important difference (MCID) (Jaeschke et al., 1989). Individuals 
participating in probability trade-off technique exercises are standing at the actual 
decision-point of treatment selection and looking down the decision tree towards 
the possible outcomes treatment (Man-Son-Hing et al., 1996). This approach helps 
people to understand the uncertainties in the treatment choices and to articulate 
their preferences. Such a process may promote patient confidence in the decisions 
that are eventually taken, possibly leading to better compliance. In contrast in 
decision analysis the investigator stands at the outcome end of the decision tree, 
looks back through the tree using probabilistic and evaluative infonnation gathered 
in the past to compute the expected utility of each treatment option, and draws 
conclusions about what the decision should be for future patients in the same 
clinical situation (Llewellyn-Thomas, 1997). The other important difference 
between these techniques is the method of decision making. In the decision- 
analysis approach the model is imposed a prion and is rigid whilst in the latter 
patients can utilise their own heuristics to make a choice for each scenario given. 
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The preference elicitation task can be described to the subjects using two 
approaches: titration (steadily changing one option) and ping-pong (going back and 
forward between options). Preferences are strongly influenced by the elicitation 
process and these two methods produced significantly different measurement on 
repeated testing (Lenert et al., 1998). In addition presenting choices to patients 
within a neutral, positive, or a negative frame produces differing responses. The 
effect of fTaming has an important role in the elicitation process (Tversky 
Kahneman,, 1981; McNeil et al., 1982). As preferences directly reflect the 
underlying values of the patient, there is a possibility that individuals will differ 
widely on which components they consider relevant to a particular decision and it 
is important to explicitly describe attributes of the outcomes of treatment using a 
systematic view of the literature and/or expert consensus (Taylor, 2000). As a 
result different principal dimensions of value in the choice between treatment 
options need to be clarified (e. g. safety, harins and inconvenience, benefits and 
survival effects, etc) to help individuals for informed decision making which 
project their attitudes. 
Patients' views about preventive drug treatment have been gathered in a range of 
studies. Most using probability trade-off estimates of willingness show that 
patients are less enthusiastic for treatment than doctors or other clinicians and the 
median benefit demanded is often far greater than that demonstrated in any clinical 
trial (Steel, 2000; McAlister et aL, 2000; Lewis & Barton, 2003). However there 
are no previous studies which have measured ant1hypertensive preferences 
specifically in South Asians and compared them with Caucasians. 
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5.2 AIM OF THE STUDY 
9 To establish people's willingness to receive ant1hypertensive treatment for 
primary prevention of CVD 
To explore the relationship between ethnicity and individual attitude to 
prescribed ant1hypertensive as primary prevention drugs 
5.3 METHODS 
5.3.1 Participants 
A sample of Sheffield residents aged 35-74 years with or without history of 
cardiovascular disease were interviewed. Names of potential participants were 
identified from the Sheffield Population Health Register which holds the names 
and addresses of all patients who are registered with a Sheffield General 
Practitioner. This list is maintained by Sheffield South East Primary Care Trust 
(PCT) on behalf of all four Sheffield PCTs and is updated on a regular basis (Coy 
et al, 2002). 
The computer program, Nam Pelichan (Nam Pelicham, version 1.1) was used to 
select possible South Asian names ftom which to sample. This computer 
programme was developed by Bradford City Council and Health Authority in the 
1980's. The software contains a dictionary of South Asian names which it attempts 
to match against the complete name or the name stem (usually the first five 
characters of an individual's name) in order to identify a list of South Asians 
together with a language and religion marker for each person. Cummins et al. 
(1999) reported that this computer programme misclassified some names and 
produced inconsistent results across the United Kingdom's South Asian population. 
However, with the names from Yorkshire area, where the software was developed 
it performed satisfactory. 
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A sample of 1080 South Asian was selected. A group of Caucasians matched for 
age (± 5 years range), gender, and residence in the same Electoral Ward was then 
selected to give two similar goups. In an earlier study in Sheffield (Price & 
Skinner, 2003), South Asians had lower response rate (about half) compared with 
Caucasians. In an attempt to produce roughly equal numbers of South Asians and 
Caucasians eventually interviewed the size of the Caucasian gToup was reduced to 
540 by a simple random selection process. No exclusions other than age were 
applied. 
5.3.2 Preference measurement 
A modified version of the tool developed by McAlister et al to elicit MCIDs for 
ant1hypertensive therapy was used (McAlister et al., 2000). 
5.3.2.1 Questionnaire 
The questionnaire had two parts. The first part presented three hypothetical 
scenarios with different baseline cardiovascular risks. At each baseline risk of 10, 
20,, and 40% over 10 years participants MCIDs were identified. In the second part, 
subjects were asked to provide basic demographic data including age, sex, 
ethnicity, educational level, occupation, history of CVD, and whether they were in 
receipt of antihypertensive drugs. 
5.3.2.2 Scenarios 
Brief descriptions were given in lay ternis about the personal impact of 
hypertension, myocardial infarction, stroke, and the effect and tolerability of drug 
treatment. After describing the treatment options and the potential outcomes 
participants were asked to choose between not accepting the therapy (given the 
baseline risk of an adverse outcome) and accepting the therapy (given a reduced 
risk of the adverse outcome but also incurring the inconvenience, cost and side 
effects associated with that therapy). Choices were presented to subjects both 
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graphically and numerically with risks expressed in positive and negative terms. 
The gTaphical presentation used 100 stick figure icons to show percent frequencies 
at risk and benefiting from treatment (Schwartz et al., 1997; Gigerenzer, 1996; 
Elting et al., 1999). To determine the MCID the event rates were varied back and 
forth by halving steps until participants switched from accepting to declining 
treatment or vice versa. Figure 5.1 is an illustration of steps for the scenario with a 
risk without treatment of (10%) over 10 years. 
A Subjects' MOD for a given scenario is the smallest benefit for which he or she 
would accept treatment. If a subject chooses to accept therapy when the 
cardiovascular risk is reduced with treatment from 10% to 1%, 2%, 3% or 4% but 
not when the risk is reduced with treatment from 10% to 5%, his or her MCID will 
be 6% for this scenario (10 -4= 6%). 
MCID 
9%, 
No oil ý'o 
No 7% Y 
No 6%j 01 /0 
No 
YCS lp 3 c"s Ycs 
No No No 
ý4' 
2% No 
No 1 1% 0. Yes 01 
No 0. Yes 0,0"'o 
No* Notat ; ýtll 
Figure 5.1 Steps for elicitation the MCI D if a baseline heart attack and stroke risk without 
taking antihypertensive medication is 10% over the next 10 years (the scenario 1) 
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5.3.3 Study procedure 
5.3.3.1 Making contact 
The PCT identified the South Asian and Caucasian subjects, as described in 
participants- methods section in this chapter (page 94), and sent them a covering 
letter and an information sheet (appendix I& 3) via post in March 2004. Stamped 
addressed envelopes were provided for replies (appendix 4& 5) to the research 
group. Names of the respondents from the information sheet was detennined and 
fed these back to the PCT. The difference between the full list of names held by the 
PCT and the respondents was used by them to produce a list of non-respondents. 
Up to two reminders (appendix 2) were mailed to people who had not replied 
within two weeks after each mail shot by this method which maintained 
confidentiality. Then positive respondents were contacted to arrange a convenient 
time for interview. These were held in participants' homes or at the hospital 
according to participants' preference. Travel expenses were offered if interviews 
took place at the hospital. The background information (appendix 8) was sent to 
each interviewee after setting the date of interview to make sure she/he had enough 
time to read it before the interview appointment. 
5.3.3.2 Collecting data 
An interviewer fluent in the appropriate language to each non-English speaking 
informant was allocated so that the interview could be conducted in the informant's 
own language. Interviewers were recruited from native speakers of these languages 
amongst clinical students and health professionals and underwent specific training. 
The complexity of the study requires that a number of procedures in the interview 
be described in detail and it was essential that this process was as reproducible as 
possible. Interviewers attended two training sessions and also received a manual 
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of operation for the interview (appendix 7). To ensure that participants had all 
information required before embarking on the study answers to the following 
question were provided in the training sessions: 
* What is the study trying to find out? 
9 What is involved in the study? 
e How paiticipants have been chosen? 
e What is involved in the interview? 
* What is involved in the questionnaire and scenarios? 
9 Where the interview will take place? 
* What is in the interview process? (explaining the inforination sheet, signing 
the consent forin (appendix 6) , using the standard method 
for presenting 
background infonnation and scenarios). 
Most importantly potential interviewers also undertook role-play of the actual 
interview to help standardize the process. 
5.3.3.3 Translation of the survey material 
All letters of invitation, survey materials and questionnaires were translated into 
five languages: Hindi, Gujarati, Punjabi, Urdu, and Bengali to elicit individual 
responses and avoid the use of other household members as interpreters. 
Translators were qualified members of the UK Institute of Translation & 
Inteipretation (htt-D: //www. iti. org. uk/). 
5.3.4 Sample size 
McAlister et al (McAlister et al., 2000) reported mean patients' MCID for 10% 
CHD risk in 5 year as 4.0, SD (c) =3.73 (calculated from 95% Q. A difference 
of one percent in MCID (p, - P2) or greater between South Asians and 
Caucasians is likely to be of practical importance. The risk of Type I and 11 errors 
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accepted were 5% (a ) and 20% (, 8) respectively; therefore, the calculated sample 
size was 216 in both South Asian and Caucasian groups. 
f (a,, 8) xc2x 
(PI - P2 ) 
7.9 x 13.7 x2= 216 
1 
Price and Skinner (Price & Skinner, 2003) reported 30% and 50% response rates to 
an earlier postal questionnaire for South Asians and Caucasians in Sheffield 
respectively. It was assumed that the response rates for interview would be lower, 
perhaps 20% for South Asians and 40% for Caucasians. The numbers of letters 
distributed to achieve the estimated sample size were therefore 540 in Caucasians 
and 1080 for South Asian ethnic groups. 
5.3.5 Data analysis 
Responses fTom completed surveys were entered into the Statistical Package for 
the Social Sciences (SPSS) for Windows version 11.5. Maximum MCIDs in a 
given scenario were assigned to participants who indicated that they would never 
take medication at all (10,20, and 40 in scenarios 1,2, and 3 respectively). The 
distribution of the MCIDs in all three scenarios was assessed. The miMMal 
clinically important differences of South Asians and Caucasians were compared 
using the Mann-Whitney test. The proportions of South Asians and Caucasians 
choosing treatment in each case were compared using the Chi-square and Fisher's 
Exact tests. For all tests, the alpha level for statistical significance was 0.05. 
Socioeconomic status was measured using Carstairs deprivation scores (Carstairs 
& Moms, 1991) an indicator based on male unemployment, overcrowding, social 
class, and car ownership using data from the 2001 UK census. This index was 
constructed by Carstairs and Moms for the analysis of Scottish health data. 
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However it has been used as a discriminator of health status in England. In 
addition, the social class of participants between South Asians and Caucasians was 
analysed based on the categories for job titles developed by the National Statistics 
Socio Economic Status Classification -2001. 
5.3.6 Ethics 
The study protocol was approved by the South Sheffield Research Ethics 
Committee. Written consent was obtained prior to the interview for all participants 
and all responses were kept confidential. 
5.4 RESULTS 
During the 3 months of interview (from April 2005, to July 2005), 110 South 
Asians and 153 Caucasians were interviewed by 14 interviewers (6 for South 
Asians). Table 5.1 gives details of the responses to the invitation letters. 
More Caucasians replied to the initial invitation letter, 126 (81.8%) compared to 61 
(55.5%) South Asians (Chi-square test, P<0.0001). In contrast nearly half of the 
South Asians replied after the first or second reminders. 
Interyiews averaged 30-45 minutes and characteristics of participants are shown in 
the Table 5.2. More than 60% of women and about 58% of men had a positive 
history of CVD in their first-degree relatives (Table 5.2). No statistically 
significant differences were found in the prevalence of a personal or family history 
of CVD or current treatment with ant1hypertensive medications between South 
Asians and Caucasians of either gender. There were trends however for all these to 
be greater in South Asian respondents seen most strongly in South Asian women 
who were more likely to have a family history of CVD (P = 0.06). , 
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Table 5.1 Details of responses to the invitation letters in South Asians and 
Caucasians 
South Asians Caucasians 
Letters sent 1080 540 
Letters returned by post (addressee 
47(4.4%) 25(4.6%) 
unknown or has gone away) 
Responses received 416(40.3%) 322(62.5%) 
Interview accepted 138(13.4%) 163(31.7%) 
Interview declined 263 (25.5%) 159(30.9%) 
Refused or moved when contacted by 
9 10 
research team 
Error in ethnicity allocation by software 18 0 
Died before being interviewed 0 
Participants who were interviewed 110(10.6%) 153 (29.7%) 
Up to 17% of participants in both ethnic groups indicated that they would not take 
medication however great the benefit, but this proportion declined with Increasing 
CVD risk, Figure 5.2. The proportion of South Asian men unwilling to take 
medication regardless of benefit was higher than Caucasians for all scenarios. The 
reverse trend was seen in women apart from in the highest risk scenano in which 
Caucasian women were less likely to refuse the treatment compared to South 
Asians. A subgroup of 9 participants (5 south Asians and 4 Caucasians) turned 
down medication in all three scenarios. 
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Table 5.2 Characteristics of participants by gender and ethnicity 
Men Women 
South Asians Caucasians South Asians Caucasians 
(n = 58) (n = 75) (n = 52) (n = 77) 
Age, mean (SD) 50.2(11.6) 52.2(12.0) 52.0(11.2) 51.7(10.7) 
Years of education 
< 6yr 0 0 5 (9.8%) 0 
6-12 yr 26(44.8%) 30(40.0%) 23(45.1%) 31(39.7%) 
> 12yr 32(55.2%) 45(60.0%) 23 (45.1%) 47(60.3%) 
Family history of CVD 34(58.6%) 43 (57.3%) 40(76.9%) 47(61.0%) 
History of CVD 13(22.4%) 14(18.7%) 7(13.5%) 7(9.1%) 
Currently taking BP 
19(32.8%) 15(20.0%) 11(21.2%) 9(11.7%) 
lowering medications 
The distnbution of MCIDs chosen was heavily skewed and medians were therefore 
estimated and non-parametric hypothesis tests employed. There was a strong 
positive correlation between the individual MCIDs expressed in scenario I and 3 
for both ethnicities, Spearman rho = 0.77, P<0.0001 and Spearman rho = 0.69, 
P<0.0001 in South Asians and Caucasians respectively. The overall median 
MCIDs for Caucasians was 4% in all scenarios (Table 5.3). Whilst for South 
Asians median MCIDs were 1%, 2%, and 1% in scenarios 1,2 and 3 respectively. 
Differences between both ethnic groups, independent of gender, were statistically 
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significant in scenario 1, P=0.002, but not In scenarios 2 and 3, P=0.24 and P=0.06 
respective y. 
Generally South Asians required less benefit before accepting treatment in all three 
scenarios (10,20, and 40% CVD in 10 years) compared to Caucasians, Table 5.3. 
The trend is consistent across the groups but was not statistically significant in 
men. In both ethnic groups participants who were taking blood pressure lowering 
medications had a lower MCID compared to those who were not, in all three 
scenarios (P < 0.0001, Man-Whitney U test). In addition people with a personal or 
family history of CVD had lower MCIDs in both ethnic groups although the trend 
was not consistently statistically significant. 
20.0 
16.0 
14.0 
12.0 
11 South Asian 
10.0 
E Caucasian 
8.0 
6.0 
4.0 
2.0 
; LO 
0.0 
Men 
ý 
Women Men Women Men 
ý 
Women 
1 O%CVD risk 20% CVD risk 40% CVD risk 
Scenarios 
Figure 5.2 Medication refused according to scenario, gender and ethnicity 
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Table 5.3 Minimal clinically important differences for the blood pressure lowering 
medication in South Asian and Caucasian men and women 
Men Women 
South Asians Caucasians South Asians Caucasians 
58) (n = 75) (n = 52) (n = 77) 
Scenario I 
(10% CHD risk 
in 10 years) 
Scenario 2 
(20% CHD risk 
in 10 years) 
Scenario 3 
(40% CHD risk 
in 10 years) 
Median 
(IQR**) 1.5 (1 -9) 3 (1 -7) 
*p=0.32 (0.40) 
(1 -5) 5 (2-9) 
*p=0.001 (0.001) 
Median 
(IQR) 3(l -14) 4(l -6) 
*p=0.64 (0.59) 
1 (1-10) 5 (1 - 11.3) 
*p=0.032 (0.018) 
Median 
(IQR) (1 -12.3) 4(1-8) 
*p=0.44 (0.28) 
1 (1-6) 4.5 (1-10.3) 
*p=0.063 (0-017) 
Mann-Whitney U test 
** Interquartiles 
§ After excluding subjects with history of CVD 
South Asian participants lived in more deprived areas compared to their Caucasian 
counterparts (Table 5-4). 
Table 5.4 Median and interquartiles of the Carstairs score in both ethnic groups 
by gender 
Men* Women** 
South Asian Caucasian South Asian Caucasian 
(n = 58) (in = 75) 
Carstairs score, Median 
(interquartiles) 
6.0 6.0 
(-1.0 to 8.0) (1.9 to 9.5) 
* P=0.03 5, ** P=0.020 (Mann -Whitney U test) 
52) (n = 77) 
4.9 6.0 
(-0.3 to 6.9) (2.6 to 8.0) 
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Socio-economic status classification according to occupation could only be derived 
for males but showed markedly different disthbutions for the two ethnic groups, 
P<0.0001 (Figure 5.3). More than 55% of South Asians had manual occupations 
whereas more than 63% of Caucasians had managerial occupations. Socio- 
economic scores derived from area of residence had no statistically significant 
effect on the MCIDs comparing South Asians and Caucasians. 
Figure 5.3 Socio-economic status classification in 
males by ethnicity 
1- Higher managerial 2- Lower managerial 
3- Intermediate 4- Small employers 
5- Lower supervisory and craft 6- Semi-routine occupations 
7- Routine occupations 8- Never worked (students) 
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5.5 DISCUSSION 
South Asian women given relevant information accepted antihypertensive therapy 
offering lower benefits than Caucasian women for all three scenarios (Table 5.3). 
The picture in men is more complex with a greater proportion of South Asian men 
totally declining treatment in all scenarios. However amongst those South Asian 
men who would accept treatment the picture was similar to that in women. Similar 
analysis excluding people who refused to take medication gave corresponding 
results for both, genders in most scenarios. 
5.5.1 Strength and weakness 
A standard and validated method was employed in this study and outcome data 
were presented to subjects both graphically and numerically with risks expression 
in positive and negative terms. This will have minimized framing effects 
influencing participants' selections. Use of visual illustration of the differences 
between treatments' effects, using icons, as well as numerical rates should also 
have facilitated understanding (Elting et al., 1999). Nevertheless the complex 
issues associated with lack of personal certainty makes such choices difficult. 
However the strong correlation of individual MCIDs between scenarios I and 3 
(Figure 5.3) and the trend for fewer people of both ethnic groups to reject treatment 
outright as the chance of benefit increased gives some reassurance that responses 
were not random and that complexity did not prevent rational decision-making ZDI 
In an attempt to guard against interviewer bias the interviewers were trained using 
standard training materials combined with a role-playing session, and used 
interviewers of identical ethnicity to that of the participant. Apart from the formal 
training and role-playing there was no check to assess consistency between 
interviewers. 
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Whilst the sampling frame was representative of the Sheffield population our 
results may have been subject to selection bias, because of the low response rate in 
both ethnic groups. Based on the reported response rate to an earlier postal 
questionnaire study in Sheffield it was expected the response rates for an interview 
to be about 20% for South Asians and 40% for Caucasians. In practice overall 
responses (both yes and no) in our study were similar to the earlier study but 
positive responses for interview were less than expected in both ethnic gToups. 
More women than men responded to this study, about 56% of non-respondents 
were men in both ethnicities. Non-respondents were 3.1 years younger in 
Caucasians and half a year in South Asian. They were more likely to live in 
deprived areas. In addition a post-hoc power calculation showed that the achieved 
sample size of 220-260 provides a power of 80.1 - 86.3% for comparison between 
South Asians as a whole with Caucasians. 
Trewby et al. (2002) showed that people with a history of CVD would accept 
treatment for smaller benefit. The comparison therefore was repeated between 
South Asians and Caucasians after excluding subjects with history of CVD. As is 
shown in the Table 3 the differences in MCID between South Asians and 
Caucasians persisted in all scenarios in both genders except scenario one in women 
(Table 5.3). Similarly results were largely unaltered by excluding subjects who 
were taking antihypertensive drugs. MCID differences changed only in scenario 
two for in women. 
Famillarities with CVD and concern about its prevention may have motivated 
people to particIpate in this research which could 
bias the MCIDs recorded. Fear of 
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stroke was reported as the most important factor influencing the MCID of warfarin 
therapy for the treatment of nonvalvular atrial fibrillation (Man-Son-Hing et al., 
1996). 
One possible explanation for these ethnic differences might be the higher 
prevalence of personal or family history of CVD or current receipt of 
ant1hypertensive treatment in South Asians but these factors would not explain the 
high rate of treatment refusal by South Asian men. 
Although the importance of standardized procedures for translation of instruments 
to other languages to ensure equivalency of translations was recognized, funding 
did not allow this check. All documents were translated using formal translation 
methods by translators recommended in the UK Institute of Translation & 
Interpretation website. 
Socio-economic status classification based on occupation is only presented for 
male subjects (Figure 5.3). Occupational status is an important component of 
socioeconomic status, summarizing the power, income and educational 
requirements associated with various positions in the occupational structure. It 
reflects the outcome of educational attainment, provides information about the 
skills and credentials required to obtain a job, and the associated monetary and 
other rewards (Burgard et al., 2003). However its validity might be in question 
because of difficulties in categorizing occupations. Failure to find a statistically 
significant difference of acceptance for ant1hypertensive therapy between South 
Asian and Caucasian men in this study might be due to the small number of 
112 
Chapter 5 
subjects in the different categories of this occupation classification. This 
classification is a national standard by the Office of National Statistics 
(http: //www. statistics. gov. uk/) and they do not recommend any adjustment for 
different ethnic groups. . 
5.5.2 Ethnic differences in use of preventive medicine 
In contrast to the higher cardiovascular morbidity and mortality among South 
Asian people in the United Kingdom, South Asian patients are less likely to be 
prescribed lipid-lowering drugs (Patel et al., 2005). This is not due to differences 
in rate of testing lipids (France et al., 2003) but might be related to use of tools 
such as Framingham which underestimate risk in South Asians and the use of 
specific total cholesterol thresholds. For a given risk South Asians will tend to have 
a lower total cholesterol concentration. Despite significantly lower baseline blood 
pressure levels among diabetic South Asian patients, the level of improvement over 
a mean period of 5.3 years in routine clinical practice was smaller in South Asians, 
compared to Europeans, commensurate with the significantly smaller proportion of 
South Asians who were on anti-hypertensive medication (Mukhopadhyay et al., 
2005). In this retrospective analysis it was also notable that use of insulin therapy 
was no higher in South Asians despite greater year-on-year deterioration in HbA,,, 
suggesting a deficit of South Asian insulin-treated Type 2 diabetes patients. 
Slightly greater reductions over time in systolic and diastolic blood pressure in 
European when compared with the South Asian diabetic patients have been 
reported in Blackburn, north-west England (McElduff et aL, 2005). Possible 
explanations for poorer control in South. Asians may include less intensive 
treatment, biological differences in response, and poorer compliance. Our results 
show South Asians acceptance of primary prevention treatment is similar if not 
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greater than, that for Caucasians. A difference in treatment acceptance is therefore 
unlikely to explain differences in prescribing patterns. 
5.5.3 Guidelines v patients wishes 
It appears irrational that some participants were unwilling to take therapy even 
when told it would abolish their personal risk of CVD. This pattern has been 
reported before (Man-Son-Hing et al., 1996; Reed et al., 1993; McAlister et al., 
2000) and it may be important to understand whether this reflects contrasting 
priorities between patients and clinicians or a flaw in the methods used to elicit 
patients' wishes. Similar disagreements were reported when the results of decision 
analysis were compared with guidelines for preventive warfarin therapy In atrial 
fibiallation patients (Protheroe et al., 2000; Lip et al., 2002). These illustrate the 
contradiction in our current approach to patients when we are supposed to be 
providing them with choice and putting them and their biographical experience at 
the centre of decisions but at the same time following practice based on research 
evidence (Sweeney & Heath 2006). 
One advantage of the MCID approach is that is a reflection of the decision making 
process patients may use in practice taking information provided by their nurse or 
doctor along with their own personal values to make a decision. 
5.5.4 What proportion of informed patients might be expected to 
refuse treatment 
In the current guidelines (Williams et al., 2004; JBS-2,2005) the threshold for 
initiating treatment in patients with mild hypertension is a 20% CVD risk in the 
next ten years. Given a 20% relative risk reduction with antihypertensive therapy 
this corresponds to aI 0-year MCID of 4%. Judged from our 20% CVD in 10 years 
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scenario 36-52% of Caucasians and South Asians would decline antihypertensive 
therapy at this level of risk. The existence of such subgroups points to the need for 
decision aids that can incorporate patients' individualized risk factors and make 
explicit their achievable risk reduction, given various modifications in their risk 
profiles (Llewllyn-Thomas et al., 1997). It is a matter of debate whether it is a 
doctors role to try to change patients views. 
5.6 CONCLUSION 
In conclusion South Asian participants were at least likely as Caucasians to accept 
antihypertensive treatment for primary prevention should be targeted for this type 
of treatment. Differences may in part be explored by different health and 
demographic factors between South Asians and Caucasians e. g. the former being 
more likely have a personal or family history of CVD. However given that this 
reflect the population burden of disease for these 2 groups this should still translate 
into a greater desire for treatment amongst South Asians at large. 
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BLOOD PRESSURE CONTROL IN SOUTH 
ASIANS AND CAUCASIANS IN THE UK 
Chapter 6 
6.1 INTRODUCTION 
Blood pressure has an approximately normal distribution in the population and 
those in the upper tail of the distribution are described as having high blood 
pressure or hypertension. Although high blood pressure is not in itself a 
symptomatic illness it is known to be a risk factor for cardiovascular disease 
(CVD) as it increases the likelihood of future stroke, coronary heart disease 
(CHD), and heart failure (Vasan et al., 2001; Kannel, 1996). No cause can be 
found in the vast majority of people with high blood pressure, and for these it is 
described as essential hypertension. Lifestyle factors such as: obesity, lack of 
exercise, excessive alcohol consumption, and too much salt in the diet can however 
exacerbate high blood pressure. 
Both systolic and diastolic blood pressures have continuous relationships with the 
nsk of developing CVD (MacMahon et al., 1990). This relationship is consistent in 
different populations, in younger and older subjects, in men and women, and is 
independent of other cardiovascular risk factors. Several clinical trials have 
demonstrated a reduction in cardiovascular events as a result of lowering blood 
pressure (Turnbull et al., 2003). A reduction in blood pressure by an average of 
12/6 mm Hg can be expected to reduce stroke by 40% and CHD by 20%. This 
definition of hypertension as a risk factor worthy of treatment is largely pragmatic 
and based on inclusion criteria in those clinical trials which showed benefits of 
blood pressure lowering in terms of reducing CVD. Hypertension is commonly 
defined in adults as a clinic systolic blood pressure ý! 140 mm Hg and/or a 
diastolic blood pressure ý! 90 mm. Hg. In patients with diabetes the benefit from 
drug treatment of hypertension may be greater and there is evidence that greater 
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blood pressure reduction down to a target of 130/85 provides greater benefit. 
Recent guidelines advise these separates targets for diabetic patients. The size of 
benefit from blood pressure lowering is dependent on pre-treatment risk. Although 
no risk directed stratification has been performed in trials, post-hoc analyses show 
that some groups e. g. white women who are at low risk gain little or may even be 
harmed by drug treatment of mild hypertension. For this reason a dual threshold of 
both risk and blood pressure is used to detennine whether or not to institute drug 
treatment of mild hypertension. Hypertensive patients with systolic pressures 140- 
159 mm Hg or diastolic pressures 90-90 mm Hg only warrant intervention with 
drug therapy if their total CVD risk over the subsequent ten years is >- 20%. In 
contrast patients with end organ damage have identified themselves as at high risk 
and automatically warrant treatment of hypertension. Indeed the HOPE (Yusuf et 
al., 2000) and PROGRESS (Staessen, 2001) studies suggest that for these groups 
antihypertensive drug treatment may be of benefit independent of blood pressure. 
Hypertension is one of several cardiovascular risk factors and should be treated as 
part of a multiple risk factor strategy. Measurement should be done using accurate, 
validated, and well maintained monitors with an appropriate cuff size (Williams et 
aL, 2004). 
Differences in the prevalence of raised blood pressure among minority ethnic 
groups have been found across the world and in different areas in England. Some, 
(Cappuccio et al., 1997; Chaturvedi et al., 1993) but not all studies, (Cruickshank et 
A, 1983) showed higher rates of raised blood pressure among people of South 
Asian origin. A study based on self-reporting, which investigated differences 
among subgroups within the South Asian communities as well as Whites, 
found 
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that people from the White, Pakistani and Bangladeshi groups reported similar 
rates of diagnosed hypertension, while Indians reported lower rates (Nazroo, 
1997). Using combined data from Health Surveys for England (HSE) 1992-1996, it 
can be seen that South Asian men older than 40 years are more likely to be 
hypertensive (systolic BP ý! 160 mm Hg or diastolic BP ý! 95 mm Hg, or be on 
antihypertensive medication) compared to Whites (OR 1.9; 95% Cl 1.4 to 2.4), 
after adjustment for age, BMI, smoking status, alcohol consumption, and social 
class (Primatesta et al., 2000). However the numbers of South Asians included in 
this analysis were small and reported mean blood pressure levels may be 
insufficiently robust. 
Agyemang & Bhopal (2003) reported discrepancies between the results of different 
studies in the prevalence of hypertension in South Asians living in the UK. Some 
reported lower mean systolic blood pressures, while others showed higher diastolic 
pressures in South Asian men. In women, more studies showed lower systolic 
blood pressures and higher diastolic pressures. 
In order to make an accurate assessment of the effectiveness of health programmes 
aimed at controlling high blood pressure, it is important first, to establish the mean 
blood pressure levels and the prevalence of hypertension in the population, 
particularly amongst the different ethnic groups, and secondly, to determine the 
proportion of people achieving adequate blood pressure control on 
antihypertensive treatment. The 'rule of halves' is a device used to illustrate the 
inadequacy of blood pressure management. This suggested that only 50% of 
hypertensives are diagnosed, and of these only 50% are treated, with only 50% of 
those on treatment being well controlled (Meade et al, 1978). As a consequence 
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only I in 8 of those with hypertension both receives ant1hypertensive therapy and 
achieves adequate blood pressure control. There is some evidence that this 
proportion may have changed at least in Western countries (Marques-Vidal & 
Tuomilehto, 1997). Colhoun and colleagues reported the rates for awareness, 
treatment, and control of hypertension (SBP ý! 140 mm Hg and/or DBP ý! 90 mm 
Hg) as 40%, 26%, and 6% respectively in England using data from the Health 
Survey for England 1994 (Colhoun et al., 1998). Rates of detection, treatment, and 
control of high blood pressure among the UK South Asians appear similar to those 
of the Caucasians (Lane & Lip, 2001). 
6.2 AIM AND OBJECTIVES 
9 To investigate the prevalence, treatment, and control of hypertension in the 
UK South Asian and Caucasian populations using HSE 1998 and 1999 
datasets 
* To explore the need for treatment in undiagnosed hypertensives in both UK 
South Asian and Caucasian communities (ý! 20% CVD risk over ten years) 
6.3 METHODS 
6.3.1 Participants 
Data from Health Surveys for England 1998,1999, and 2003 were used to study 
ethnic differences in blood control. More details regarding the methodology of this 
survey can be found in chapters 2&3 (2.5.3 & 3.2.1). People older than 35 years 
were included in the analysis determining the prevalence hypertension. 
6.3.2 Blood pressure definition 
In the Health Survey for England blood pressures were measured three times. To 
allow for the alerting response the mean of the second and third 
blood pressure 
measurements has been used in the current analysis. 
The value of the first reading 
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has been discarded. The definition of hypertension used was: SBP ý! 140 mm Hg 
and/or DBP ý! 90 mm Hg or being on ant1hypertensive medications. As some 
antihypertensive drugs are used for conditions other than blood pressure control 
drug treatment of hypertension was defined as taking one of the four common 
classes of antihypertensive medications (diuretics, beta blockers, calcium 
antagonists, and angiotensin converting enzyme inhibitors) prescribed by a doctor 
for the treatment of high blood pressure. Hypertension, control was defined as 
receiving antihypertensive medication with measured systolic blood pressure and 
diastolic blood pressure less than nominal treatment targets, :!! ý 140/85 mmHg in 
people without renal impairment, diabetes, or established CVD (Williams et al., 
2004). 
6.3.3 Prediction tool 
In those subjects aged 35-75 years with undiagnosed high blood pressure the 
Framingham equation was used to predict CVD risk. Risk derived from the 
Framingham equation was multiplied by a factor of 1.79 to provide a more 
accurate risk estimate for non-diabetic South Asians. This adjustment to predicted 
risk is described in details in chapter 2 of this thesis. Further discussion about the 
relationship between CVD and CHD risk is provided in the discussion sections of 
chapters 3 and 4. It remains a possible limitation to work introduced here. 
6.3.4 Statistical Analysis 
Analysis was carried out using Statistical Package for Social Sciences (SPSS) for 
windows software version 12.0. The proportion of South Asian participants eligible 
for treatment of hypertension (as defined above) and subjects who were taking 
antihypertensive drugs was compared with that of Caucasians, meeting the same 
eligibility criteria, using the Chi-square test. Analysis of variance and 
logistic 
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regression were used to adjust for age, gender and the presence of other 
cardiovascular risk factors. 
6.4 RESULTS 
The data from a total of 24,115 men and women (21,717 Caucasian and 2,398 
South Asians) 35 years and older from HSE 98,99, and 2003 were used in the 
analysis. Characteristics of participants included in the analysis broken down by 
gender and ethnicity are shown in Tables 6.1 to 6.4. Systolic and diastolic blood 
pressures were lower in 2003 compared to 1998-99 in both ethnic groups in both 
men and women. These differences were statistically significant after adjustment 
for age in Caucasians but not for systolic blood pressure in South Asian men or for 
diastolic blood pressure in South Asian women. The trends in blood pressure were 
however consistent between groups and the non-significant p-values in South 
Asians are likely due to smaller numbers of subjects available for analysis in these 
groups. 
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Table 6.1 Characteristics of South Asian men older than 35 years by the 
year of study 
1998-99 2003 p-value 
(% or 95% Cl) (% or 95% Cl) 
p-value after adjustment 
for age 
Number 
Age 
Systolic blood 
pressure 
Diastolic blood 
pressure 
Total 
Cholesterol 
HDL- 
cholesterol 
History of 
Stroke 
History of 
Myocardial 
infarction 
History of 
Angina 
Diabetes 
1042 
50.2 
(49.5 - 50.9) 
136.0 
(134.5 - 137.4) 
79.8 
(78.9 - 80.6) 
5.52 
(5.43 - 5.60) 
1.14 
(1.11 - 1.17) 
28(2.7%) 
62(6.0%) 
76(7.4%) 
154(14.8%) 
160 
50.4 
(48.9 - 52.0) 
134.4 
(131.5 - 137.2) 
76.7 
(74.9 - 78.5) 
5.58 
(5.35 - 5.82) 
1.26 
(1.20 - 1.32) 
4(2.0%) 
4(2.0%) 
10(6.3%) 
24(15.0%) 
0.77 
0.33 
0.003 
0.56 
* 
0.194 
0.006 
0.554 
* 
0.89 
0.07 
0.63 
0.94 
Current 
cigarette 292(28.0%) 21 (19.4%) < 0.001 
smoker 
* HDL-cholesterol analysis was carried out by different methods in 1999 and 2003 consequently 
the 2003 data are not directly comparable with those in 1998. 
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Table 6.2 Characteristics of Caucasian men older than 35 years by the 
year of study 
1998-99 2003 p-value 
(% or 95% Cl) (% or 95% Cl) 
p-value after adjustment 
for age 
Number 
Age 
Systolic blood 
pressure 
Diastolic blood 
pressure 
Total 
Cholesterol 
HDL- 
cholesterol 
History of 
Stroke 
History of 
Myocardial 
infarction 
History of 
Angina 
Diabetes 
Current 
cigarette 
smoker 
5158 4520 --- 
55.6 56.3 
< 0.0001 
(55.2 - 56.0) (55.9 - 56.7) 
139.4 137.2 
< 0.0001 
(138.8 - 139.9) (136.6 - 137.7) 
79.6 74.7 
< 0.0001 
(79.2 - 79.9) (74.3 - 75-0) 
5.68 5.90 
< 0.0001 
(5.65 - 5.72) (5.85 - 5.94) 
1.29 1.40 
(1.28 - 1.30) (1.39 - 1.41) 
171 (3.3%) 169(3.7%) 0.26 
302(5.9%) 285(6.3%) 0.35 
388(7.5%) 352(7.8%) 0.62 
225(4.4%) 269(6.0%) < 0.0001 
1282 (24.9%) 960(21.2%) < 0.0001 
0.0001 
0.0001 
0.0001 
* 
* HDL-cholesterol analysis was carried out by different methods in 1999 and 2003 consequently 
the 2003 data are not directly comparable with those in 1998. 
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Table 6.3 Characteristics of South Asian women older than 35 years by 
the year of study 
1998-99 2003 
p-value 
(% or 95% Cl) (% or 95% Cl) 
p-value after adjustment 
for age 
Number 
Age 
Systolic blood 
pressure 
Diastolic blood 
pressure 
Total 
Cholesterol 
HDL- 
cholesterol 
History of 
Stroke 
History of 
Myocardial 
infarction 
History of 
Angina 
Diabetes 
944 
48.4 
(47.7 - 49.1) 
132.2 
(130.5 - 133.4) 
74.9 
(74.0 - 75.8) 
5.22 
(5-13 - 5.31) 
1.34 
(1.31 - 1.38) 
8(0.9%) 
10(1.1) 
28(3.0%) 
91(9.6%) 
172 
48.0 
(46.6 - 49.3) 
127.5 
(124.3 - 130.7) 
73.9 
(72.0 - 75.7) 
5.47 
(5.24 - 5.71) 
1.53 
(1.44 - 1.62) 
4(2.3%) 
1 (0.6%) 
6(3.5%) 
16(9.3%) 
0.60 
0.011 
0.32 
0.032 
* 
0.002 
0.269 
0.033 
* 
0.08 
0.56 
0.68 
0.89 
Current 
cigarette 24(2.5%) 6(3.5%) 0.48 
smoker 
* HDL-cholesterol analysis was carried out by different methods in 1999 and 2003 consequently 
the 2003 data are not directly comparable with those in 1998. 
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Table 6.4 Characteristics of Caucasian women older than 35 years by the year of 
study 
1998-99 2003 p-value p-value 
(% or 95% CI) (% or 95% CI) after adjustment 
for age 
Number 6323 5716 --- 
Age 
Systolic blood pressure 
Diastolic blood pressure 
Total Cholesterol 
HDL-cholesterol 
History of Stroke 
History of Myocardial 
infarction 
History of Angina 
Diabetes 
Current cigarette smoker 
56.6 
(56.3 - 57.0) 
137.0 
(136.4 - 135.8) 
74.3 
(74.0 - 74.6) 
5.85 
(5.81 - 5.88) 
1.58 
(1.57 - 1.59) 
183(2.9%) 
161 (2.5%) 
350(5.5%) 
193(3.1%) 
1557 (24.6%) 
57.1 
(56.7 - 57.5) 
133.9 
(133.3 - 134.5) 
73.1 
(72.8 - 73.4) 
5.99 
(5.95 - 6.03) 
1.68 
(1.66 - 1.69) 
179(3.1%) 
171(2.4%) 
278(5.2%) 
246(4.3%) 
1288 (22.5%) 
0.066 
* 0.0001 
* 0.0001 
* 0.0001 
0.45 
0.61 
0.22 
* 0.0001 
0.007 
0.0001 
0.0001 
0.0001 
* 
* HDL-cholesterol analysis was carried out by different methods in 1999 and 2003 consequently 
the 2003 data are not directly comparable with those in 1998. 
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Tables 6.5 & 6.6 show the prevalence of hypertension, as diagnosed by a doctor or 
with SBP and/or DBP ý! 140/90 mm Hg measured by the survey nurse among the 
two ethnic groups based on those who had blood pressure measurements. The 
overall prevalence of hypertension was higher in Caucasians compared with South 
Asians. Prevalence of diagnosed or undiagnosed hypertension was similar in 2003 
compared to 1998-99 in Caucasian and South Asian men and women, Tables 6.5 & 
6.6. 
More South Asian and Caucasian men and women were diagnosed as hypertensive 
in year 2003 compared to year 1998-99, Tables 6.7 & 6.8. These improvements in 
diagnosis are statistically significant in both gender in Caucasian and South Asian. 
In addition undiagnosed hypertension declined in both groups. 
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Table 6.5 Prevalence of high blood pressure in men with blood pressure 
measurement by ethnicity and year of study 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(714) (99) (4398) (3009) 
Diagnosed hypertension or 326 48 2356 1576 
BP ý! 140/90 45.7% 48.5% 53.6% 52.4% 
Normal blood pressure 388 51 2042 1433 
54.3% 51.5% 46.4% 47.6% 
* (Comparison between year 2003 and 1998-99 in each ethnicity) 
P= 0.59 (South Asians), P= 0.31 (Caucasians) 
1998-99 2003 1998-99 2003 
(626) (107) (5220) (3688) 
Diagnosed hypertension or 232 
BP ý! 140/90 37.1% 
39 
36.4% 
2455 
47.0% 
1722 
46.7% 
Normal blood pressure 394 68 2765 1966 
62.9% 63.6% 53.0% 53.3% 
(Comparison between year 2003 and 1998-99 in each ethnicity) 
P= 0.90 (South Asians), P= 0.75 (Caucasians) 
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Table 6.7 Diagnosis of hypertension by a doctor in all hypertensive men by ethnicity 
and year of study 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(326) (48) (2356) (1576) 
152 33 1077 989 
Diagnosed hypertension 
46.6% 68.8% 45.7% 62.8% 
174 15 1279 587 
Undiagnosed hypertension 
53.4% 31.3% 54.3% 37.2% 
(Comparison of diagnosed hypertension between year 2003 and 1998-99 in each ethnicity) 
South Asian: OR diagnosed/u nd iag nosed hypertension = 2.5 (95% Cl 1.3 to 4.8), P=0.004 
Caucasian: OR diagnosed/undiagnosed hypertension = 2.0 ( 95% Cl 1.8 to 2.3), P<0.0001 
Table 6.8 Diagnosis hypertension by a doctor in all hypertensive women by ethnicity 
and year of study 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(232) (39) (2455) (1722) 
103 31 1328 1113 
Diagnosed hypertension 
44.4% 79.5% 54.1% 64.6% 
129 8 1127 609 
Undiagnosed hypertension 
55.6% 20.5% 45.9 35.4% 
* (Comparison of diagnosed hypertension between year 2003 and 1998-99 in each ethnicity) 
South Asian: OR diag nosed/u ndiag nosed hypertension = 4.9 (95% Cl 2.1 to 11.0), P<0.0001 
Caucasian: OR diagnosed/und iag nosed hypertension ý 1.6 (95% Cl 1.4 to 1.8), P<0.0001 
129 
Blood pressure control in South Asian 
More than a half of the hypertensive men of both ethnicities received 
antihypertensive in 2003. Although the trend with time was similar in both ethnic 
groups the change in this proportion was only statistically significant in 
Caucasians, Table 6.9. 
Receipt of ant1hypertensive drug treatment in diagnosed hypertensive South Asian 
women was similar in 2003 and 1998-99 in contrast to the significant increase seen 
in Caucasian women during the same period of time, Table 6.10. 
Tables 6.11 & 6.12 show the adequacy of blood pressure control in South Asian 
and Caucasian men and women receiving treatment for hypertension. Effective 
treatment was higher in both genders in the Caucasian population and in South 
Asian women in 2003 when compared with 1998-99. The trend of improvement in 
adequate treatment was statistically significant for all groups except South Asian 
men. 
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Table 6.9 Receiving anti hypertensive in diagnosed hypertensive men by ethnicity 
and year of study 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(152) (33) (1077) (989) 
77 22 461 
On treatment 
50.7% 66.7% 42.8% 
565 
57.1% 
75 11 616 424 
Not treated 
49.3% 33.3% 57.2% 42.9% 
(Comparison of diagnosed hypertension between year 2003 and 1998-99 in each ethnicity) 
South Asian: ORon treatment/not treated 'ý 1.9 (95% Cl 0.9 to 4.3), P<0.095 
Caucasian: ORon treatment/not treated ": 1.8 (95% Cl 1.5 to 2.1), P<0.0001 
On treatment 
Not treated 
1998-99 2003 1998-99 2003 
(103) (31) (1328) (1113) 
52 16 698 728 
50.5%% 51.6% 52.6% 65.4% 
51 
49.5% 
15 
48.4% 
630 
47.4% 
385 
34.6% 
* (Comparison of diagnosed hypertension between year 2003 and 1998-99 in each ethnicity) 
South Asian: OR on treatment/not treated ý1 -1 (95% Cl 0.5 to 2.2), P=0.91 
Caucasian: OR on treatment/not treated = 1.7 (95% Cl 1.4 to 2.0), P<0.0001 
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Table 6.11 High blood pressure control (::: ý140/85 mmHg) in hypertensive men on 
treatment by ethnicity and year of study 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(77) (22) (461) (565) 
23 5 125 215 
Treated and controlled BP 
29.9% 22.7% 27.1% 38.1% 
Treated but not controlled 54 17 336 350 
BP* 70.1% 77.3% 72.9% 61.9% 
* (Comparison of controlled BP between year 2003 and 1998-99 in each ethnicity) 
South Asian: OR controlled/not controlled BP '= 0.7 (95% Cl 0.2 to 2.1), P=0.51 
Caucasian: OR controlled/not controlled BP = 1.7 (95% Cl 1.3 to 2.2), P<0.0001 
Table 6.12 High blood pressure control (:! ý; 140/85 mmHg) in hypertensive women 
on treatment by ethnicity and year of study 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(52) (16) (698) (728) 
Treated and controlled BP 15 10 169 247 
28.8% 62.5% 24.2% 33.9% 
Treated but not controlled 37 6 529 481 
BP* 71.2% 37.5% 75.8% 66.1% 
* (Comparison of controlled BP between year 2003 and 1998-99 in each ethnicity) 
South Asian: OR controlled/not controlled BP = 4.1 (95% CI 1.3 to 13.3), P=0.015 
Caucasian: OR controlled/not controlled BP = 1.6 (95% CI 1.3 to 2.0), P<0.0001 
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Table 6.13 & 6.14 show the number of ant1hypertensive drugs taken by South 
Asian and Caucasian men and women. A high proportion of subjects in both ethnic 
groups was ta ing only one drug in 1998-99. This decreased by 2003 in Caucasian 
men and women and in South Asian men. Consequently more in these groups were 
taking two or more tablets in 2003. Changes in South Asians women were in the 
opposite direction but due to the small numbers this may be a chance finding. 
Table 6.13 Number of anti hypertensive drugs prescribed for blood 
pressure control in treated hypertensive men by gender and year 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(77) (22) (461) (565) 
48 12 293 250 
1 tablet 
62.3% 54.5% 63.6% 44.2% 
2 tablets or 29 
more 37.7% 
10 168 315 
45.5% 36.4% 55.8% 
Table 6.14 Number of antihypertensive drugs prescribed for blood 
pressure control in treated hypertension women by gender and year 
South Asian Caucasian 
1998-99 2003 1998-99 2003 
(52) (16) (698) (728) 
33 13 416 325 
1 tablet 
63.5% 81.3% 59.6% 44.6% 
2 tablets or 19 3 282 403 
more 36.5% 18.8% 40.4% 55.4% 
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Under current guidelines only those with a CVD risk ý! 20% and mild hypertension 
(SBP and/or DBP > 140/80 mm Hg) warrant drug treatment. 47.3% and 84.6% of 
Caucasian and South Asian men , in the HSE 2003 dataset, receiving no treatment 
had blood pressures above threshold (140/90 mm Hg) and 10 years CVD risk ý! 
20% and were therefore eligible for treatment, Table 6.15. More South Asian 
women need to be targeted for treatment compared to Caucasians in 2003,18.3% v 
10.4% respectively, Table 6.16. 
Table 6.15 Treatment needs in men with untreated hypertension 
(diagnosed or not) aged 35-75 without previous CVD 
South Asian 
1998-99 2003 
(148) 
Caucasian 
1998-99 2003 
(13) (1160) (556) 
CVD risk ý--20% 108 
(treatment 
73.0% 
indicated) 
11 
84.6% 
640 
55.2% 
263 
47.3% 
CVD risk < 20% 
40 
27.0% 
2 520 293 
15.4% 44.8% 52.7% 
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Table 6.16 Treatment needs in women with untreated hypertension 
(diagnosed or not) aged 35-75 without previous CVD 
South Asian 
1998-99 
(109) 
Caucasian 
2003 1998-99 2003 
(10) (1112) (588) 
CVD risk ý--20% 40 2 203 61 
(treatment 
indicated) 
36.7% 20.0% 18.3% 10.4% 
CVD risk < 20% 
69 8 909 527 
63.3% 80.0% 81.7% 89.6% 
6.5 DISCUSSION 
This analysis shows that South Asian men and women had lower systolic blood 
pressures but higher diastolic pressures in 1998-99 and 2003 compared with their 
Caucasian counterparts. Hypertension (diagnosed by a doctor or blood 
pressure ý! 140/90) was more common in Caucasians than South Asians. South 
Asian men and Caucasian men and women were more likely to have their 
hypertension diagnosed. However the prevalence of uncontrolled hypertension was 
higher in South Asian men than in Caucasian men. In contrast South Asian women 
were less likely to have uncontrolled hypertension than their Caucasian 
counterparts. Because of their greater risk of CVD South Asian men and women 
should be targeted for treatment intervention. 
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Based on the recent guidelines (JBS-2,2005) people with mild hypertension SBP 
140-160 DBP 90-100 need a 10 year CVD risk estimation and people with 
moderate hypertension (SBP >160 and/or DBP ý! t 100) need drug therapy as well 
as lifestyle intervention. In this analysis eligibility for treatment within the 
hypertensive population was judged according to estimated risk alone. In practice 
some patients with low risk (< 20%) but moderate blood pressure (SBP and/or 
DBP ý! 160/100) will receive treatment (Williams et al., 2004). As South Asians 
have on average lower systolic pressure but higher risk the population falling into 
this low risk high blood pressure group will be smaller than Caucasians. The 
estimated difference between ethnicities in need for treatment will therefore be 
slightly exaggerated. 
The large nationally distributed random sample of the HSE 1998-99 overcomes 
some of the potential problems of sample bias in other studies (for example, in 
studies based on GP lists, those registered with a doctor might be more likely to 
self-report than the non-registered; and workplace studies which deal with a 
population less likely to have ill health than those who are not working). There is 
however still the possibility of non-response bias and if response in South Asians 
less than that in Caucasians this could have a differential effect. The number of 
South Asian subjects in the HSE 2003 is too small for a robust analysis of changes 
with time and the numbers can only give an idea of the trends of blood pressure 
and its control. In addition it did not allow me investigate differences between 
subgroups within South Asian community. Past studies showed marked 
heterogeneity among South Asian subgroups, with Indians having similar blood 
pressure to Whites, Pakistanis having slightly lower pressures and Bangladeshis 
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having the lowest blood pressures (Agyemang & Bhopal, 2003). Part of this 
inconsistency can probably be explained by the differences between studies in 
terms of age and gender of samples, definition of South Asians, and geographical 
variation between London (comparatively high blood pressure in South Asians) 
and the rest of the UK (comparatively low or similar blood pressure). 
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GENERAL DISCUSSION 
Chapter 7 
7.1 GENERAL FINDINGS 
it is clear that South Asians living in the West have substantially greater relative 
(coronary heart disease) CHD mortality and morbidity than the general population. 
Despite this statistic originally being identified 3 decades ago there remain huge 
gaps in our understanding of the causes and natural history of CHD in this group. 
Such knowledge is necessary to solve current challenges in disease control. This 
thesis has demonstrated that: 
* The greater risk of CHD in South Asians is not explained well by 
differences between them and the Caucasian population in either the values 
or impact of conventional risk factors alone. Risk in non-diabetic South 
Asians appears to be underestimated by a risk function based on classical 
nsk factors alone. Although based on a single study of hypertensive men 
CVD nsk in South Asians was 79% greater. In contrast risk of CHD in a 
study of newly diagnosed diabetics was similar in South Asians and 
Caucasians. This apparent discrepancy in relative risk between diabetic and 
non-diabetic cohorts may be because non-diabetic South Asians had a 
higher fasting blood glucose and HbAlc than Caucasians after adjustment 
for other CHD risk factors. This dysglycaemia may explain part of the 
excess susceptibility of South Asians to CHD although it is not clear that is 
the only explanation. 
eA simple adjustment method was devised to allow current paper-based risk 
estimation tools to be used for the UK South Asian population. Adding 10 
years to age, although crude, provides adequate sensitivity and specificity 
to take into account an "ethnicity factor" accounting for average risk in 
individual South Asians in general practices still using paper-based risk 
139 
General discussion 
prediction methods. This will help South Asians who are currently poorly 
served by risk estimation tools but are a group at greater need of treatment 
for primary prevention of CVD. 
e More UK South Asian men and women, 12.1% (95% Cl: 9.3 to 14.8) and 
5.1% (3.2 to 7.3) respectively, are candidates for secondary prevention of 
CVD than Caucasian men and women, 7.4% (6.4 to 8.2) and 4.6% (3.9 to 
5.3) respectively. This is due to a greater prevalence of symptomatic CVD 
in this population. Based on the above suggested ethnically adjusted risk 
estimate, 18.4% (95% Cl: 14.9 to 21.8) of South Asian men aged 35-74 
have CHD risk ý: 30% over 10 years. These people need lipid-lowering 
therapy according to the National Service Framework for CHD. Eligibility 
for intervention in Caucasian men is less than one-third that of South 
Asians. Similarly South Asian women have a greater need for primary 
prevention than Caucasian women, 2.3% (95% Cl: 0.9 to 3.8) and 0.5% 
(0.3 to 0.7) being eligible respectively. Using the threshold recommended 
by the current guidelines overall 43 % of South Asian men were predicted 
to have a CHD risk > 15% (20% CVD nsk). This proportion was 29.8% in 
Caucasian men. In women, overall, 13.5% and 7.2% of South Asian and 
Caucasian women respectively were above this level of CHD risk and 
eligible for intervention treatment 
9 South Asians are at least equally accepting of treatment as Caucasians 
when given information about the personal impact of hypertension, MI, and 
stroke, and the effect and tolerability of antihypertensive treatment. 
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Outright rejection of treatment, independent of the size of benefit, was 
however more common in South Asian men. 
* Iýypertensive South Asian men and women eligible for treatment are more 
likely to be identified by doctors than Caucasians despite them having on 
average lower systolic and diastolic blood pressures. Importantly and in 
contrast uncontrolled hypertension is more common in South Asian men 
than in Caucasians. This could be due to a variety of reasons; e. g. 
hypertension control is different and more difficult to be controlled in 
South Asians, more adverse effects happened in South Asians who take 
antihypertensives, or there might be more treatment rejection in this ethnic 
group. 
7.2 STRENGTH AND WEAKNESSES OF THIS THESIS 
The major hurdle in studying health in ethnic minorities is the dearth of high 
quality published epidemiological information. The estimate of the "ethnicity 
I 
factor" is based on a single small observational study of 528 (62% men) and 106 
(79% men) hypertensive Caucasian and South Asian patients respectively (Khattar 
et aL, 2000). Similarly, our knowledge of the ethnic risk difference in patients with 
diabetes is based on the results of a single study. This was however a much larger 
controlled trial of differing intensities of treatment for diabetes and included 432 
South Asians, 32.6% of whom were women. 
It is likely that there are differences between individual ethnic groups within the 
South Asian community. Unfortunately, the data available are insufficient to 
provide separate adjustments for each ethnic group (Indian, Pakistani, and 
Bangladeshi). In addition, there is some suggestion of an age effect on the 
differences between South Asians and Caucasians implying a possible difference 
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between 1 st and subsequent generation immigrants. If this were confirmed any 
adjustment method might need to be recalibrated for second and subsequent 
generation South Asians. 
6.2.1 Low response rate 
The HSE datasets were used in several areas in this thesis. Low response rates to 
the request for a blood sample, especially in South Asians, might be a weakness in 
using this source of information. Nearly one thirds of Caucasian and half of South 
Asian adults aged 35-74 years did not have a measurement of plasma total 
cholesterol. This might introduce non-response bias leading to a biased estimate of 
risk and requirement of treatment. Non-respondents (those without blood 
cholesterol measurement) were excluded from the analysis of current thesis and 
this group had higher blood pressures, were more commonly cigarette smokers, 
and would therefore be at higher risk. However assuming as much as 3% higher 
total cholesterol in non-respondents would only increase the proportion of subjects 
eligible for treatment by 0.5% and 0.3% in men and women respectively. 
Interestingly the proportions of South Asians who were interviewed and visited by 
a nurse were similar to Caucasians. Lower rates of agreement to give blood 
samples might be due to language, cultural, or religious barriers in the survey 
process for South Asians. Despite these weaknesses the Health Survey for 
England series are the best available national representative datasets. It is likely 
that the alternative of using local social settings as the research framework to 
achieve higher response rates might violate the nationally representativeness of the 
data. 
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A low overall response rate was also seen in my patients' acceptance study and this 
again might introduce weakness because only about half and two-thirds of South 
Asians and Caucasians approached were interviewed. However this hides the fact 
that a considerable proportion of recipients of the approach letter did respond, 40% 
and 62.5% of South Asians and Caucasians respectively. However as has been seen 
before about 63% of South Asians respondents made a positive decision not to 
participate compared to the about half of Caucasians respondents who made a 
negative response. This low response rate was despite including a translated 
approach letter in five South Asian languages in the invitation pack to increase 
accessibility. These low rates might be due to concern about being involved in a 
face-to-face interview or misunderstanding of the inclusion criteria for this 
research. Feedback suggested that potential participants thought the interview was 
only for people with a history of CVD. Of note is that subjects who did not agree to 
be interviewed were more likely to live in deprived areas compared with subjects 
who did participate. However investigation of the relationship between deprivation 
and readiness to take medication suggested that this was unlikely to be an 
important source of bias. 
This is probably as robust an answer as it is possible to achieve for this research 
question. The high rate of cardiovascular disease in the South Asian community 
and the previous suggestion that they receive less rather than more preventive 
treatment made it crucially important to make a quantitative estimate of any 
differences in attitude towards drug treatment. Although a higher response rate 
would have been ideal it is unlikely to be achieved by any method which comply 
with current standards of research ethics. The problems introduced 
by poor 
response generally relate to the selection bias. To overcome this bias methods of 
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enhancing response rates, described in Chapter 5, were employed. In addition using 
the Population Health Register as the sampling frame gave me the opportunity of 
targeting all individuals living in Sheffield with an equal chance. It was tried to 
avoid introducing information bias by providing similar and standard basic 
information of cardiovascular disease and hypertension to both ethnic groups. 
Although identified forms of bias can be investigated and where possible adjusted 
for it is still possible that there are as yet unidentified sources of bias in these data. 
6.2.2 Performance of CVD risk assessment 
Although there is no strong evidence supporting the assumption that cardiovascular 
risk assessment performed by a clinician improves health outcomes (Brindle et aL, 
2006) this forms the basis of policy for prevention of CVD. The Framingham 
Study of cardiovascular diseases and its risk prediction equation is known to all 
cardiologists, most epidemiologists, many physicians, and even some laypersons. 
The Framingham risk score is valid for its original population but its external 
validity and accuracy in other populations has been questioned (D'Agostino et al., 
2001). Whilst effective in ranking risk in all populations investigated its estimate 
of absolute risk may be biased. Several groups have tried to recalibrate the 
equation against population measures of morbidity and mortality or have suggested 
different thresholds to allow acceptable prediction of risk for groups other than 
those individuals in the original study. Adding factors like first degree family 
history of CVD and an index of social deprivation might improve the 
discriminatory ability of this risk prediction function still further (Brindle et al., 
2005). However each additional factor included would need subsequent validation. 
Also the incidence of CVD seems to be changing with time independent of 
variation in risk factors such that any prediction function accurate today may be 
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inaccurate tomorrow. Whatever the current accuracy of the Framingham equation 
in the UK population, this fonns the basis for calculating risk in clinical practice 
and is central to judging eligibility for antihypertensive, lipid-lowering and aspirin 
treatment. As South Asians and Caucasians have similar values of traditional 
cardiovascular risk factors under or over estimation of risk by this equation should 
not affect my predictions of the number of patients likely to be offered treatment 
for primary prevention in the UK population. 
Cardiovascular risk estimated by the Framingham and related scores is misleading 
in guiding treatment decisions among people at different levels of social 
deprivation. Tunstall-Pedoe & Woodward (2006) reported that the estimated effect 
of being in the highest 20% of deprivation rather than the lowest 20% is equivalent 
in risk scoring terms to 10 years or more in age or to a diagnosis of diabetes. 48% 
(95%Cl 44% to 52%) underestimation by the Framingham risk score was reported 
in manual workers in West Scotland (12,000 men and women) compared to 31% 
(19 to 40%) in non-manual participants (Brindle et al., 2005). This underestimation 
was worse among people from deprived areas (P=0.0017). Recalibration of the 
Framingham score for manual and non-manual subjects would add a substantial 
number of individuals mainly from manual social classes to those eligible for 
primary prevention treatment. These data suggest that as used currently risk 
scoring tools foster relative undertreatment of the socially deprived, exacerbating 
the social gradients in disease, which national policies seek to minimise. Their use 
has the potentially undesirable attribute of directing treatment towards higher 
social classes whose risk is overestimated and away from lower social classes 
whose risk is underestimated. This may be exacerbated further by the availability 
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of low dose statin without prescription. Class differences in risk may have more 
effect on South Asians as they are disadvantaged socio-economically compared to 
Caucasians. Added to this is the discrepancy in deprivation between different 
South Asian groups which might explain intra-ethnic differences in CVD risk. The 
interaction between deprivation and ethnicity when predicting CVD ideally could 
be modelled to explore this relationship further. Of note is that a statistically 
significant effect on the MCBDs comparing South Asians and Caucasians of area of 
residence, a crude surrogate for social status, was not found. 
7.3 FUTURE WORK 
6.3.1 Needs for prospective studies 
The considerably increase in mortality and morbidity of CHD in South Asians and 
the size of this ethnic group in the UK highlights the need for both a large British 
cross-sectional study to investigate the prevalence of CHD risk factors in the local 
Indian, Pakistani, and Bangladeshi population and a prospective cohort study to 
examine their impact. This is a necessary first step to facilitate intensive focussed 
risk factor modification strategies which need to be devised specific for this racial 
group. One step in this direction is the London Life Sciences Prospective 
Population Cohort, the LOLIPOP study, (Chambers et al., 2006) a large cohort 
study of South Asian and European men and women, which is being assembled as 
part of a cardiovascular community programme in west London to identify genetic 
and envirom-nental factors underlying the increased rates of CHD, obesity, 
diabetes, and renal failure in Indian Asians compared to Northern Europeans. 
24,000 participants (half South Asians) are to be recruited by the end of 2006 and 
data collection will include long-term storage of blood samples for biochemical 
and genetic analysis. This research may answer some of the questions regarding 
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the susceptibility of South Asians to coronary disease and the importance of 
current risk factors in South Asians. 
6.3.2 Targeting South Asians for medical treatment 
It is important that any measures for UK South Asians be applied sensitively and 
effectively to improve the quantity and quality of preventive care provided for 
them. Although there are no clinical trials that directly support drug treatment for 
specific ethnic groups like South Asians this should be used for treatment of 
dyslipidemia and hypertension. Given the similar risk factors and pathophisiology 
in this group the default assumption must be that such treatment will be as effective 
as in the Caucasian population studied. In the absence of evidence of clear 
differences between ethnic groups these drugs should be seen as necessary 
treatment to reduce and prevent clinical cardiovascular events regardless of the 
baseline level of each individual risk factor as long as there is trial evidence of 
benefit for that cohort. For example the Heart Protection Study (HPS, 2002) 
showed clear benefit from cholesterol lowering in patients whose blood cholesterol 
concentrations were well within the normal range. However trial evidence must be 
interpreted with some caution because of lack of significant involvement of ethnic 
minorities. There remains the possibility of ethnic differences in drug metabolism 
leading to possible drug toxicity or alternatively lack of efficacy (Levy & Polatsek, 
2002; Burroughs et aL, 2002). Further uncertainty relates to the treatment 
thresholds and targets for ethnic minorities. Targets for blood pressure control are 
reasonably well established but are based mainly on studies in Caucasians. 
Thresholds in current guidelines (Williams et al., 2004; JBS-2,2005) are moving 
towards ones based on overall CVD risk as the detenninant for intervention but 
retaining levels of need for a systolic or diastolic blood pressure ý: 140/90 mmHg 
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as an additional requirement. This emphasizes that there may be need for a 
definition of ethnic specific thresholds as well as recalibration of the risk equation. 
With non-nal blood pressures being quite different in the various ethnic groups it is 
possible that the blood pressure at which risk increases varies with ethnicity. 
Investigation of risk prediction functions to date has simply not had the power to 
detect such potential differences. Cholesterol targets, although enshrined in 
guidelines are based only on post-hoc extrapolation, again from trials in 
Caucasians. Just as with thresholds for treatment it is certainly plausible that 
different ethnic groups would have different optimal targets. Perhaps a more 
important question is whether the incidence of adverse effects is any different. This 
might impact on compliance with preventive treatments which has not been 
investigated in the South Asian or other ethnic minority populations. 
6.3.3 Preventing metabolic syndrome and diabetes 
An important initial step to reduce the burden of CVD would be to prevent 
progression of high risk individuals to developing diabetes (Lakka et al., 2002). It 
is possible that identification of metabolic syndrome would be one simple way to 
recognise those at high risk especially when waist measurement is a simple 
diagnostic criterion (Alberti et al., 2005). Encouraging South Asians to make such 
measurement themselves might be an easy method for identifying at risk 
individuals and giving them information to improve their lifestyle especially if they 
have a family history of CVD. There are some data to suggest that involving 
patients in diagnosis makes them more committed to alter their risk factors (Kaplan 
et aL, 1989). Treating risk factors associated with the metabolic syndrome is a 
rational strategy not only to prevent CVD but also to reduce the incidence of type 2 
diabetes in non-diabetic South Asians with dysglycaemia. Just as with thresholds 
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and targets it is important to consider whether the components of the metabolic 
syndrome should be redefined or have adjusted cut-points for South Asian people 
(Alberti et al., 2005). Although levels of modifiable risk factors in migrant South 
Asians are far higher compared with their non-migrant relatives living in India they 
are still below levels seen in Caucasians (Ramachandaran et al., 2001). This might 
suggest the threshold of "nonnality" used for the general population in western 
countries may be too high for South Asians and need to be reduced or adjusted. 
Most of these risk factors follow a continuum and cut-offs are arbitrarily defined 
based on centiles of the population distribution. For those population in which the 
distribution is shifted e. g. South Asians different diagnostic cut-offs might be 
appropriate. 
Interruption of the renin-angiotensin system by angiotensin inhibitor enzymes 
(ACE) may improve insulin sensitivity (McFarlane et al., 2003). Several trials, 
beginning with the Captopril Prevention Project (CAPPP) (Niklason et al., 2004), 
suggest that ACE inhibitors reduce the incidence of type 2 diabetes in hypertensive 
patients. This might be seen as a reason to prefer ACE inhibitors as first line 
treatment for high blood pressure in South Asians. However their risk of stroke is 
proportionately higher and this class of drug is probably less protective against 
cerebrovascular disease than thiazide diuretics or calcium channel blockers 
(Jackson & Ramsay, 2002). 
Management of the metabolic syndrome is usually focused on lifestyle intervention 
to reduce obesity by dietary change and increasing physical activity (Stone et al., 
2005). Unfortunately we have few data to show whether these are acceptable or 
effective in South Asians. In addition a great deal needs to be done to determine 
the causes for the increased susceptibility of South Asians to diabetes. It could be 
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possible that Caucasians are protected from diabetes by underlying genetic 
differences. Alternatively differences in socioeconomic situation and lifestyle 
might contribute. A further complication is added by the possibility that some 
ethnic groups might have greater susceptibility to diabetic complications. For 
example the high rates of diabetes in Pima Indians are not associated with huge 
elevation of CHD risk (Nelson et al., 1990). 
6.3.4 Reducing in smoking 
Due to the strong evidence linking smoking and CVD (Anderson, 1991) smoking 
cessation is crucial to reduce the prevalence of these diseases. Of relevance here is 
the distinct ethnic differences in the prevalence of cigarette smoking which is 
particularly high in the Bangladeshi population (Erens et aL, 2001). This illustrates 
the importance of cultural factors in disease incidence and prevention. 
6.3.5 Recalibrating the Framingham equation 
The weaknesses of the Framingham function as currently implemented were 
discussed above. Use of a simple cheap recalibration of the Framingham function 
would allow estimates of absolute CHD risk as a means of identifying those South 
Asian people who need targeting for aggressive primary prevention strategies. 
Absolute risk estimation has also been proposed as a tool for motivating patients to 
comply with preventive strategies although there is little evidence to confirm the 
efficacy of such a ploy. It is however pressing now to provide an appropriate 
recalibration to prevent the high risk South Asian population being excluded from 
the current national strategy for primary prevention of CVD. Cappuccio et al. 
(2002) suggested a lower threshold of CHD risk for treating mild uncomplicated 
hypertension in people of South Asian origin. This was only necessary because the 
higher risk of stroke relative to MI in this population which made overall CVD risk 
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estimation using the calculated CHD risk inaccurate. As my adjustment factor is 
based on differences in CVD risk this is now unnecessary. It was suggested adding 
10 years to the age of non-diabetic South Asians (chapter 2, this thesis). An 
alternative approach suggested by Brindle et al. (2006) in the recently launched 
ETHRISK, a web based risk calculator for British Black and minority ethnic 
groups, is estimation base on a population recalibration of the Framingham CHD 
and CVD risk equations. The ETHRISK model uses the prevalence ratios for CHD 
and CVD for each ethnic group compared to the general population, and adjusts for 
differences in mean risk factor levels (age, total cholesterol/HDL ratio, and systolic 
blood pressure) and prevalence of smoking between each ethnic group. They used 
hazard ratios and coefficients for CHD risk factors consistent with results from 
four contemporary British cardiovascular cohort studies and assumed similar 
hazard ratios in the different ethnic groups (Brindle et al., 2006-b). These risk 
adjustment and recalibration tools could improve identification of high risk South 
Asians who might benefit from primary prevention therapy. 
Another possible but as yet untested, method to achieve a simple cheap 
recalibration of existing risk equations would be to use data collected at the level of 
general practices. As computerized datasets are now widespread it would be 
possible to perfonn anonymous retrieval of CVD risk factors and mortality data. 
Although there is no standard software for the collection of patient information in 
primary care in the UK, the range of main systems is small. In addition, there are 
now software tools e. g. MYQUEST which can mine data from such databases 
without breaching patient confidentiality. Substantial work has already being 
perfonned with such databases looking for evidence of drug toxicity. These could 
be employed to derive risk prediction models for South Asians and other ethnic 
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minorities based on individual data rather than population averages. This would 
however require recording of ethnicity in general practices (Gill & Johnson, 1995) 
but should be ethically acceptable because of the anonymous use of the data. 
Perhaps an even more important use of these data would be an efficient rapid 
updating of derived prediction tools necessary because of the constant change in 
nsk factors and their impact. 
6.3.6 Tackling childhood obesity 
Obesity in children is now reaching epidemic proportions internationally and 
probably reflects poor dietary habits and physical inactivity, resulting from societal 
changes in lifestyle. This may be one further explanation for differences in 
incidence of diabetes and CVD between groups. Childhood obesity differs between 
ethnic groups with South Asian children having an increased chance of being 
overweight and obese compared to the general population (Saxena et aL, 2004). 
Furthermore, factors associated with insulin resistance are apparent in childhood of 
South Asian ongin (Whincup et al., 2002). Childhood obesity increases the risk of 
obesity in adulthood and the risk of developing metabolic syndrome in adulthood 
(Vanhala et al., 1998). Important here is the possibility of a change in impact of 
current risk factors in different generations of South Asian people. Identifying 
suitable risk-ad ustment tools for the current South Asian population is only a first i 
step. Since a growing proportion of people from ethnic minorities are UK-bom, 
epidemiological research among second-generation Asians is necessary to 
re-examine the prevalence of risk factors of cardiovascular disease and to identify 
how disease patterns may be changing so that future interventions are correctly 
targeted. If the risk factor patterns are deteriorating in second-generation South 
Asians as some data might suggest the current high rates of CVD may only be a 
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prelude to even worse. one possible explanation of this change is that a mixture of 
westernized and traditional diet combined with physical inactivity is making 
second and subsequent generations of South Asians more vulnerable to CHD and 
CVD. This hypothesis will need to be investigated in the near future as well as 
examining prevention and management of childhood obesity in younger age South 
Asians if necessary targeting them at the school ages. This illustrates the need for 
the calibration of risk prediction tools in all population groups to be reassessed 
periodically to ensure their continued validity for ftiture generations. Although 
changes in disease incidence do largely follow changes in risk factors a substantial 
proportion as yet remains unexplained. Some changes observed in South Asians 
may only reflect changes in the wider population where increasing obesity is not in 
fact worsening the incidence of CVD. Although after suggesting several new areas 
worthy of research in South Asians it is worth remembering that conducting 
research in CVD in South Asians, as a high risk group, is more likely to be 
cost-effective. Their higher event rates make it possible to investigate treatment 
efficacy in smaller studies. 
6.3.7 Stress and acculturation 
Popular opinion holds that stress is an important risk factor for coronary heart 
disease. However, compared with other major risk factors, psychosocial variables 
such as stress are difficult to define objectively. Several constructs within the broad 
conceptual framework of stress are increasingly regarded as being causally related 
to coronary heart disease (Hemingway & Marmot, 1999; Ferketic et al., 2000; 
Rosengren, et al., 2004) and approaches aimed at modifying these factors should 
be developed. The process of immigration and adjustment to another country is a 
source of considerable stress. Acculturative stress has been defined as the physical, 
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biological, social, cultural, and psychological difficulties faced by an immigrant 
(Krishnan & Berry, 1992). Those stresses towards acculturation and lack of 
integration to the western societies may contribute to the risk of CVD in South 
Asian migrants in addition to possible genetic and lifestyle issues considered 
above. Lack of social support, long working hours, having members of family in 
the original country, and lack of control in bringing up their children according to 
traditional values are some of sources of stress in Indian immigrants to the USA 
(Kalra et al., 2004). More research on psychological and cultural factors should 
add to the understanding of the relationship between cultural factors, stress, and 
prevalence of CVD in South Asians. It might be of importance for adults' socio- 
cultural adaptation to have access to the special intercultural training programs 
advocated for easier social integration. It is likely that adults and children from 
second and further generations experience different stress in the final outcome of 
acculturation. This will make it necessary to adopt different approaches among 
children and adolescents in immigrant families with due consideration of their 
cultural and religious values. In addition current stress due to the societal response 
to terrorism largely attributed to Islamic fundamentalists may particularly affect 
Muslim immigrants and their families. It is yet to be seen whether this resolve or 
leads to a long-terrn source of stress and further changes in their socioeconomic 
situation. 
6.3.8 Acceptance of preventive treatment 
Perception of disease and taking medication, especially primary prevention, has 
generally been under-researched among ethnic groups. It affects patients' 
acceptance and their adherence or non-adherence to 
drug treatments. Indo-Asian 
patients with atrial fibrillation were significantly 
less aware of their cardiac 
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condition and its relationship with thromboembolism and stroke compared to 
Caucasians, P<0.001, (Lip et al., 2001). Importantly only a minority of them felt 
that their doctor had given them enough information about their warfarin therapy 
and also felt that they were careless about taking their medications. In diabetic 
patients, various factors may influence Pakistani and Indian patients' adherence to 
oral hypoglycaemia therapy such as: confidence in the British prescribers, 
perceptions of Western medications as efficacious, expectations that drugs should 
provide instant relief of symptoms, and beliefs that Western medicines can have 
detrimental effects if taken in excess or without traditional foodstuffs (Lawton et 
al., 2005). Part of these perceptions among South Asians may derive from popular 
ideas about drugs on the Indian subcontinent. Second and subsequent generations 
may see drugs in different light and we have no information as to how health 
beliefs are changing with time. Health beliefs may well impact on concordance of 
treatment in South Asians and explain differences with Caucasians. Further 
research in concordance of preventive therapy is warranted in this ethnic group. 
Lack of awareness of individuals or holding different beliefs may reflect the prior 
knowledge and attitude on the effect of poor counselling and inforination provision 
to patients by health care professionals. 
6.3.9 Culturally acceptable services 
Health care professionals involved in cardiovascular rehabilitation are responsible 
for providing effective and appropriate services to all patients, regardless of their 
I 
age, gender, and ethnicity. Language and other communication 
difficulties are 
likely to be particularly pertinent for members of some minority ethnic groups. 
Over half of South Asian patients have little or no understanding of spoken English 
with women and older people the least 
likely to speak English (Gerrish, 2001). The 
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limited use of professional interpreters, or bilingual health professional, and the 
concomitant heavy reliance on family members to translate highlights how ethnic 
minority patients and carers who are not fluent in English could be disadvantaged. 
For instance, in order to obtain a diagnosis of hypertension the informant must 
have visited the doctor, been able to explain their reason for attending, more 
difficult in context of asymptornatic disorder, and obtained an answer that they 
were able to understand and communicate persisting concerns to the doctor. The 
observed language barriers raise the possibility that advice on matters such as 
compliance with treatment regimens might not be fully understood. Psychological 
support of patients and carers is also severely restricted (Gerrish, 2001). Moreover, 
in this study the fact that follow-up visits were on occasions made for patients 
when there was no one available to interpret constrained on-going assessment of 
patients' needs. As South Asians have similar attitudes to taking antihypertensive 
treatment, when they were provided with ftill information, it is important that 
special support is in place to meet their specific cultural requirements so that their 
goal of avoiding CVD can be achieved. Patient should be made aware of the 
available support team (doctor, practice nurse, and others) before embarking on 
treatment that involves regular contacts with members of the team and essential 
follow-up visits. Current evidence suggests that diabetic South Asians have poorer 
glycaemic, blood pressure and lipid control than Caucasians (Chowdhury et al., 
2006; Mukhopadhyay et al., 2005; McElduff et al., 2005) which may simply 
reflect differences in interaction with their health teams given them equal 
acceptance of therapy. Interestingly differences between ethnic groups of how 
patients view some aspects of their general practices (GP) appear to have widened 
in over the past years. Based on the NHS patients survey programme in 1998 
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(Boreham et al., 2003), White respondents reported the most favorable views or 
more positive experiences, whilst South Asian respondents tended to have the most 
negative experiences. By 2002, these differences between White and South Asian 
respondents had increased particularly in the following areas: prompt and 
convenient access to GPs (waiting times, difficulties with staff and convenience of 
surgery times); how patients said they were treated by GPs during physical 
examinations; whether respondents felt GPs listened to them; and whether 
respondents felt like making a complaint. The source of these widening differences 
is not clear but obviously needs for further studiy. The differences could arise from 
reorganizations in primary care services impacting differentially on areas with a 
high ethnic minority population or may reflect increasing confidence in the South 
Asians community to express negative views. Clearly dissatisfaction with the 
service providing preventive treatment can only impede its effectiveness. Primary 
care teams should work towards meeting the general needs of South Asian 
population and provide appropriate services for patients with symptomatic CVD or 
those at high risk of developing CVD. 
Screening procedures based on chance of visits to general practices, e. g. 
hypertension, can be of importance dependent on the frequency of attending. 
Indicators and definitions in the Quality and Outcomes Framework (QOF, 2003), 
which is a component of the new General Medical Services contract for general 
practices introduced from April 2004, are based on the identification and control of 
individual risk factors (hypertension, diabetes, cigarette smoking) and not on the 
basis of overall CVD risk. This could unfortunately introduce indirect 
discrimination. Defining instead specific targets according to appropriately 
calculated risk would automatically flag hig risk ethnic minorities like South 
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Asians for enhanced intervention and could improve the quantity and quality of 
services provi ed for them. 
6.3.10 Role of genetic factors 
Tests of traditional risk factors and their failure alone to explain the greater 
coronary risk in South Asians highlights a possible role of genetics in the aetiology 
of CHD. The epidemic of CHD in South Asians as a consequence of 
westernization following migration to urban areas or immigration is postulated to 
have a root in adverse gene- environmental interactions (Samani & Sharma, 2005). 
It is important to note when considering this the implicit assumption that ethnic 
groupings defined on social, cultural and ethnographic grounds are equated with 
genetic homogeneity with little evidence to support this. Most of the large genetic 
projects in Western countries have excluded non-white (King, 2002) subjects and 
few genetic studies in CHD have been done in South Asians. However recruitment 
of ethnic minority groups into genetic studies may not be easy (Swanson & Ward, 
1995) as the infonnation provided will be sensitive to issues of culture and 
religion, as well as language. 
6.3.11 Acceptance of behavioural modifications 
Although the need for an acceptance of drug therapy for primary prevention of 
CVD have been looked it is necessary to consider the role of health behaviour and 
the possibility of modifying behaviour in preventive approaches. Less effort has 
been made to investigate the relationship between the cultural aspects of ethnicity 
and lifestyle risk factors for CVD. Changing behaviour in a health-enhancing way 
can be achieved by campaigns to increase knowledge and awareness of services to 
assist in risk reduction, but must include changes in 
individual beliefs and 
perceptions, or influence social norms. Simply changing 
knowledge and attitudes 
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alone may do little to modify behaviour. Delivering equitable services to modify 
risk factors in South Asians is faced by additional challenges above and beyond 
those for the Caucasian population such as; barriers to communication, lack of 
awareness by healthcare professionals of dietary habits, and cultural and religious 
matters specific to this ethnic group. Culturally sensitivity in delivering services is 
also an important issue. If significant change is to be made initiatives need to be 
developed to address these challenges. For instance arranging separate exercise 
sessions for South Asians may be more likely to encourage increased physically 
active when compared to the normal UK provision of mixed-gender facilities 
which are often poorly accepted because of cultural and religious beliefs. Lawton 
et al. (2006) reported that practical considerations (e. g. lack of time, lack of 
opportunities to partake in physical activities) were often interwoven with social 
rules and cultural expectations, such as the prioritization of obligations to kin, 
restrictions on (women) leaving the home (especially to enter mix-sex settings), 
and lack of socialization into sporting and other outdoor activities in influencing 
inactivity in Pakistani and Indian type 2 diabetes patients. Consequently 
motivation, beliefs, and cultural and religious issues need to be considered when 
providing cardiovascular rehabilitation programmes for South Asians. 
Kuppuswamy and his colleagues (2004) showed that culturally appropriate cardiac 
rehabilitation programmes could significantly improve uptake and adherence to 
such programmes. This randomised control parallel group trial studied a culturally 
focused cardiac rehabilitation programme in increasing uptake in participation 
amongst ethnic groups in East London (CADISAP). 
Similarly it is possible that attitudes to other aspects of lifestyle changes might 
differ according to ethnic group. It is not known despite the importance of diet 
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whether South Asians have enthusiasm to take part and accept this type of 
interventions. For instance cultural values which encourage consumption of 
traditional food with high fat level, barriers to adaptation of cooking methods, or 
modifications to existing diet need to be recognized. Qualitative methods have 
been helpful in gathering some information in this area although quantitative 
confinnation is lacking. Asian Indians in focus groups in the USA identified 
specific advice required from nutritionists on how to modify Indian recipes to 
make them healthier. In addition they expressed their concerns regarding the 
individual lack of control and limited choice of food items at community functions, 
parties, and sites of worship (Kalra et aL, 2004). As is always of concem it is 
possible that these views were biased by methods of recruitments to the Focus 
Groups. 
7.4 CONCLUSION 
In this chapter findings of this thesis have been briefly summarized and other 
studies relevant to this area were considered. The published evidence suggests that 
primary care teams currently fail to target the South Asian people adequately. 
However, this population is keen to accept preventive treatment, and efforts should 
be focused on finding the best means to prevent mortality and morbidity in this 
susceptible goup. Further research is required in many areas such as risk factor 
prevalence, risk estimation and recalibration, lifestyle intervention, and preventive 
drug therapy. Because this population is at high risk the benefits of appropriate 
research will also be high. 
Although the evidence base for a CVD risk estimation procedure in South Asians 
is slight it is better that they have their risk estimated, albeit with less precision, 
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than, be excluded from the risk estimation and management process completely. 
The present work provides a properly researched evidence base and adds support to 
recently proposed web-based method of risk estimation for ethnic minorities, the 
ETHRISK. Moreover, it provides its own very simple but in practice acceptable 
adjustment for currently used paper risk estimation tools. 
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Appendix 1 Covering letter 
)tdýf The University of Sheffield 
Division of Clinical Sciences (South) 
Clinical Pharmacology and Therapeutics: Floor L 
The Royal Hallamshire Hospital, Glossop Road, a Nwl Sheffield S 10 2JFý UK. Tel: (0 114) 271 3 664 
Acceptance of antihypertensive therapy: effect of ethnicity 
Researchers: Dr PR Jackson & Dr MAarabi 
Date 
Dear Sir/Madam, 
How keen are people to take tablets to prevent heart disease? A 
research Project 
I am writing to ask if you would like to take part in a project to find out 
people's views about taking tablets to prevent heart disease. You are 
one of 1620 people in Sheffield who have been chosen to participate in 
this study which is being carried out by researchers from the Royal 
Hallamshire Hospital. Your involvement will help us to improve the 
treatment for patients at risk from heart disease. 
Your name has been taken from Sheffield Primary Care Trusts' 
Information Service list, which holds the names and addresses of all 
people registered with local family doctors. This list is confidential to 
Sheffield Primary Care Trusts and is used only for the purposes of 
managing and planning health services. 
Please read the enclosed Information Sheet which tells you more about 
the project. If you need help in reading the Information Sheet please 
contact the researcher, on 0114 271 3664. 
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If you would like to take part please complete the Reply Form to 
indicate a suitable way for us to contact you. Otherwise still return the 
form, but tick the box marked "Please do not contact me again". 
Nobody will be personally identified and no information will be passed 
on to anyone else. Please be assured that the information you give will 
be treated in the strictest confidence and the replies will only be seen by 
myself and the staff working with me on this study. 
Yours sincerely 
Dr PR Jackson 
Honorary Consultant Physician 
Reader in Medicine/Clinical Phannacology and Therapeutics 
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Appendix 2 Follow-up letter 
The University of Sheffield 
Division of Clinical Sciences (South) 
Clinical Pharmacology and Therapeutics: Floor L 
The Royal Hallamshire Hospital, Glossop Road, 
Sheffield S 10 2JF, UK. Tel: (0 114) 2713 664 
COGROSC90 Acceptance of antihypertensive therapy: effect of ethnicity 
Researchers: Dr PR Jack-son & Dr M Aarabi 
Date 
Dear Sir or Madam, 
We wrote to you a couple of weeks ago about a research project 
gathering people's views about treatments to prevent heart disease. 
So far we have not had any reply. We know that sometimes such 
things are left for further consideration. If you would like to help us, 
please read the enclosed Information Sheet about a research project 
we are undertaking to gather people's views about treatments to 
prevent heart disease. If you are interested in helping then complete 
the Reply Form to indicate a suitable way for us to contact you. 
Otherwise please still return the form, but tick the box marked 
"Please do not contact me again". 
Yours sincerely 
Dr PR Jackson 
Honorary Consultant Physician 
Reader in Medicine/Clinical Phan-nacology and Therapeutics 
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Appendix 3 Information sheet 
The University of Sheffield 
Division of Clinical Sciences (South) 
Clinical Pharmacology and Therapeutics: Floor L 
The Royal Hallamshire Hospital, Glossop Road, 
Sheffield S 10 2JFI UK. Tel: (0 114) 271 3 664 
Acceptance of antihypertensive therapy: effect of ethnicity 
Researchers: Dr PR Jackson & Dr M Aarabi 
Introduction 
We are Sheffield University researchers based at The Royal Hallanishire 
Hospital and are asking for your help to find out what influences whether 
people are happy to take tablets to prevent heart disease and how that 
varies in people from different cultures. Dr Aarabi is doing this research 
as part of his PhD degree. Please read this Infonnation Sheet carefully 
and if you have any quenes, don't hesitate to telephone us on (0114) 271 
3664. Even if we can't speak to you immediately, one of our team will 
get back to you. 
What is the study trying to find out? 
People now want to know more about the drugs they are taking before 
starting any treatment. We want to find out how keen people are to take 
tablets to prevent heart disease when they are given the full facts about 
the tablets including side-effects, the disease, and the likely benefit 
gained. In particular we are interested to find whether there are 
differences between ethnic groups in the population in their wish to have 
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treatment. This infon-nation should help doctors planning health services 
and in giving advice to individual patients. 
What is involved if I decide to help? 
The study involves an interview with one of our researchers, who will 
visit your home at a time that is convenient to you. If you prefer the 
interview can be arranged at the Hallanishire Hospital. We will ensure 
that our interviewers are able to give information in a way that you can 
understand. They will describe the symptoms of some blood vessel 
diseases, what it is like to live with them and all about tablets to help 
prevent them. The interviewer will then ask you to imagine that you are a 
person who is at 
risk of these diseases and to think about the treatment choices you might 
make. They will show you a number of diagrams which show how likely 
you are to benefit from treatment and all we ask is that you tell us 
whether you might decide to take treatment or not. We are not suggesting 
that you have any of these diseases, and are only asking for your opinion. 
If at any stage you become upset or tired with the questions, the 
interviewer will leave if you ask. 
How have I been chosen? 
It is very important when getting views about diseases and their 
treatments that we do not concentrate on people who are already ill and 
attending their doctors or the hospital. Because of that we are aiming to 
speak to a number of people in the community, some of whom may be 
ill, others who will be perfectly well. This letter has been posted to you 
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by Sheffield West Primary Care Trust on behalf of all four Sheffield 
PCTS. Your name has not been released to the researchers by the Trust 
and no medical or other information about you has been passed on. 
What about my own state of health? 
As we said before we know nothing about you or your health and it is 
important that we speak to people in all kinds of health. We will only ask 
a few simple questions about your health and whether you are taking any 
tablets, but won't ask any other questions. 
Do I have to take part? 
No. It is completely up to you to decide whether you want to want to take 
part in the study or not. If you do initially decide to go ahead, but then 
change your mind, we will not trouble you again once you have let us 
know. 
If you would prefer not to help with the research and do not wish to be 
contacted again, please fill in the box on the response card and send it 
back to the research team. They will make sure that you are not contacted 
again. Otherwise you will receive a reminder letter in about 2 weeks 
time. If you do wish to 
help, just fill in the positive box on the response fonn and we will 
contact you to arrange a convenient time and place for the interview. 
If you decide not to help it will not influence your treatment by your own 
doctor or any of the hospitals now or in the future. 
What will happen to the information I give? 
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Apart from when we first write to you and if we contact you to confirm 
the time to visit, we will not be using your name, address or telephone 
number. All information provide by you will be kept under a code 
number and not linked to your name. We will not release any information 
I"k aDOUt youor anything that you tell us. We will eventually publish the 
results, but no one will be able to identify you or anything about you 
from our report. 
What if I wish to complain about the way in which this study has 
been conducted? 
If you have any cause to complain about any aspect of the way you have 
been approached or treated during the course of the study, the normal 
University and NHS complaints mechanisms are available to you and are 
not compromised in any way because you have taken part in a research 
study. If you would like to complain or have any concerns please contact 
Dr Jackson on Tel. (0114)271 2615. If you would prefer to use the 
normal University complaints procedure (contact Mr Richard Hudson, 
Research Consultative Unit, 85 Wilkinson Street, University of 
Sheffield, Tel: 0 114 222 1448). 
Thank you for taking the time to read this Information Sheet 
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Appendix 4 Reply form (South Asians) 
Reply Form for helping the research project 
"Acceptance of antihypertensive therapy: effect of ethnicity" 
El Yes, I would like to help. Please contact me on: 
Title: ......... Last name ......... : ................ First name: ........................ 
Telephone number: ................................ 
Postal address: ............................................................. 
............................................................ Post Code: ....................... 
Would it be helpful to have a bilingual interviewer? 0 Yes 0 No 
If Yes, please indicate the language: 
0 Urdu 
0 Punjabi 
0 Bengali 
0 GuJ arati 
0 Hindi 
El No, please do not contact me again. 
7 M, n, h, 2004 - RJR 4. (. )rn. i version I datex-11 .1 if ltý-A', - 
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Appendix 5 Reply form (Caucasians) 
Reply Form for helping the research -project 
"Acceptance of antihypertensive therapy: effect of ethnicity" 
Title: ......... Last name ......... : ................ First name: ........................ 
El Yes, I would like to help. Please contact me on: 
Telephone number: ................................ 
Postal address: ............................................................. 
Post Code: ....................... 
El No, please do not contact me again. 
,. -Cly 
Form I dated 1. f 004 , R. R. 
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Appendix 6 Consent form 
Study Number: 
Participant Identification Number for this study: 
CONSENT FORM 
Title of Project: Acceptance of antihypertensive therapy: effect of ethnicity 
Name of Researchers: Dr P. R. Jackson & Dr M. Aarabi 
Please initial box 
1.1 confirm that I have read and understand the information sheet 
dated 
............................ 
(version ............ 
) for the above study and have had the 
opportunity to ask questions. 
0 
2.1 understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected. 
3.1 agee to take part in the above study. 
0 
0 
Name of Participant Date Signature 
Name of Interviewer Date Signature 
I for participant; I for researcher; (volunteer study) 
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Appendix 7 Interview Manual 
Acceptance of antihypertensive therapy: effect of 
ethnicity 
Interview manual 
Academic Unit of Clinical Pharmacology 
Division of Clinical Sciences (South) 
University of Sheffield 
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An introduction for interviewers 
This is the manual of operation for the Acceptance of an "Antihypertensive 
Therapy: effect of ethnicity Study". The complexity of the Study requires that a 
number of procedures in the interview need to be described in detail. 
What is the study trying to find out? 
People now want to know more about the drugs they are taking before starting any 
treatment. We want to find out how keen people are to take tablets to prevent heart 
disease when they are given the full facts about the tablets including side-effects, 
the disease, and the likely benefit gained. In particular we are interested in finding 
whether some ethnic groups are happier to have treatment than others. This is of 
importance because of the high risk of CHD in some communities e. g. South 
Asians. This information should help doctors planning health services and in giving 
advice to individual patients. 
What is involved in the study? 
The study involves an interviews with selected participants. They are Sheffield 
residents aged 35-74 years with or without history of cardiovascular disease. 
Participants have been selected from the Sheffield Population Health Register 
which holds the names and addresses of all patients who are registered with a 
Sheffield General Practitioners. 
How participants have been chosen? 
It is very important when getting views about diseases and their treatments that we 
do not concentrate on people who are already ill and attending their doctors or the 
hospital. Because of that we are aiming to speak to a number of people in the 
community, some of whom may be ill, others who will be perfectly well. A letter 
will be passed on to randomly selected names by the Primary Care Trust. Their 
names have not been released to the research group by the Trust and no medical or 
other information about them has been passed on. 
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What is involved in the interview? 
Interviewers should give information in a way that is far as possible standardized 
and that participant can understand. The symptoms of some cardiovascular diseases 
(hypertension, myocardial infarction, and stroke) will be described, what it is like 
to live with them and all about tablets to help prevent them. The interviewer will 
then ask the participant to imagine that s/he is a person who is at risk of these 
diseases and to think about the treatment choices s/he might make. They will show 
the participant a number of pictures which show how likely s/he is to benefit from 
treatment and all they ask is that s/he tell the interviewer whether might decide to 
take treatment or not. We are not suggesting that they have any of these diseases, 
and are only asking for their opinion. 
Questionnaire 
The questionnaire has two parts. The first part presents three hypothetical scenarios 
with different baseline cardiovascular risks. The scenarios detail cardiovascular 
risks (coronary death and fatal and nonfatal myocardial infarction or stroke) of 
10%, 20% and 40% over 10 years. 
In the second part, subjects will be asked to provide possible explanatory 
demographic data including age, sex, ethnicity, educational level, occupation, 
history of CVD, and receipt of antihypertensive drugs. 
Scenarios 
After describing the treatment options (medication and no medication) and the 
potential outcomes participants are asked to choose between not accepting the 
therapy (given the baseline risk of an adverse outcome) and accepting the therapy 
(given a reduced risk of the adverse outcome but also incurring the inconvenience, 
cost and side effects associated with that therapy). Choices will be presented to 
subjects both graphically and numerically with risks expressed in positive and 
negative terms. The graphical presentation will use 100 stick figure icons to show 
percent frequencies at risk and benefiting from treatment. The event rates will 
be 
varied in 1% steps until participants switch from accepting to declining treatment 
or vice versa. Interviewers must be careful not to influence the participant choice. 
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Where the interview will take place? 
Interviewers will visit participant's home at a time that is convenient to them and 
the participant. If participants prefer, the interview can be arranged at the 
Hallamshire Hospital. 
If at any stage the participant becomes upset or tired with the questions, the 
interviewer will leave if s/he asks. If the participant decides not to help it must be 
stressed that this will not influence his or her treatment by their own doctor or any 
of the hospitals now or in the future. 
197 
Appendix 
Interview flowchart 
Brief description in lay terms about 
hypertension, heart attack, and stroke 
Hypothetical scenarios with different 
baseline cardiovascular risks 
Participants are asked to choose between not 
accepting the therapy and accepting the 
therapy 
The on-treatment event rates will be varied 
until participants switch from accepting to 
declining treatment or vice versa 
Demographic data including age, sex, 
ethnicity, educational level, occupation, 
history of CVD, and receipt of 
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More details about an interview 
The interview can be started by: 
"Hello, I am ....................... 
"We had an arrangement to meet today. " 
"Is it still convenient for you to have the meeting? " 
The first thing is to tell them what the structure of the meeting will be. 
"What I would like to do today is first of all to go through the information 
sheet. Then if you still happy with the study I would like you to sign a consent 
form. This is just to ensure that I have been fully honest with you about what 
the study involves, and if you still happy at that stage we will go on. " 
"This is simply asking your opinion about the number of different treatments 
of prevention of heart disease. " 
"Do you understand all that? Are there any question you want to ask? " 
In this stage you can start going through the Information Sheet (bringing 
out some key points): 
"First: What is this project about? 
"It is about finding how happy different people are to take tablets to prevent 
heart disease. It is part of Dr Aarabi's PhD research project but the infonnation 
will also be useful in developing health services. " 
"Next: What is it actually trying to do? " 
"It is trying to find out how keen or enthusiastic people are to take tablets to 
prevent heart disease when they know the full infonnation about the benefits 
and risks. " 
"Third: How will we do that? " 
"Well it is by a simple interview that is going to take place today. 
I will ask 
you to imagine you are the person considering whether or not to take 
tablets. I 
will give you three different situations and you must then 
imagine as that 
person whether to take treatment or not. " 
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"Next: How you have been chosen? " 
I want to reassure you that although you were identified from a list of general 
practice patients we were not given any information about you and the letters 
came from the Primary Care Trust not us. You have not been chosen because 
we think you are at particular risk of heart disease. You have just been chosen 
by a random selection process from Sheffield residentes. " 
"Finally: It is important for you to know that in helping us with this project 
you are acting as a volunteer, you really don't need to take part if you prefer not 
to but obviously we would very much like you to take part and we are grateful 
if you continue. " 
"If you have any problems or questions just let me know. If you want any 
further information you can call Dr Jackson or the research office in the 
University. 
"Do you want to ask me any question? " 
"If not then we will begin. " 
Signing the consentform: 
At this stage you now need to consent the interviewee. 
"Now I would like you to sign this consent form, what I stress is this is not 
committing you to anything, it is just to make sure that we have been 
completely honest in the way we have approached you. What is says is firstly 
that you had opportunity to read the information sheet, that we have given you, 
and you had chance to ask questions about it. " 
"Secondly, you have got to understand that helping us is purely voluntary and 
if in any time you want to stop you can do that. " 
"If you are happy to continue can I ask you to tick each of these 
boxes, then to 
put your name and to sign it? " 
When they have signed that, the interviewers should say: 
"Thank you very much for that if you still happy we will continue with 
the 
interview. " 
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"The actual interview itself is in three parts. First of all I am going to describe 
what is like to have high blood pressure and problems that arise because of that 
and what taking tablets is like. Then I want you to put yourself in a position of 
somebody who has got high blood pressure deciding whether to take tablets or 
not. We will do that several times each with slightly different amount of 
benefit from the tablets. At the end I will ask you one or two question about 
yourself just to help us understanding answers better. " 
Background information 
At this stage it is important that the information is read word for word 
from the booklet with checks at several points to ensure understanding. 
At the end of background the interviewees need to be asked if they have 
any questions. 
"Do you want to ask any questions about the conditions or the tablets? " 
"Do you want me to go over any of things again? " 
"If not we will move on and ask your opinion about some imaginary 
situations. " 
Scenarios 
Now we come to heart of the interview process. At this stage the person who is 
being interviewed has some information about what is like to have a heart attack or 
stroke and what is like to have tablets. We now want to put them into a position 
where they to decide whether to take tablets or not. 
We are going to do that for three different scenarios. In each of these there are 
slightly different starting risks of having a heart attack or stroke. We then adjust the 
chance of them having a heart attack or stroke when taking tablets until we 
find a 
point on which they will just accept the tablets. In other words we would 
like to 
find the point at which benefit from taking the tablets is just enough to persuade 
them that it is worthwhile. The way we do that is with the scenario sheet. 
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In each scenario there is a brief description at the top outlining the risk of having 
stroke or heart attack when they are not taking any treatment and then at the bottom 
there are the two descriptions of what is like not to take medication and to take 
medication. First of all we explain what is like not to take medication. We remind 
them no medication means no inconvenience, no side effects, and no costs. 
The interviewer can say: 
"If you take the medication you have got to do it everyday for ten years. There is 
the possibility of having side effects and if they pay for their prescription charges it 
costs them f-6.40 each month. " 
"What is likely to happen to you in this situation if you have no medication is that 
you have a 10% risk of having a heart attack or stroke. In the stick men diagram 
that means these people in the top will have a heart attack or stroke (point to the 
black stick men). These people at the bottom (point to the white stick men) will 
escape and not have a heart attack or stroke. " 
You have to remind them the numerical termfOr each situation. 
"This means there is 90% chance that you will not have a heart attack or stroke. " 
Then for the right side of scenario page you would say: 
"What is likely to happen to you in this situation if you have medication is that you 
have a 5% risk of having a heart attack or stroke. That means these stick men here 
would have a heart attack or stroke (point to the black stick men) in next ten years 
and the others would escape having a heart attack or stroke in next ten years. 
7 
These people at the bottom (point to the white stick men) will escape and not 
have 
a heart attack or stroke. " 
You need to put words as well. 
"This means there is a 95% chance that you will not having a 
heart attack or 
stroke. " 
Then you ask them: 
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"Would you take tablets or not comparing these situations? 
Then you follow the instruction at the bottom of page. Based on the answer you 
have two choices: going to another page or recording the mentioned value. If you 
are instructed to go to another page you open the booklet 2 at that page and place it 
over the half right side of the scenario. Then you will explain the new situation 
using stick men diagram and words, numerically. You can do the recording at the 
last page of the Interview booklet 1. 
It is better at each stage if you remind them of nsk of not having the tablets as well 
as the new risk with tablets. 
Once you have completed a record then you move to the next scenario. 
For each new scenario you have to remind them that you are presenting a new 
situation. It is important to emphasize the change in the risk of having heart attack 
or stroke for example scenario two presents 20% risk in ten years. 
You remind them that there is no inconvenience, no side effect, and no cost if they 
do not take medication. If they do decide to take it daily for ten years they may 
have side effects and it costs about E6.40 per month if they pay for their 
prescription. 
Then explain the outcomes in the next ten years if they take no medication (10% 
risk of having heart attack or stroke). After that, go to the page that is instructed in 
the bottom of the page. 
At that time you will move to the 3d scenario. Again you read the top of the page 
and emphasize the text in bold. The 3d scenario is in the next ten years 
but the 
amount of risk is different from the l't and 2 nd ones. Each time ask the 
interviewee 
whether they are still comfortable. 
When you finish the 3 rd scenano you will ask some questions 
in the last page of 
interview booklet 1. Ask the interviewee to provide possible explanatory 
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demogTaphic data including age, sex, ethnicity, educational level, occupation, 
history of CVD, and receipt of antihypertensive drugs. 
Appendix 8 Interview Booklet 
Acceptance of antihypertensive therapy: effect of 
ethnicity 
Interview Booklet (part 1) 
Academic Unit of Clinical Pharmacology 
Division Of Clinical Sciences (South) 
University of Sheffield 
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Interview Booklet I 
Acceptance of antihypertensive therapy: effect of ethnicity 
Thank you for participating in this research study. This study is divided into three 
parts. In the first part, we will describe high blood pressure and how it leads to 
stroke or heart attack. We will describe what usually happens when someone has a 
stroke or heart attack, and discuss a medication which can help to prevent strokes 
or heart attacks in people with high blood pressure. 
In the second part, we will descnbe six situations and ask you to imagine each 
situation applied to you. Then we will ask your opinion about whether or not you 
would want to take a blood pressure-lowering medication in each situation. 
From this information, we will be able to let doctors know what people think about 
blood pressure medication. 
In the third part, we will ask some questions about you which will allow us to 
analyze your answers with those of other people similar to yourself 
All of your answers will be kept confidential. 
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BACKGROUND INFORMATION 
High Blood Pressure 
High blood pressure (also known as "hypertension") is a condition in which a 
person's blood pressure is higher than normal for someone their age and sex. 
Generally, high blood pressure doesn't cause any symptoms and people do not even 
know they have it. The only way it can be detected is by measuring the blood 
pressure with a blood pressure cuff. 
High blood pressure is a very important condition as it can cause strokes or heart 
attacks. In the next page you will learn more about strokes and heart attacks. 
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STROKE 
A stroke is caused by a blockage in the blood supply to part of the brain. 
The effects of a stroke range from being completely normal within a few minutes to 
being dependent on others for eating, toileting, and movement for the rest of your 
life. In between these extremes, most people have either minor symptoms or major 
symptoms. 
The stick figures below represent 100 people who have had a stroke. They will be 
used to show the chances of different things happening. About I in every 5 people 
who have a stroke dies within the first month. Of the survivors, about one third 
recover completely and are able to return home, one third are able to return home 
but need some help with walking or talking, and one third need to go to a nursing 
home as they need help with feeding, toileting, and walking. 
Home (independent) 
Home (with some help) 
Nursing home/long term care 
Dead within one month 
On the next page, I will describe what a stroke is like. 
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STROKE 
Initial Physical Symptoms: 
" Suddenly unable to move or feel your an-n and/or leg on one side 
" No physical pain 
" May not be able to swallow 
Initial Mental Symptoms: 
" May not be able to fully understand what is being said to you 
" May not be able to say what you want to say 
" Speech may be slurred and difficult for others to understand 
Initial Recovery: 
Will be admitted to hospital 
Weakness, numbness, and speech may improve 
Stay in hospital for 1-2 weeks 
Initial Chance of Dying: 
* About 1 in 5 people who have a stroke die within one month 
Long-term Recovery: 
This varies from person to person (see previous page) 
About I in 2 people who suffer a stroke will recover and be able to return 
home again 
9 About 1 in 3 people who survive a stroke will have trouble with slurred 
speech 
About I in 10 people who survive a stroke will be unable to control 
their 
bowel or bladder 
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HEART ATTACK 
A heart attack is caused by a lack of blood flow to a region of the heart muscle. 
/ 
The stick figures below represent 100 people who have had a heart attack. They 
will be used to show the chances of different things happening. 
About half of all people who have a heart attack die within one month. Of the 
people who survive one month, half will recover and be able to resume a normal 
life and the other half will recover but will have occasional chest pain (angina) or 
shortness of breath. 
Complete recovery 
Occasional pain 
or shortness of breath 
Dead within one month 
On the next page, I will describe what a heart attack is like. 
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HEART ATTACK 
Initial Physical Symptoms: 
9 Suddenly get a heavy feeling or pain in the chest 
e May feel dizzy, nauseated, or short of breath 
Initial Mental Symptoms: 
9 May not be able to fully understand what is being said to you 
Initial Recovery: 
Will be admitted to hospital 
Chest pain and other symptoms will improve with treatment 
Stay in hospital for about a week 
Won't be able to return to work for at least six weeks 
Initial Chance of Dying: 
9 About one in every two people who have a heart attack die within one 
month 
Long-term Recovery: 
Will feel fatigued and low in energy for several weeks or months after 
About one in two people who recover from a heart attack are able to resume 
their normal activities after a few weeks 
About one in two people who recover from a heart attack are limited by 
further attacks of chest pain or shortness of breath while doing their usual 
activities 
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Treatment with a blood pressure-lowering medication 
The goal of treatment with a blood pressure-lowering medication is to prevent a 
stroke or heart attack in people with high blood pressure. However, the pills are 
only partially effective and do not prevent strokes or heart attacks in everyone who 
takes them. This means that some people will benefit from taking the treatment 
while others will take the treatment without any benefit. 
NI 
Because high blood pressure is a lifelong condition, most people will have to 
continue taking these pills for the rest of their life. These pills are usually taken 
once or twice a day. 
, 9. 
Careful studies in thousands of patients have shown that most people don't feel any 
different when taking the pills and can still do their normal activities. 
Of every 100 people who take these pills, 7 have to stop because of side-effects 
(such as fatigue, difficulty sleeping, impotence, leg cramps, or minor abnormalities 
in the blood sodium or potassium). The other 93 people do not have any side 
effects from the pills. These side effects usually disappear within two weeks after 
stopping the pills. Blood pressure-lowering pills cost about f6.40 per month, but if 
you don't pay you got it free. 
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SUMMARY 
Taking blood pressure-lowering medication has: 
ADVANTAGES 
9 reduced chance of stroke or 
heart attack 
DISADVANTAGES 
* inconvenience (take every day) 
0 side effects 
0 cost 
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How much benefit you think you would want? 
Now its time to consider how much benefit you think you would want before 
taking the medication every day. 
In this section, we will present a series of IMAGINARY s1tuations and ask you to 
make a choice about whether you would want to take a blood pressure-lowering 
medication based on its advantages and disadvantages. These situations are 
imaginary and the same scenarios are being given to all of the people involved in 
this study. 
Remember, this is not a test and there are no right or wrong answers. We are 
interested in your opinion. You can look at the Information charts from Part 2 and 
ask the interviewer questions to clarify any points. 
We will use 100 stick figures to show the chances of different things happening. 
C) 
6A 
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Scenario I 
Now, imagine that your risk of having a heart attack or stroke in the next ten years 
is 10%. If you take a blood pressure-lowering medication every day for ten years, 
you can reduce your chance of having a heart attack or stroke. You have two 
choices: 
NO MEDICATION 
No inconvenience 
No side effects 
No cost 
MEDICATION 
Take daily for ten year 
May have side effects 
Costs about E6.50 per month if you pay 
for your prescription 
OUTCOMES IN NEXT TEN YEARS 
NO MEDICATION 
You have an 10% risk of having 
a heart attack or stroke 
chance that you will not 
MEDICATION 
You have a 5% risk of having 
a heart attack or stroke 
C) 
r..., I'A 
F? 
This means there is a 95% 
chance that you will not 
have a heart attack or stroke have a heart attack or stroke 
WOULD YOU TAKE THE 
MEDICATION? 
If Yes go to page 9 (booklet 2) 
If No go to page 3 (booklet 2) 
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Scenario 2 
Now, imagine that your risk of having a heart attack or stroke in the next ten years 
is 20%. If you take a blood pressure-lowerIng medication every day for ten years, 
you can reduce your chance of having a heart attack or stroke. You have two 
choices: 
NO MEDICATION 
No inconvenience 
No side effects 
No cost 
MEDICATION 
Take daily for ten year 
May have side effects 
Costs about f 6.50 per month if you pay 
for your prescription 
OUTCOMES IN NEXT TEN YEARS 
NO MEDICATION 
You have an 20% risk of having 
a heart attack or stroke 
Y%6 
) ol C) p 
This means there is a 80% 
chance that you will not 
MEDICATION 
You have a 10% risk of having 
a heart attack or stroke 
chance that you will not 
have a heart attack or stroke have a heart attack or stroke 
WOULD YOU TAKE THE 
MEDICATION? 
If Yes 4 go to page 16 
If No 4 go to page 6 
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Scenario 3 
Now, imagine that Your risk of having a heart attack or stroke in the next ten years 
is 40%. If you take a blood pressure-lowering medication every day for ten years, 
you can reduce your chance of having a heart attack or stroke. You have two 
choices: 
NO MEDICATION 
No inconvenience 
No side effects 
No cost 
MEDICATION 
Take daily for ten year 
May have side effects 
Costs about f 6.50 per month if you pay 
for your prescription 
OUTCOMES IN NEXT TEN YEARS 
NO MEDICATION 
You have an 40% risk of having 
a heart attack or stroke 
MEDICATION 
You have a 20% risk of having 
a heart attack or stroke 
This means there is a 60% 
chance that you will not 
have a heart attack or stroke 
This means there is a 80% 
chance that you will not 
have a heart attack or stroke 
WOULD YOU TAKE THE 
MEDICATION? 
If Yes 4 go to page 31 
If No 4 go to page 11 
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Some questions about you 
Serial number ................. 
Date of interview 
Gender Male El 
Female El 
Month of birthday 
Year of birthday 
White El 
Indian 1-: 1 
To which group do you belong? 
Pakistani El 
Bangladeshi El 
Other ........................ El 
Age at leaving full time education: ............... years old 
Occupation .............................. 
Heart attack El 
Have you suffered any of the following? 
Angina El 
Stroke El 
Is there any history of cardiovascular disease (heart attack, 
angina, stroke) in your family (father, mother, brother, Yes 
sister, children, spouse)? No El 
Do you use any tablets for high blood pressure? Yes El 
No 
Record for Scenarios 
Scenario 1: 
...... 
% Scenario 2: 
...... 
% Scenario 3: 
...... % 
Thank you very much for your participation 
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